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Recently, there has been an increasing demand for more and higher quality 
evidence of the comparative effectiveness of different health technologies. Much of the 
comparative effectiveness research (CER) designed to address this demand will compare 
widely-used technologies and will be closely integrated with clinical care. These design 
features raise the question of whether current standards of informed consent should 
always be required for CER studies. Considering the acceptability of alternatives to 
informed consent is important as alternatives may improve the efficiency and quality of 
this research.  
This dissertation considers whether alternatives to informed consent are morally 
and socially acceptable by addressing three aims, each of which is explored in a separate 
paper. Aim one explores which alternatives to informed consent are acceptable to key 
stakeholders for low-risk CER trials of widely-used therapies. To address this aim, 
interviews were conducted with institutional review board members and researchers and 
focus groups were conducted with patients at two health systems. The results demonstrate 
that many participants felt that although it was important for eligible individuals to be 
informed about CER trials, it was acceptable to streamline the amount of information 
disclosed and to ask individuals to opt-out if they would prefer not to participate.  
Aim two considers which alternatives to prospective informed consent are 
morally permissible for CER studies. Addressing this aim, paper two is a moral analysis 
that argues that when enrolling individuals in these activities, it is sometimes acceptable 
to limit individual choice in situations where the decision to participate is unlikely to 
engage important self-determination interests that individuals have. Based on this 
   
iii 
 
argument, several recommendations regarding the moral permissibility of altering 
consent requirements for CER are provided. 
Aim three develops preliminary policy recommendations for reforming the 
informed consent regulations. Building on aims one and two, paper three suggests that it 
may be appropriate to streamline disclosure statements for low-risk CER trials and that it 
may also be appropriate to ask participants to opt-out instead of opt-in. However, in order 
for policy change to occur, it is necessary to continue to build the case for the importance 
of conducting CER studies. 
 
Primary Readers: Nancy Kass, ScD (Advisor) 
Jodi Segal, MD, MPH (Chair) 
Ruth Faden, PhD, MPH 
Maria Merritt, PhD 
Alternate Readers: Albert Wu, MD 
Darcy Phelan, DrPH  




Conducting the multi-site qualitative research project and the moral analysis 
described in this dissertation required the mentorship and assistance of many different 
individuals – without whom I would never have been able to complete this work. I am so 
thankful for all the help and advice I have been provided with during these past few 
years. 
I would first like to thank my advisor, Dr. Nancy Kass, who has been the best 
mentor I ever could have hoped for. Nancy has always challenged me to further refine my 
research and writing and to reach out and work with other colleagues at the School of 
Public Health as well as at other institutions. She has also provided constant and 
thoughtful feedback throughout my time in the PhD program at the Johns Hopkins 
Bloomberg School of Public Health. Her support and her dedication to her students is one 
of the primary reasons I have had such a wonderful experience at Hopkins and I am 
certainly going to miss our bi-weekly meetings to discuss my dissertation work. 
I would also like to thank Dr. Ruth Faden, who, along with Nancy, was 
instrumental in helping me develop my dissertation proposal and whose advice regarding 
my dissertation work has been invaluable. In addition to providing me with mentorship 
through the course of my dissertation, both Nancy and Ruth allowed me to work on a 
number of different projects with them. The experience of being able to work with two 
such thoughtful and intelligent women in the fields of public health and bioethics has and 
will continue to have an influential role in shaping my career in those fields.  
 
   
v 
 
Other members of my dissertation committee have also provided me with a huge 
amount of useful advice and support throughout my dissertation work. I very much 
enjoyed my conversations with Dr. Maria Merritt. Maria’s thoughtful comments on my 
moral analysis helped shape that work and also helped to further my own knowledge of 
the field of moral philosophy. Additionally, I want to acknowledge the support of Drs. 
Jodi Segal and Albert Wu. Jodi and Albert provided valuable advice on my research plan 
and project materials.  
I would also like to thank several other individuals who acted as members of 
either my dissertation proposal or defense committees including Drs. Holly Taylor, Marie 
Nolan, and Darcy Phelan as well as Dr. Hilary Bok who graciously agreed to review a 
draft of my moral analysis and provide me with feedback.  
In addition to members of my exam and advisory committees, it would not have 
been possible to complete this dissertation without the assistance of individuals from both 
the Johns Hopkins Community Physicians network and the Geisinger Health System. In 
particular, I would like to thank Dr. Gary Noronha, Wendy Greenberg, and Rebecca 
Mead for their help with the recruitment of patients from the Johns Hopkins Community 
Physicians network as well as Dr. Walter Stewart, Dr. Stephen Steinhubl, and Rebecca 
Search for their help with recruitment of participants from Geisinger Health System. I 
would also like to thank Dr. Stewart for his assistance in developing the idea for the 
qualitative research project as well as for his guidance on creating the case studies that 
were used for that project. 
I feel that it is also important to thank all of those individuals who participated in 
interviews and focus groups as part of my qualitative research project.  The insights and 
   
vi 
 
ideas the participants shared with me were so insightful and I had a great time speaking 
with everyone them.  
In addition to the research communities and participants, I relied heavily on the 
support of my family and friends throughout this process. I would especially like to thank 
my mother, my brother Jon, and Amir. My mother has always been there to give me 
advice, review drafts, and generally provide me with all her love and support. Amir has 
patiently listened to numerous practice presentations, has always been willing to listen to 
my ideas and review materials, and has always been there to encourage me when I 
needed encouragement and to make me laugh when I needed to laugh. 
Last but certainly not least I would like to acknowledge the Agency for 
Healthcare Research and Quality who provided me with a dissertation grant award to 
support my dissertation work. This dissertation was supported by grant number 
R36HS021064. However, the content is solely the responsibility of the authors and does 
not necessarily represent the official views of the Agency for Healthcare Research and 
Quality.  
  




Table of Contents  
Introduction ..........................................................................................................................1 
 
Paper 1: Stakeholders’ Views of Alternatives to Prospective Informed Consent for Low-
Risk Pragmatic Comparative Effectiveness Trials ..............................................................7 
Background and Introduction ..................................................................................8 
Methods..................................................................................................................11 
Results from Interviews with Research and Institutional Review Board Members
................................................................................................................................18 
Results from Focus Groups with Migraine and Hypertension Patients .................27 
Discussion ..............................................................................................................36 
Conclusion .............................................................................................................42 
Tables and Figures .................................................................................................44 
References ..............................................................................................................49 
 
Paper 2: Rethinking the Balance of Self-Determination Interests with Interests in 
Achieving High Quality Health Care  ................................................................................53 
Background and Introduction .........................................................................................54 
Demonstrating Respect for the Moral Status of Individuals Enrolled in QI and CER 
Activities ........................................................................................................................57 
Features of QI and CER Activities that are Relevant to the Acceptability of Waiving or 
Altering Informed Consent Requirements .....................................................................59 
   
viii 
 
Discussion: Recommendations Regarding the Moral Permissibility of Limiting an 
Individual’s Ability to Decide Whether to Participate in a QI or CER Activity ...........86 
Conclusions and Next Steps ...........................................................................................95 
References ......................................................................................................................97 
 
Paper 3: Simplified Disclosure Statements and Opt-Out Approaches as Policy 
Alternatives to Prospective Informed Consent for Low-Risk CER Trials ......................102 
Introduction ..................................................................................................................102 
Constructing Viable Alternatives to Prospective Informed Consent ...........................103 




Appendix 1: Johns Hopkins Bloomberg School of Public Health IRB Approval Notice
 ......................................................................................................................................110 
Appendix 2: Geisinger Health System IRB Approval Notice  .....................................113 
Appendix 3: Johns Hopkins Community Physicians Research and Projects Committee 
Approval .......................................................................................................................118 
Appendix 4: Extended Methods Section for Aim 1 Qualitative Study Exploring 
Stakeholders’ Views of the Acceptability of Different Models of Consent, Disclosure, 
and Authorization .........................................................................................................119 
Appendix 5: Participant Consent Forms ......................................................................137 
A. Johns Hopkins/Geisinger Comparative Effectiveness Researchers ...................137 
   
ix 
 
B. Johns Hopkins/Geisinger Institutional Review Board Members .......................140 
C. Johns Hopkins/Geisinger Patients with Hypertension .......................................143 
D. Johns Hopkins/Geisinger Patients with Migraines .............................................147 
Appendix 6: In-depth Interview Guide and In-depth Focus Group Guide ..................151 
A. In-Depth Interview Guide ...................................................................................151 
B. Focus Group Guide.............................................................................................155 
Appendix 7: Case Studies  ...........................................................................................161 
A. Hypertension Case Study Description ................................................................161 
B. Migraine Case Study Description .......................................................................164 
Appendix 8: Description of the Models of Consent, Disclosure, and Authorization ...167 
Appendix 9: Participant Surveys ..................................................................................172 
A. Survey for Researchers and Institutional Review Board Chairs/Longstanding 
Members .............................................................................................................172 
B. Survey for Institutional Review Board Community Members...........................175 
C. Survey for Patients with Hypertension or Migraines .........................................178 
Appendix 10: Interview and Focus Group Coding Scheme .........................................182 
 




List of Tables 
1.1: Description of Hypothetical Case Studies and Models of Disclosure and 
Authorization .....................................................................................................................44 
1.2: Demographic Characteristics of Interview Participants .............................................45 
1.3: Selected Participant Comments Related to the Theme of Respect for Autonomy or 
Components of Respect for Autonomy..............................................................................46 
1.4: Demographic Characteristics of Focus Group Participants ........................................48 
A.1: Focus Group Composition .......................................................................................123 





List of Figures 
1.1: Comments Related to the Amount of Information that Should Be Provided to 






Over the last several decades, there have been increasing calls for more and 
higher quality evidence of clinical effectiveness.  This has included increased demand for 
knowing how technologies or other health care innovations impact health outcomes and 
clinical care in the real world (Committee on Comparative Effectiveness Research 
Prioritization, 2009, 1; Olsen et al, 2007; Tunis et al, 2003). Determining the 
effectiveness of drugs and technologies in clinical practice requires the development of a 
research paradigm that draws “clinical research closer to the experience of clinical 
practice, including the development of new study methodologies adapted to the practice 
environment” (Olsen et al, 2007, 5).  This shifting clinical research paradigm in which 
research is more closely integrated within clinical care raises a number of unique and 
important ethical issues that must be addressed to ensure that this type of research is 
conducted in socially and morally appropriate ways.  
Much of the research ethics literature to date has focused on ethical issues in 
traditional clinical trials, while newer literature has begun to address issues related to the 
use of data from electronic medical records for research purposes, including how to 
manage privacy and confidentiality and whether informed consent is required from 
patients. However, relatively little has been written about the ethical issues that emerge 
when comparative effectiveness studies are conducted in ongoing clinical practice 
settings, including whether current standards of prospective informed consent should 
always be required for pragmatic clinical trials (PCTs). PCTs are randomized controlled 
trials designed to demonstrate how effective health technologies are in routine clinical 




integrated with clinical practice and generally impose few, if any, additional burdens on 
participants (Thorpe et al, 2009; Olsen et al, 2007, 9). Moreover, given their frequent use 
of widely-prescribed, non-experimental therapies, PCTs often have a lower risk and 
uncertainty profile than traditional Phase 3 trials, and certainly lower than Phase 1 and 2 
safety studies.  Because of these differences, researchers’ duties regarding respect and 
consent may fall somewhere in between the fairly modest and more informal consent 
norms of clinical practice (Braddock et al, 1997; Braddock et al, 1999) and the far stricter 
consent norms of clinical research. Therefore, consistent with the arguments that some 
scholars have made (Truog et al, 1999), it may be appropriate to implement alternatives 
to prospective informed consent for at least some randomized comparative effectiveness 
trials of widely-used, non-experimental therapies. When waiving or altering informed 
consent requirements is morally permissible, doing so may be preferable because current 
consent requirements are time consuming, resource intensive, difficult to integrate into 
clinical care, and can result in selection bias. 
This dissertation addresses the question of whether there are morally permissible 
and socially acceptable alternatives to prospective informed consent for low-risk PCTs 
comparing two or more widely-used, non-experimental medical interventions.  
To address this question, this dissertation has three aims: 
(1) to explore which of several different models consent, disclosure, and 
authorization are acceptable to patients, institutional review board (IRB) 
members, and comparative effectiveness researchers for PCTs comparing 




which factors affect stakeholders’ perceptions of the acceptability of these 
models; 
(2) to conduct a moral analysis outlining which models of consent, disclosure, and 
authorization are morally permissible for quality improvement and comparative 
effectiveness activities, including PCTs; and 
(3) to provide preliminary policy recommendations for reforming the informed 
consent regulations in morally and socially acceptable ways as well as guidance 
on how to further refine those recommendations and move toward 
implementation. 
Each of these aims is addressed in a separate paper included in this dissertation. 
Aim 1 is addressed in the first paper which describes a qualitative study that engaged 
three different types of stakeholders – patients, IRB members, and comparative 
effectiveness researchers – from Johns Hopkins Health System and Geisinger Health 
System in discussions about waiving or altering informed consent requirements for low-
risk PCTs comparing widely-used, non-experimental interventions. Specifically, eight 
focus groups were conducted with migraine or hypertension patients and eighteen 
interviews were conducted with IRB members and comparative effectiveness researchers. 
The results of this study demonstrate that many participants felt that although it was 
important for eligible individuals to be informed about low-risk PCTs, it was also 
acceptable for the amount of information disclosed to be simplified. Additionally, many 





Aim 2 is addressed in the second paper. This moral analysis argues that when 
enrolling individuals in quality improvement or comparative effectiveness activities, it is 
sometimes acceptable to limit the autonomous choice of those individuals in situations 
where there is a strong justification for doing so and where the decision to participate is 
unlikely to engage important self-determination interests that an individual has. This 
analysis also describes specific features of quality improvement and comparative 
effectiveness activities that impact the likelihood that the decision to participate in those 
activities will engage important self-determination interests. Based on this analysis, a 
number of recommendations regarding the moral permissibility of waiving or altering 
informed consent requirements for these types of activities are provided.  
Finally, aim 3 builds on the results of aims 1 and 2 and is addressed in the third 
paper. This paper considers the policy implications of this work as well as appropriate 
next steps that should be undertaken in order to move towards both morally and socially 
appropriate policy changes to the current informed consent regulations in the United 
States. Specifically, based on the results of aims 1 and 2, the third paper recommends that 
study-specific disclosure statements for low-risk PCTs be simplified such that the 
information provided about widely-used, non-experimental interventions is similar to the 
amount of information provided about those interventions as part of appropriate standard 
clinical care practices. This paper also recommends that patients be asked to opt-out of 
these activities if they would prefer not to participate. Nevertheless, in order for policy 
change to occur, this third paper suggests that it is necessary to continue to build the case 




This body of work contributes to the growing research ethics literature by 
providing data, as well as a normative analysis, concerning the acceptability of waiving 
or altering prospective informed consent requirements for pragmatic comparative 
effectiveness trials of widely-used interventions.  However, more work of this sort is 
needed to help identify what constitutes appropriate public policy in this context. For 
instance, there is a need for additional discussion regarding what appropriate clinical 
standards for disclosure of information about medical interventions are. There is also a 
need for more work that considers if and how a community’s level of trust in a medical 
institution should factor into moral and policy analyses about the appropriateness of 
different alternatives to prospective informed consent. Moreover, although the results of 
the qualitative study presented in the first paper provide useful information on the views 
of important stakeholders, because this was a relatively small study, it is necessary to 
engage even more stakeholders from additional institutions in discussions about the 
appropriateness of waiving or altering informed consent requirements for pragmatic 
comparative effectiveness trials. Finally, there is a need to ensure that there are efficient 
and effective mechanisms for implementing the results from these types of trials back in 
to clinical care so that they have a positive impact on the quality of health care delivered 
to patients. 
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Paper 1: Stakeholders’ Views of Alternatives to Prospective Informed 
Consent for Low-Risk Pragmatic Comparative Effectiveness Trials 
Abstract 
As interest in conducting comparative effectiveness research continues to build, 
questions have emerged regarding whether it is ever acceptable to waive or alter 
prospective informed consent requirements for research when individual patients are 
randomly assigned to different evidence-based and widely-used therapies.  This paper 
reports on a qualitative research project that aims to understand the views of Institutional 
Review Board (IRB) members, researchers, and patients regarding the acceptability of 
four different models of disclosure and authorization for low-risk pragmatic comparative 
effectiveness trials of widely-used therapies. Participants were recruited from two 
institutions: the Geisinger Health System in Danville, PA and the Johns Hopkins Health 
Care System in Baltimore, MD. A total of 18 interviews were conducted with IRB 
members and researchers and a total of 8 focus groups were conducted with Geisinger 
and Johns Hopkins patients between July, 2012 and June, 2013. During the interviews 
and focus groups, participants discussed the acceptability of the four different models of 
disclosure and authorization in relation to either a hypertension or migraine treatment 
case study developed for this project.  Each case study described a pragmatic trial 
comparing widely-used therapies for the condition in question. The results suggest that 
participants value autonomous choice and therefore, most did not find models that they 
viewed as significantly infringing on autonomous choice to be acceptable. However, 
many participants also believed that it was acceptable to simplify the amount of 




acceptable to ask eligible individuals to opt-out if they would prefer not to participate (as 
opposed to opting-in). Participants from Geisinger were more likely than participants 
from Johns Hopkins, and patients and researchers were more likely than IRB members, to 
state that alternatives to prospective informed consent were acceptable. This work 
provides some preliminary evidence that important stakeholders find alternatives to 
prospective informed consent acceptable for low-risk pragmatic comparative 
effectiveness trials of widely-used therapies as long as a sufficient amount of patient 
control is preserved. 
 
Background and Introduction: 
Although technological innovation has led to important advancements in medical 
care, patients continue to receive many health services for which the evidence regarding 
whether the service is effective is incomplete or unavailable (Tunis et al. 2010).  
Recognizing the need for robust evidence to support clinical and health policy decision 
making, increasing attention has focused on the importance of conducting comparative 
effectiveness research (CER) (Committee on Comparative Effectiveness Research 
Prioritization 2009).
 
To support such efforts and to underscore the public’s interest in 
having such evidence, the Federal Government has recently devoted substantial resources 
to support CER both through the American Recovery and Reinvestment Act of 2009 and 
the Patient Protection and Affordable Care Act of 2010, which also established the 
Patient Centered Outcomes Research Institute to coordinate and fund CER activities.  
CER has been defined as “the conduct and synthesis of research comparing the 




monitor health conditions in “real world” settings” (Federal Coordinating Council for 
Comparative Effectiveness Research 2009).
 
Understanding how different widely-used, 
evidence-based interventions work in the “real world” generally requires that CER 
studies be closely integrated with clinical practice.  Further, although some CER 
questions can be answered with observational studies, generating robust evidence of 
comparative effectiveness will, at times, require randomized controlled trials (RCTs). 
Pragmatic clinical trials (PCTs) are a type of RCT design that is meant to be closely 
integrated with clinical care while maintaining the benefits in terms of improved study 
validity that result from randomly assigning individuals to treatment arms (Mullins et al. 
2010). So that they reflect the effectiveness of interventions in the “real world”, PCTs 
generally have minimal exclusion criteria, include a wide range of clinical settings, 
collect data on patient-relevant outcomes, and are designed to have only a minimal 
impact on the clinical care experienced by participants (Luce et al. 2009; Tunis et al. 
2003). Given these features, PCTs will be an important strategy by which to address 
many CER questions (Mullins et al. 2010).  
Since PCTs are often designed to understand the effectiveness of widely-used, 
evidence-based interventions, these trials will differ in ways that are significant, morally, 
from more traditional clinical research measuring efficacy and safety. Unlike PCTs, 
efficacy and safety studies generally compare experimental interventions, impose greater 
burdens on participants, and are conducted in carefully selected patients and settings. 
Given these differences, PCTs often have different risk, benefit, and burden profiles than 
traditional clinical research and as such, as CER becomes a more widely-used and 




consent strategies required for traditional RCTs should always be required for PCTs 
(Kass et al. 2012; Faden et al. 2013). 
The moral justification for informed consent is the need to respect the autonomy 
of potential research participants as well as the desire to protect individuals from risks 
that they did not agree to accept (Emanuel et al. 2003; Faden and Beauchamp 1986, 294).  
Obtaining informed consent is required, with few exceptions, by U.S. federal regulations, 
in part, because research is assumed to carry both increased risk of harm and uncertainty 
of effectiveness and/or safety. While current regulations do allow, in certain 
circumstances, some low-risk studies to obtain a waiver of informed consent 
(45CFR46.116), it is extremely rare for trials that randomize individuals to clinical 
interventions to qualify for such waivers. This may be because the paradigm for clinical 
research that emerged over the last several decades was that RCTs were used to study 
therapies of uncertain efficacy and as a result were thought to routinely carry higher 
risks.
1
 However, as discussed above, these assumptions often do not apply to PCTs and 
as such, researchers’ duties regarding consent may fall somewhere in between the more 
informal consent norms of much of clinical practice (Braddock et al. 1997; Braddock et 
al. 1999) and the far stricter consent norms of clinical research.   
Unfortunately, there is very little information about stakeholders’ views regarding 
the acceptability of implementing alternative approaches to prospective informed consent 
for low-risk PCTs comparing widely-used, evidence-based interventions (Rogers et al. 
                                                          
1
 Also relevant is that the US Food and Drug Administration (FDA) guidelines hardly ever allow informed 
consent requirements to be waived (21 CFR 50.23). This is perhaps because of the assumption that studies 
being submitted to the FDA are for approval of experimental drugs or for approval of new indications for 
previously approved drugs (off-label), and are therefore more risky. However, there are cases where this 
assumption does not hold such as in situations where investigators would like to compare evidence-based 
therapies to each other and may ultimately submit the results to the FDA for additional labeling, even for 




1998).  Understanding stakeholders’ views is important because informed consent, as 
currently solicited and documented, is logistically burdensome, time consuming, resource 
intensive, and introduces selection bias.  If alternative models were both morally 
permissible and acceptable to relevant stakeholders, regulatory changes could be made 
that might facilitate the more efficient implementation of these trials and potentially the 
increased participation of more diverse populations and practices. We conducted a 
qualitative study designed to understand Institutional Review Board (IRB) members’, 
researchers’, and patients’ views of the appropriateness of several different models of 
disclosure and authorization for enrolling patients in PCTs comparing widely-used, 
evidence-based interventions.  
 
Methods 
To explore stakeholders’ views, this study conducted a series of 18 semi-
structured interviews with IRB members and researchers and 8 semi-structured focus 
groups with patients between July, 2012 and June, 2013. Qualitative methods were used 
because they are appropriate when little information exists about a given topic as well as 
when a research project aims to understand people’s perspectives and the reasons behind 
them (Taylor et al. 2010, 193-195).  This study was approved by the Johns Hopkins 
Bloomberg School of Public Health IRB and the Geisinger Health System IRB. 
 
I. Study Setting and Sample 
Interviews and focus groups were conducted within two health care systems:   




sites were selected because they differ in ways that may impact individuals’ views on the 
appropriateness of implementing alternatives to prospective informed consent. GHS is a 
private, non-academic institution located in rural Pennsylvania that serves a 
predominantly Caucasian patient population and which has been “developing and 
refining an innovation infrastructure that can adapt to new evidence efficiently, and 
rapidly translate that evidence into care delivery” (Paulus et al. 2008). JHS is a large 
academic medical institution located mainly in an urban setting- Baltimore, Maryland 
that serves a racially diverse patient population. Although there is significant ongoing 
research within this institution, explicit policies and commitments for adapting and 
translating research findings similar to GHS do not exist in the same way at JHS.   
 
a. IRB Member and Research Interviews 
IRB members were eligible to participate if they were either an IRB chair or had 
been an IRB member for one year or longer. IRB community members were also 
included given their considerable IRB experience as well as their perspectives as non-
scientists.  Researchers were eligible if they were known to have, or were identified by 
colleagues as having, experience conducting CER.  A purposefully chosen sub-sample of 
eligible individuals at each institution was sent an invitation email explaining the study as 
well as how to opt-out. Specifically, IRB chairs were invited to participate first as were 
researchers who had a greater amount of experience conducting CER studies. If invited 
individuals did not respond or opt-out within a week, they were contacted by telephone to 
seek their willingness to participate.  Additional individuals were recruited using this 





b. Patient Focus Groups 
As described below, during the interviews and focus groups, participants 
discussed one of two hypothetical case studies; one case described a PCT comparing 
migraine drugs and the other described a PCT comparing hypertension drugs (table 1.1). 
Since individuals who have been diagnosed with a given health condition are more 
knowledgeable about that condition and it was thought that this knowledge made the 
topics discussed during the focus groups more relevant, only individuals who had been 
diagnosed with either migraines or hypertension were eligible to participate. Four of the 
eight focus groups (two at each site) were attended by individuals who had been 
diagnosed with migraines and 4 (two at each site) were attended by individuals who had 
been diagnosed with hypertension. Eligible individuals also had to be over the age of 18 
and had to have been receiving their health care at the health care system where the focus 
group was taking place for at least one year to ensure some familiarity with that system.  
At GHS, a random sample of patients who met the eligibility criteria and who 
lived within a short distance of the health care facility in Danville, PA were identified 
through Geisinger’s electronic medical record system and were mailed an invitation 
letter. The letter informed individuals about how to opt-out of the study and informed 
them that if they did not opt-out, they may receive a follow-up telephone call. A GHS 
representative called individuals who did not opt-out until a sufficient number of 
individuals had been recruited to the focus groups. At JHS, recruitment posters were 
hung in waiting rooms and exam rooms of two sites within the Johns Hopkins 




to contact the study investigator who screened individuals to verify that they met 
eligibility criteria. 
 
II. Interview and Focus Group Structure 
At the beginning of each interview and focus group, oral informed consent was 
obtained from participants. All interviews and focus groups were conducted by the same 
study investigator (DW). Interviews with professionals from GHS were conducted by 
telephone while most interviews with professionals from JHS and all focus groups were 
conducted in-person.  
 
a. Introductory Questions 
Participants were first asked several introductory questions. IRB members and 
researchers were asked about their professional experience and their perceptions of 
current informed consent regulations.  Patient participants were asked to discuss whether 
they had ever been asked to participate in medical research, what they believed the term 
‘medical research’ meant, and whether they thought it was important to conduct more 
research about treatments for migraines or hypertension.  
 
b. Discussion of a Hypothetical Case Study 
Participants were then given a brief description of CER and were read one of two 
hypothetical case studies developed for this project. The purpose of reviewing these case 
studies was to provide a more concrete example to which study participants could react. 




Administration (FDA) approved and widely-used drugs that are both taken orally and that 
are similar in terms of their side effect profiles. Also, in both cases, some additional 
burden was imposed on individuals enrolled in the PCT (table 1.1). The case study 
described why doing the hypothetical PCT was important, what participation in the PCT 
would entail, and how being enrolled in the PCT was different from receiving clinical 
care outside of the trial. One of the hypothetical case studies described a PCT comparing 
anti-hypertension drugs and the other described a PCT comparing drugs prescribed to 
relieve migraines. These two disease areas were selected because both are important 
areas for future CER. However, they also differ in ways that may affect individuals’ 
perceptions about the disease and treatments and subsequently their views about 
participation in a PCT as well as appropriate models of disclosure or authorization. 
Specifically, while migraines are a symptomatic condition, hypertension is a silent 
disease and while migraines are an acute, episodic condition, hypertension is a chronic 
condition.   
After reviewing the hypothetical case, participants were asked to discuss any risks 
of harm they thought existed for patients enrolled in the case study, any benefits to 
enrolled patients, and any social benefits resulting from the case study being conducted. 
IRB members and researchers only were also asked whether they were aware of any trials 
like the one described in the case study.   
 
c. Discussion of Four Different Models of Disclosure and Authorization 
Next, participants were told about four different models of disclosure and 




each. Most interviewees and all focus group participants were also told that a major 
difference between models 2 and 3 versus model 4 is the amount of information provided 
to eligible individuals. All 3 models inform patients about the PCT but with models 2 and 
3, the amount of information provided about the drugs being studied is similar to the 
amount of information provided in standard care, meaning patients are told about the 
main risks and are given additional information when they pick up the drug at the 
pharmacy. With model 4, the amount of information provided is typical of a standard 
informed consent form meaning patients are told about all the risks associated with the 
drugs.  
Participants were asked the following about each model:  
1. Please discuss whether or not you think this is an acceptable way of telling people 
about the medical research study we just discussed. 
2. Please discuss what you think the benefits of using this approach are. 
3. Please discuss any concerns you have about this approach. 
Participants were then asked to discuss which model they felt was most appropriate to use 
when enrolling patients in the PCT described in the case. During the focus groups, the 
study investigator (DW) specifically asked each participant in the group to state which 
model they preferred. 
Last, participants were asked to complete surveys with some demographic 
questions. The IRB member and researcher survey also had questions about participants’ 
experience conducting human subjects research and their past experience participating in 
research. The patient surveys had questions about participants’ past experience 




medical decisions to be made, and their trust in medical researchers. The materials used 
during the interviews and focus groups were very similar except that patients were 
provided with more information on key concepts such as medical research, CER, 
randomization, and selection bias. Prior to beginning the study, all project materials were 
pilot tested.  
 
III. Data Management and Analysis 
All interviews and focus groups were audio recorded and transcribed. Data 
analysis progressed in an iterative fashion. Transcripts were reviewed for accuracy and 
personal information was redacted. During this review, significant quotes and themes 
were noted.  Transcripts were then read more carefully and a coding scheme was 
developed. Once the coding scheme was finalized, all transcripts were read again and 
coded. Additionally, a second coder used the coding scheme to independently code three 
transcripts and a study investigator (DW) checked the coded transcripts for consistency. 
Because there was a high level of consistency among the way the codes were applied by 
the two coders, only minor changes were made to the organization of the coding scheme. 
The coded transcripts were then reviewed a final time and summary documents that 
described the main themes from each interview and focus group were developed. The 
study investigator (DW) also noted how many interviewees discussed each specific code. 
For the focus group data, the investigator noted how many focus groups discussed a 
certain theme, since recording numbers of participants would suggest false precision. 




were entered into excel, double checked to ensure accurate data entry, and analyzed to 
understand background characteristics of participants.   
This manuscript reports on data related to participants’ perceptions of the 
different models of disclosure and authorization. Data on patients’ perceptions of the 
importance of research, how patients prefer medical decisions to be made, and whether 
there is any relationship between these variables and the model of disclosure and 
authorization an individual prefers is reported elsewhere. 
 
Results from Interviews with Researchers and Institutional Review Board Members 
Interviews lasted between an hour and an hour and a half. One of the interviews 
was dropped from the analysis because the participant did not speak English very well 
and it was not clear that she understood the materials. The demographic characteristics of 
GHS participants were similar to those of JHS participants except that GHS participants 
were, on average, slightly younger (table 1.2). Additionally, interviewees from JHS had 
been employed by the institution for a longer period of time compared to interviewees 
from GHS and more JHS interviewees saw patients clinically (table 1.2). At each 
institution, one of the researchers interviewed was also an IRB member. Finally, the two 
African American interviewees from JHS were IRB community members. 
Three current or recent IRB community members from GHS were invited to be 





I. Perceptions of the Case Studies 
Most researchers and IRB members commented that there are problems with 
current informed consent requirements (n=14) including that consent forms are too long 
and complex (n=9) and that the process is ineffective (n=1) or overly protective (n=2). 
When asked if they were familiar with research like the PCT described in the 
hypothetical case, although many participants did provide an example or two (n=11) or 
mentioned that they thought that trials like this were going on (n=3), their comments 
suggest that they did not believe that these kinds of trials were common. When asked 
about risks of the case study trial, most participants commented that there were either no 
or minimal risks (n=8) or that the risks were the same as standard care (n=6). Other risks 
mentioned included the potential for a breach of confidentiality (n=8), the potential for 
conflicts of interests if the doctor treating a patient is also an investigator in the research 
(n=2), and the toxic side effects associated with the drugs (n=5). However, of those 
individuals who mentioned the risks associated with the drugs, over half commented that 
these are no different than the risks associated with standard care (n=3).  
Regarding benefits, many participants mentioned that patients in the case studies 
would receive closer monitoring (n=11), while others mentioned that the benefits to 
patients in the case studies are not greater than those associated with standard care (n=4). 
A large majority of participants also believed the results from the study would be socially 
beneficial:  
There’s benefit for society at large in advancing the field and 
knowledge…We’re going to learn something. We’re going to either 
learn that one of the drugs is better than the other, or they’re essentially 




Since there were no significant differences in the themes discussed by interviewees who 
reviewed the hypertension case study and interviewees who reviewed the migraine case 
study, the results from all interviews will be described together.  
 
II. Perceptions of Model 1: Disclosure of Institutional Policy 
A majority of participants felt that model 1 was unacceptable. Only three 
participants, all from GHS (2 researchers and 1 IRB member also involved in CER), 
believed that model 1 was acceptable and of these, only one participant felt that this was 
the best approach to use for enrolling patients in the hypothetical case study. Also, over 
half of the GHS respondents mentioned that the institution uses a similar model as a way 
of broadly informing patients that the institution does research using de-identified 
medical information and that they may be contacted to participate in research; patients 
can opt-out of either (n=5).   
 
a. Views Expressed by Participants who found Model 1 Acceptable 
The three GHS participants who found this model acceptable justified their views 
by describing the benefits this model would have in enhancing study validity (n=3) and 
improving the efficiency of the research (n=1). Additionally, all three emphasized that the 
study compares similar and widely-used drugs (n=3), one commented that doctors have 
the ability to switch a patient’s drug at any time (n=1), and another commented that the 
risk of harm to participants is minimal (n=1). One participant also mentioned that he 
believes that patients in a health care system should be helping to advance knowledge:  
My view is that if you’re part of the health care system… you should 
be part of advancing knowledge… [by] participating in research. I think 




However, because they recognized that model 1 infringes on the autonomous choice of 
individuals, one participant commented that patients should be able to broadly opt-out of 
participating in this type of research and two said there would need to be strict criteria 
regarding what types of activities qualify for this model:  
There will have to be really, really strict guidelines about what sets of 
drugs, and the relations between those drugs, in terms of evidence of 
superiority, inferiority, and risks are allowed to be called comparable 
and fall under this type of category. (GHSIRB1)  
 
 
b. Views Expressed by Participants who found Model 1 Unacceptable 
Although many participants recognized the benefits of model 1 for the case study, 
a majority of those who found it unacceptable justified their view with comments related 
to the theme of respect for autonomy (table 1.3) (Beauchamp and Childress 2009, 118-
135). Some participants mentioned that model 1 infringes on autonomous choice (n=6), 
many were concerned that information about the hypothetical study is not disclosed to 
participants (n=10) and many also felt that this model infringes on the ability of patients 
to make voluntary decisions (n=9). In order to justify their views further, most 
participants discussed aspects of the hypothetical case study design or the study setting 
including that the study imposes burdens on participants (n=9), may impose additional 
financial risks (n=2), alters clinical care (n=5) by limiting treatment options (n=1) or by 
randomly assigning patients to different treatments (n=3), and involves drugs which are 
inherently risky interventions (n=3). Additionally, several participants from JHS 
mentioned that there is a significant amount of distrust in the surrounding community and 
therefore, this is a particularly bad model to implement at JHS (n=3). Indeed, a few 




lack of trust in the community, felt that implementing this model could result in people 
feeling wronged or angered and could decrease trust in the institution (n=4): 
 [I would be] more concerned about the issue of people participating in 
research and not being aware of it, and the downstream bad effects of 
that in terms of undermining trust. (JHUIRB2)  
 
A couple participants also worried that if this model were used, studies would get done 
under this model that really required individual informed consent (n=2). 
 
III. Perceptions of the Acceptability of Model 2: Study Specific Disclosure with 
No Routine Option to Opt-Out 
Most participants also felt that model 2 was unacceptable. Only two participants, 
both of whom were from GHS and also found model 1 acceptable (1 researcher and 1 
IRB member also involved in CER), felt that model 2 was acceptable and only one of 
those felt that this model was the best model to use.  
 
a. Views Expressed by Participants who found Model 2 Acceptable 
The two GHS participants who found model 2 acceptable commented that 
compared to model 1, this model is more respectful of patient autonomy because patients 
are informed about the study (n=2). However, these interviewees did worry that because 
model 2 does not inform patients of the option to opt-out, it limits voluntary choice. Both 
individuals further commented that model 2 retains many of the benefits in terms of 
efficiency and enhanced internal and external validity. One individual commented that 
the reason he felt that model 2 was acceptable was because the hypothetical case study is 





b. Views Expressed by Participants who found Model 2 Unacceptable 
Similar to model 1, the reasons participants provided to justify why they felt 
model 2 was unacceptable mainly related to respect for autonomy (table 1.3). A few 
participants simply stated that model 2 is disrespectful or paternalistic (n=2), most 
expressed concern that this model limits voluntary choice (n=10), and many expressed 
concern that model 2 does not inform individuals of their options regarding participation 
(n=7), which one participant described as deceptive. Related, several participants worried 
that patients would not understand their options (n= 2) or would not understand that they 
are being enrolled in research (n=2). To further justify their view, several participants 
again discussed the same aspects of study design and setting that were discussed in 
reference to model 1, including that the study imposes additional burden (n=1), involves 
drugs (n=1), and alters care by limiting treatment options (n=2) or randomly assigning 
patients (n=2). Three participants also mentioned the level of distrust in the surrounding 
community:   
One of the other things that would have to be dealt with, and it might 
be very specific to Hopkins, is trust, and we’re in a community which 
… often does not trust what we do.  So to have studies conducted 
without consent opt-in…would just reinforce many people’s opinions. 
(JHUCER3) 
 
Several participants from JHS were also concerned that model 2 could result in people 
feeling wronged or angered or could increase distrust (n=5) and two participants worried 
that if this model were used, patients would just not do the extra things requested of them, 
which included completing surveys as well as going to the doctor’s office for two extra 
blood pressure reads or completing a migraine diary. One participant also commented 




IV. Perceptions of the Acceptability of Model 3: Study Specific Disclosure with 
an Explicit Option to Opt-Out 
A majority of interviewees believed that model 3 was acceptable, including seven 
interviewees from JHS and five from GHS, and five felt that this was the best model for 
the case studies. Importantly, most interviewees who felt this model was preferable were 
researchers (n=4). Five interviewees felt that this model was unacceptable and most of 
these were IRB members (n=4). Two IRB members from JHS commented that 
prospective informed consent (model 4) is the model they have spent a good deal of time 
enforcing. As a result, it was difficult for them to think about departing from it. 
 
a. Views Expressed by Participants who found Model 3 Acceptable 
Most interviewees who found this model acceptable justified their view by 
discussing themes related to respect for autonomy (table 1.3). A few participants just 
stated that model 3 is more respectful (n=3), others stated that they believed it gives 
patients a sufficient amount of control over their participation (n=8), and one participant 
said he felt that it was appropriate to require people to expend some energy to resist 
participating in the hypothetical case studies (table 1.3). To further justify why they felt 
that model 3 was appropriate, several participants discussed study design features 
including that patients can switch medication (n=2), that the study involves widely-used 
drugs (n=2), and the minimal risk nature of the research (n=3). Additionally, several 
researchers stated that model 3 is more efficient than model 4: prospective informed 





I think this is probably in my mind, the only model that really makes 
sense because it protects the doctor/patient relationship. It preserves 
autonomy, at the same time, facilitates research in a far greater capacity 
than the current system of an informed consent for [studies comparing] 
FDA-approved medications. (JHUCER4) 
 
However, a few participants felt that model 3 was only acceptable if it was relatively easy 
for patients to opt-out (n=3) and about half of the interviewees, including six who felt 
model 3 was acceptable and two who ultimately decided it was unacceptable, commented 
that the acceptability of model 3 depended on exactly what information was provided to 
eligible individuals (figure 1). Yet, a few participants also stated that it was appropriate 
for the amount of information provided about the drugs to be less than is generally 
provided in research prospective informed consent forms and/or more similar to the 
amount of information provided in standard care (n=3). 
 
b. Views Expressed by Participants who found Model 3 Unacceptable 
Many of the individuals who thought that model 3 was unacceptable had concerns 
related to respect for autonomy. One participant commented that he felt that having more 
information is always better, a few were concerned that individuals would not understand 
the full implications of being in the research study (n=3), and one was concerned that the 
decision to participate “may not reflect an authentic choice on the part of patients” 
(JHUIRB2).  Several also commented on the same aspects of the study design that led 
them to find models 1 and 2 unacceptable including that the study involves drugs (n=3), 
alters clinical care (n=2) by randomly assigning patients or limiting treatment options, 
and imposes burdens (n=1). Lastly, one participant from JHS was concerned that this 
model could negatively impact patient trust and that researchers would try to use it for 




V. Perceptions of the Acceptability of Model 4: Prospective Informed Consent 
All participants except for two researchers (one from each institution) felt that 
model 4 was acceptable.  Ten participants (three researchers and seven IRB members) 
said they thought it was preferred. Of these, eight were from JHS.  
 
a. Views Expressed by Participants who found Model 4 Acceptable 
A majority of those individuals who felt that model 4 was acceptable again 
emphasized themes related to respect for autonomy (n=11) (table 1.3) including that 
patients are most informed under this model (n=6), that patients have the greatest 
understanding of what study participation involves (n=3), and that the decision to 
participate is completely voluntary (n=7). About half of those who preferred model 4 
discussed aspects of the study design including the fact that the study involves drugs 
(n=2) and alters clinical care (n=2). Several participants also felt patients enrolling under 
model 4 would be willing participants, more likely to do the extra things asked of them, 
resulting in increased internal validity (n=4). Further, several participants felt that this 
model would result in increased trust (n=3) and improve the public perception of research 
(n=4).  
However, several participants, including about half of those who preferred model 
4, thought that the information provided to patients could be simplified (n=5): 
I think the key for this type of research is to have the information 
regarding risk to be akin to clinical practice…sort of Option 3 is more 
like that where you kind of say, “Look, I’m going to give you this 
medicine, anyway.  Here’s some things I want you to watch out for in 





b. Views Expressed by Participants who felt that Model 4 was Unacceptable 
Of those participants who felt that model 4 was unacceptable or unnecessary, 
several commented that using model 4 would have a negative impact on the ability to 
efficiently (n=2) do valid research (n=4) because only a select group of people will 
participate:   
I think it’s not as optimal for… the purpose that the trial is trying to 
accomplish which is to get a large, unbiased sample of people to 
generate information in a timely way. (GHSCER1)  
 
As a result, one participant believed that using model 4 would result in “learning a lot 
less.” (GHSCER2) Additionally, two participants commented that the amount of 
information provided when model 4 is used could scare or overwhelm patients. To further 
justify their views, several participants also discussed study design features including that 
the study compares widely-used drugs (n=3) and is minimal risk (n=3): 
If your goal is to test a new agent for which the risk/benefit is poorly 
defined, then fine…But it’s not your goal here.  What you’re saying is, 
“Look, we know the risk and benefit of each treatment, and experts 
acting independently have determined these are both appropriate. 
(JHUCER4)  
 
Results from Focus Groups with Migraine and Hypertension Patients 
Each of the eight focus groups had between three and eight participants and lasted 
between two and a half and three hours. A total of 38 patients participated in these focus 
groups. Demographic characteristics of participants are reported in table 1.4. A majority 
of the participants were female, especially in the migraine focus groups, and, on average, 
migraine participants were slightly younger than participants with hypertension. Both 
trends were expected given that a majority of migraine sufferers are females and given 
the differences in the average age of individuals impacted by these conditions (Migraine 




anticipated, racial differences existed between participants from JHS and GHS (table 
1.4). Numbers reported in parenthesis in this section refer to the number of focus groups 
in which a certain theme was discussed, rather than the number of individuals who 
discussed a specific theme.  
 
I. Perceptions of the Hypothetical Case Studies 
When asked about risks of the case study trial, participants from five different 
focus groups mentioned that they believed that there were no or minimal risks or that the 
risks were the same as the risks associated with standard care. However, many 
participants from six different groups also commented that there are always risks 
associated with taking a newly prescribed medication. Additionally, one participant 
discussed the risk of a breach of confidentiality and one mentioned that there was a risk 
associated with narrowing treatment options available to patients. Regarding benefits, 
several participants mentioned that patients in the case studies would receive closer 
monitoring (n=5 groups), several mentioned that patients in the studies would be treated 
for their condition and/or that they might find a drug that works well for them (n=6 
groups), and a few indicated that patients in the studies can feel good about helping 
others (n=3 groups). Participants from all focus groups felt that the hypothetical case 
studies would provide useful information and/or would help to determine which drugs are 
best for which types of people: 
The more information they collect, then doctors will become more 
aware of which ones are helping and [in] which circumstances. 
(GHSMIG3 P4) 
 
One participant also commented on discussions she had had with her doctor regarding the 




Many times I say to my doctor, which one is best…And he says, flip a 





II. Perceptions of Model 1: Disclosure of Institutional Policy 
Most focus group participants from JHS and about half of the focus group 
participants from GHS felt that model 1 was unacceptable; stated differently, at least 
some individuals from seven of the eight focus groups stated that this model was 
unacceptable. Of the few JHS participants who believed model 1 was acceptable, only 
two participants from the same focus group felt it was the best model to use. At GHS, 
close to half of the individuals who believed model 1 was acceptable stated that it was the 
best model to use (n=2 groups). Interestingly, all GHS participants who stated that model 
1 was preferable were individuals with hypertension.  
 
a. Views Expressed by Participants who found Model 1 Acceptable 
Many participants who found model 1 acceptable justified their view by 
discussing different features of the study design.  This included that the case studies 
compare widely-used drugs (n=3 groups), that patients who are eligible for the case 
studies are treatment naïve and need to be prescribed a drug anyway (n=2 groups), and 
that patients can switch treatments if needed (n=2 groups): 
To me, doesn’t seem that big of a deal, because, okay, I’m newly 
diagnosed, just like what I was 13 years ago. [The doctor says] “We’re 
going to start you on this med.”  Great.  Okay.  So this med happens to 
be part of this trial.  Doesn’t really bother me, probably going to start 
me on that med anyway, and if it doesn’t work, he’s going to switch me 
from it anyhow. If it does work, great, we don’t need to mess with it.” 





A few participants from two different focus groups mentioned that their health care 
institution is a teaching/research hospital and that they expect that research is going on all 
the time: 
I was assuming that’s what was going on all the time anyway [studies 
like the ones described in the case]…it’s a teaching hospital. I think 
every hospital needs to do something like this. (GHSHTN2 F12) 
 
Additionally, several participants mentioned the benefits model 1 would have in terms of 
improving the efficiency of trial enrollment, decreasing costs, and allowing the research 
to be completed quickly (n=3 groups).  
However, like interviewees, several focus group participants felt that model 1 was 
only acceptable under certain conditions. A few participants from one focus group felt 
that model 1 was only acceptable if no additional costs would be imposed on patients.  A 
couple of participants from a different focus group thought that there needed to be some 
way to demarcate those activities that patients were being asked to do that were not part 
of standard care. Additionally, several participants felt that patients should be able to 
broadly opt-out (n=3 groups) and a few mentioned that it was important to frequently 
remind patients about the institutional policy (n=3 groups).  
 
b. Views Expressed by Participants who found Model 1 Unacceptable 
Although participants generally recognized the benefits of model 1, many 
participants who stated that this model was unacceptable justified their view with 
comments related to respect for autonomy (n=7 groups) (table 1.3). Many participants 
expressed concern that patients are not informed about the study (n=6 groups) and/or that 
model 1 infringes on voluntary choice (n=5 groups). Additionally, many participants felt 




groups), one participant mentioned that the case alters clinical care and relies on personal 
health information, and one JHS participant mentioned the lack of trust in the 
community.  
Many participants from five different focus groups, including all four JHS focus 
groups, also felt that model 1 could result in people feeling angered or upset or losing 
trust. Additionally, several participants felt that patients would not be willing to do the 
extra things asked of them (n=3 groups):  
If you’re asked … to write stuff down, you may just think that’s no big 
deal, but if you knew you’re writing this down as part of a study and 
that your opinion counted, you’d be a lot more committed to actually 
following through. (GHSMIG2 F9)  
 
Finally, one participant was concerned that if model 1 were allowed for some kinds of 
research, it would end up being used in situations where it is inappropriate.  
 
III. Perceptions of the Acceptability of Model 2: Study Specific Disclosure with 
No routine Option to Opt-Out 
A vast majority of participants from each of the eight focus groups felt that model 
2 was unacceptable. Only one JHS participant and only a few GHS participants from 
three different focus groups felt that this model was acceptable. Of those, only one GHS 
participant stated that this was the best model to use.  
 
a. Views Expressed by Participants who found Model 2 Acceptable 
The few participants who felt that model 2 was acceptable discussed features of 
the study design including that the case study allows switching (n=1 group) and compares 




So it’s not like it’s a brand [new drug] …at least it’s been out there in 
the market and people are not walking and hitting the floor, you know 
what I mean?... I really just don’t see any difference.  If I got to take 
something new, I don’t know anyway what’s going to happen to me, 
till you take it. (JHUHTN2 F2)  
 
A couple participants in the same focus group also highlighted the benefits of this 
model in terms of allowing research to be completed faster and at a lower cost and one 
participant said that she is fine with model 2 because she trusts her doctor and knows he 
would not enroll her in anything harmful.  
 
b. Views Expressed by Participants who found Model 2 Unacceptable 
A majority of participants who found model 2 unacceptable again had concerns 
broadly related to respect for autonomy (n=8 groups) (table 1.3). Many participants 
mentioned that model 2 is deceptive and/or that patients should be told about the option 
to opt-out (n=8 groups). Others commented that this model pressures people to 
participate (n=7 groups) and a few worried that participants would not understand their 
options or that they are in a research study (n=2 groups).  
Features of the study design or study setting were not widely discussed with the 
exception of participants from one focus group mentioning that the case study imposes 
additional burdens. However, some participants felt that if model 2 were implemented, 
patients would be less likely to do the extra things asked of them (n=3 groups) and/or that 
this model would result in patients feeling upset or angered or losing trust in their doctor 
or health care institution (n=6 groups):  
You know, you’re supposed to be able to trust your doctor, and…that’s 
sort of not being very trustworthy…he’s not tell you everything. In fact, 





Finally, a couple participants commented that this model is not that much more efficient 
than model 3 (n=1 group). 
 
IV. Perceptions of the Acceptability of Model 3: Study Specific Disclosure with 
an Explicit Option to Opt-Out 
An overwhelming majority of participants believed that model 3 was acceptable 
and of those who believed it was acceptable, almost half felt that this was the best model 
to use. Multiple participants from each of the eight focus groups stated that they believed 
this was an acceptable model. Although individuals from both institutions believed this 
model was acceptable, a far greater number of participants from GHS stated that this is 
the model they felt was the best model to use.  
 
a. Views Expressed by Participants who found Model 3 Acceptable 
A majority of those participants who found model 3 acceptable justified their 
view by discussing themes related to respect for autonomy (n=8 groups) (table 1.3). 
Several commented that this model is more respectful (n=2 groups), a number of 
participants liked that patients are informed about the study as well as their ability to opt-
out (n=7 groups), and several liked that patients have more control over their 
participation (n=5 groups). Related, a couple participants did not think it was overly 
burdensome for patients to have to opt-out (n=3 groups).  
A few participants also felt that, compared to model 4, the amount of information 
disclosed would be less likely to scare or overwhelm patients (n=3 groups):  
This…actually seems like a really nice balance between getting people 
to acknowledge and understand what they’re getting into versus the 




Moreover, several participants discussed the benefits model 3 could have in terms of not 
betraying trust or making people feel upset or angered (n=1 group) as well as in terms of 
selecting patients that are more willing to participate (n=3 groups). Most participants did 
not discuss features of the study design when justifying their views, although a couple did 
highlight that the study involves widely-used drugs (n=2 groups).  
However, a number of participants did express some concerns about model 3. 
Several mentioned that model 3 may result in lower participation rates (n=6 groups) 
and/or that it is less efficient and more costly compared with models 1 and 2 (n=3 
groups).  For these reasons, some participants who felt that model 3 was acceptable felt 
that model 1 was preferable, while other participants felt that because model 3 is more 
respectful of autonomy, it was still preferable to models 1 or 2.  
 
b. Views Expressed by Participants who found Model 3 Unacceptable 
Only two participants, one from each institution, stated that they felt that model 3 
was unacceptable. One JHS participant stated that she did not believe it was appropriate 
for patients to “have to go through the trouble to opt-out” (JHUMIG1 F4) if they did not 
want to participate, while one GHS participant emphasized the low-risk nature of the 
research as well as its social value and felt that giving patients the ability to opt-out really 
compromised the ability to do this type of research. 
  
V. Perceptions of the Acceptability of Model 4: Prospective Informed Consent 
A majority of participants also felt that model 4 was acceptable, including 




it was preferable. A far greater number of participants from JHS felt that model 4 was 
both acceptable and preferable when compared to participants from GHS, who found it 
acceptable but were more likely to find other models preferable. Just under half of the 
participants from GHS from three different focus groups felt that model 4 was 
unacceptable.  
 
a. Views Expressed by Participants who found Model 4 Acceptable 
A majority of participants who stated that they felt that model 4 was acceptable 
justified their view by discussing themes related to respect for autonomy (table 1.3). A 
few participants felt that model 4 was the most respectful of patients (n=2 groups) and 
several commented that patients are the most informed and/or that the decision to 
participate is completely voluntary under this model (n=6 groups). However, one 
participant who felt that this model was preferable also felt that it was unnecessary to 
give patients information on all the potential risks associated with the drugs:  
What I need to know is that this is a study, and we’re comparing two 
drugs… these are the main side effects of the one, and this is the main 
side effects of the other … if you choose to participate, you’re going to 
be randomly assigned to one of them, and we’re going to see how it 
goes, and we want you to do these things.” (JHUMIG1 F4) 
 
Additionally, a few participants felt that if model 4 were used, patients would be more 
willing to do the extra study-related activities (n=2 groups) and a couple patients from 
JHS felt that using model 4 could help improve trust (n=2 groups). 
 
b. Views Expressed by Participants who found Model 4 was Unacceptable  
Many participants who stated that model 4 was unacceptable felt that the amount 




individuals (n=3 groups). This concern was also raised by several participants who felt 
that this model was acceptable but not preferred (n=2 groups):  
I think it’s information overload… I don’t think it would benefit the 
person because they’re listing everything … [the patient would] just 
walk out of there going, huh? (GHSMIG1 F1)  
 
Additionally, several participants commented that if model 4 were used, it is likely that 
fewer patients would participate (n=4 groups) and/or that this model is more time 
consuming and more costly than the other models (n=4 groups). Finally, a few 
participants commented that they felt that model 4 was unnecessary because the case 
studies compare widely-used drugs (n=2 groups):  
What comes to my mind is … that you're using drugs that are already 
readily used in the treatment of people with blood pressure and they're 
being evaluated by their doctor ahead of time… So, to do this [model 
4]… I think is overkill… but to draw from my experience, I'm taking a 
drug that's not available in the marketplace that's reached a certain level 
of human testing so that I'm very comfortable with [it]… So that's 
where you use something like this [model 4] whereas the scenario we're 
talking about does not require this extreme control. (GHSHTN2 M13) 
 
Discussion 
The goal of this study was to understand what patients, IRB members, and 
comparative effectiveness researchers thought were acceptable approaches for disclosure 
and authorization of low-risk PCTs.  Participants were asked to discuss the acceptability 
of four different disclosure and authorization models for PCTs comparing widely-used 
blood pressure or migraine medicines.  Although participants generally agreed that doing 
this type of research was socially beneficial, of potential benefit to enrolled patients, and 
that there were no or minimal risks, participants differed in their views about the 




One thing that most participants did agree on was the importance of preserving 
autonomous choice. Both interview and focus group respondents spoke of the importance 
of information disclosure and voluntary choice in reference to all 4 models, and the 
theme of respect for autonomy emerged more than any other broad theme in this study. 
Many participants felt that respect for autonomy was particularly important because the 
PCTs described in the case studies imposed additional burdens on participants and 
because not allowing patients to make a voluntary choice could result in patients feeling 
wronged or angered or losing trust in their physician or health care institution. Since 
many participants felt that models 1 and 2 infringed on components of autonomous 
choice, most participants felt that these models were unacceptable. Participants generally 
viewed models 3 and 4 to be more respectful of autonomy since both models explicitly 
inform patients about the research as well as about the voluntariness of participation.  
Likely because of this, most participants believed that both of these models were 
acceptable.  
Nevertheless, although most participants felt that both models 3 and 4 were 
acceptable, their views were mixed in terms of which model they felt was preferable. 
About one-third of interviewees, most of whom were researchers, and about half of 
patient participants preferred model 3.  These respondents described it as best balancing 
concerns about respect for autonomy with concerns about being able to efficiently do 
high quality PCTs.  However, some participants who favored model 3 emphasized the 
importance of ensuring that it was relatively easy for patients to opt-out. Also, several 
participants explicitly mentioned that the reason that they felt that model 3 was 




used drugs that had similar side effects, and allowed switching, indicating that they felt 
that it was appropriate to have different disclosure and authorization requirements for 
different types of research. 
Just over half of the interview respondents, a majority of whom were IRB 
members, and just over a quarter of patient participants stated that they preferred model 
4.  These participants felt that model 4 was most respectful of autonomy and because of 
this, some felt it would result in the greatest cooperation with study activities and the 
greatest amount of trust.  Given this, although many recognized that model 4 would 
increase the risk of selection bias and that it was more time consuming and costly than 
the other models, they felt that the benefits described above outweighed these drawbacks.   
Still, several participants who preferred model 4 –like those who preferred model 
3-- also felt that the information disclosed to patients could be simplified. This finding is 
supported in the literature where, for more than 20 years, scholars have discussed the 
need to simplify the information disclosed in informed consent documents (Davis et al. 
1998; Dresden and Levitt 2001; Rogers et al. 1998; Strunkel et al. 2010) and more 
recently, several scholars have specifically argued that it is appropriate to simplify 
disclosure for low-risk RCTs comparing widely-used therapies (Van Staa et al. 2012; 
Wendler and Grady 2008).   
Unfortunately, since opt-out approaches are rarely allowed under the current 
human subjects research regulations for enrollment of patients in low-risk trials of 
widely-used interventions, there is little direct evidence related to the impact opt-out 
compared to opt-in models of enrollment have on patients’ willingness to do extra 




of how opt-out models impact trust in health care professionals or institutions. The one 
study of which we are aware that looked at the impact of opt-out approaches for 
enrollment suggests that the use of opt-out approaches does not have a negative impact 
on the willingness of participants to do extra activities (Roger et al. 1998). Additionally, 
there is some evidence that when opt-out approaches are used for recruitment of 
individuals to an observational study, participants are still willing to do the extra 
research-related activities asked of them (Junghans et al. 2005). Although the small 
amount of available evidence suggests that individuals are willing to participate in 
additional study-related activities when opt-out approaches are used, future research 
should verify this and there is also a need for additional research to understand if opt-out 
models like model 3 have any impact on patients’ trust in health care professionals or 
institutions.  
Another important finding is that the respondents who preferred model 4 were 
much more likely to be from JHS than from GHS. Similarly, IRB members were more 
likely to prefer model 4 than were researchers and patients.  Perhaps related, many 
respondents from JHS spoke of distrust in the community surrounding JHS. Likely as a 
result of this, participants from JHS referred to the impact that they believed explicit 
consent might have on participants’ trust in research and believed it to be important for 
this reason. The literature also has examples of individuals who have less trust in their 
health care institution or the group doing the research tending to prefer models of consent 
that give them more control over their participation (Damschroder et al. 2007). 
Additionally, as mentioned by several IRB members and researchers from GHS, GHS 




research that involves random assignment of participants to different therapies. 
Importantly, however, no patient participants mentioned that GHS has this policy, which 
could suggest that patients are not aware or do not remember that this policy is in place. 
A possible reason that IRB members were less likely than researchers and patients to 
prefer alternatives to model 4 is that, as mentioned by two interviewees, IRB members 
have spent a significant amount of time trying to enforce the current standard of 
prospective informed consent and therefore, they may be more tied to this model than 
other stakeholders. Patients may also have been more likely to prefer model 3 at least in 
part because of a view expressed by many patients, but only 2 interviewees, that the 
amount of information disclosed when model 4 is used could scare or overwhelm eligible 
individuals. 
It is also important to highlight that although there was a significant amount of 
support for the use of model 3 and although many participants agreed that the amount of 
information disclosed could be simplified, several IRB members and researchers noted 
that the acceptability of this model depends on exactly what information is provided to 
patients. Therefore, future research should be conducted to address the question of what 
information needs to be provided as part of a more streamlined study-specific disclosure. 
Also interesting is that only a few interviewees and just one patient participant discussed 
random assignment as relevant to their views regarding the acceptability of the different 
models. This could be because participants did not feel that random assignment increased 
risk of harm to individuals and therefore it was not an important consideration or because 
they recognized that when there is a lack of evidence regarding the comparative 




treatment choices are made in ordinary clinical practice” (Kass et al. 2012). However, in 
the case of patients, it is not possible to say whether this is because patients did not 
believe this was a relevant consideration or if it was because at least some proportion of 
patients did not understand the concept of randomization, even though the process of and 
rationale for random assignment was discussed in detail during each focus group.  
Other limitations of this study are that both institutions from which participants 
were recruited are engaged in a significant amount of research and it may be that 
individuals from institutions that do not regularly engage in research would have a 
different perspective on the acceptability of the different models. Further, the four models 
of disclosure and authorization were presented in the same order during each interview 
and focus group and it may be that the order in which the models are presented could 
affect participants’ perceptions of those models. Additionally, individuals who 
participated in the focus groups may have different perspectives compared with 
individuals who were unwilling or uninterested in participating in this study. Finally, no 
IRB community members from GHS participated in this study and therefore, there is no 
information on the views of this stakeholder group.  
In general, because this was the first study of this kind that we are aware of, it is 
necessary to perform additional research on this topic to gather more information 
regarding the views of different stakeholders of the acceptability of alternative processes 
to prospective informed consent. Currently, there is an ongoing effort to gather additional 
evidence of the acceptability of several of these alternative processes for enrolling 
patients in both observational and randomized CER studies where no additional burden is 




which factors are most important to patients and other stakeholders as they consider 
which approaches to disclosure and authorization are most important to them for different 
types of studies.  
 
Conclusions 
The results of this qualitative study provide some preliminary evidence that 
stakeholders favor simplifying the amount of information provided to participants about 
PCTs comparing widely-used drugs. The results also suggest that participants generally 
found opt-out approaches acceptable for this type of research as long as patients were 
informed that they could opt-out and doing so was relatively easy. Nevertheless, many 
participants still preferred traditional prospective informed consent.   Since, as was 
suggested by the comments provided by IRB members and researchers, studies like those 
described in the hypothetical cases are not widely done at this time, the additional time, 
cost, and risks to the validity of PCTs when prospective informed consent is used may 
not seem to present an important problem to these respondents and they may not think it 
is reasonable to allow alternatives to prospective informed consent to be used for such a 
small body of research.  Nevertheless, given the interest in being able to more routinely 
generate evidence of comparative effectiveness as well as interests in transforming the 
U.S. health care system into a learning health care system (Olsen et al. 2007), it is likely 
that PCTs will become more prevalent.  As they do, it may be that stakeholders’ 
perceptions of the acceptability of these alternative models to prospective informed 
consent will change as well. For now, it is important to consider the moral permissibility 




continue to collect additional information regarding stakeholders’ perceptions, and to 
continue to discuss the purpose of such research with health care consumers.  That way, 
future policy alternatives can be supported by evidence about which options are both 




Tables and Figure 
  
Table 1.1: Description of Hypothetical Case Studies and Models of Disclosure and Authorization  
 
Summary Points 
Description of:  
(1) a hypothetical 





(2) a hypothetical 




 This PCT is designed to compare two widely-used, evidence-based drugs that 
are similar in terms of their route of administration and side-effect profiles 
 To be eligible to participate, patients must be treatment naïve and their doctor 
must confirm that either of the drugs in the PCT are reasonable options for the 
patient 
 Enrolled patients are randomly assigned to one of the drugs being compared in 
the PCT 
 A physician is allowed to switch his/her patient to a different drug or prescribe 
add-on therapies if the drug is not working or if the patient is not satisfied with 
the drug 
 Care remains unchanged except: 
 Participants complete short surveys with questions about their use of and 
satisfaction with the prescribed drug 
 Participants in the migraine PCT complete a migraine diary for the next 3 
migraines they experience 
 Participants in the hypertension PCT return to the clinic for 2 additional 





 Individuals in a health care system are informed broadly that the system 
engages in CER of widely-used interventions and that sometimes patients are 
enrolled in these studies if they already need that general type of medicine.  
 Patients who might have been given either of the drugs in the study anyways 
might automatically be enrolled in these studies if they are eligible.  
 Patients are also informed how rights and interests are protected. 
Model 2: Study 
specific disclosure 
with no routine 
option to opt out  
 Patients are told that their health care system does a lot of medical research 
studies to compare widely-used drugs to each other to figure out which drugs 
work best.  
 If a patient is eligible for one of these studies, that patient is told about the 
study and then enrolled.  
 Patients can opt-out of the study, although they are not told this explicitly.  
Model 3: Study 
specific disclosure 
with an explicit 
option to opt out  
 Patients are told that their health care system does a lot of medical research 
studies to compare widely-used drugs to each other to figure out which drugs 
work best.  
 If a patient is eligible for one of these studies, that patient is told about the 
study and is also told that if he or she does not want to be part of the study, he 
or she can opt-out.  
 If a patient does not opt-out, he or she is enrolled in the study.  
Model 4: 
Prospective 
informed consent  
 Patients are told that their health care system does a lot of medical research 
studies to compare widely-used drugs to each other to figure out which drugs 
work best.  
 If a patient is eligible for one of these studies, that patient is told about the 















Total                        
(n=17) 
Variable n n n n 
Gender 
Female 2 2 4 
Male 8 5 13 
Race 
Caucasian 8 7 15 
African 
American 
2 0 2 
Other* 0 0 0 
Ethnicity Hispanic 0 0 0 
Age 
< 39 0 2 2 
40-59 8 5 13 
> 60 2 0 2 




<10 years 0 7 7 
>10 years 7 0 7 
Sees Patients 
Clinically (n=14)  
Yes 5 0 5 




Research (n=14)  
< 39% 1 1 2 
40%-59% 3 2 5 
> 60% 3 4 7 
Previous Experience 
Participating in 
Research as a Patient 
or Healthy Volunteer 
Yes 6 4 10 
No 4 3 7 
*Other includes American Indian or Alaska Native, Asian, Native Hawaiian or Other 
Pacific Islander 
**No IRB community members participated from Geisinger Health System 
This question was not asked of IRB community members because it was not relevant to 
this stakeholder group. Therefore, the total number of participants who answered this 




Table 1.3: Selected Participant Comments Related to the Theme of Respect for Autonomy or Components of Respect for Autonomy 




“I just don’t think it respects 
people’s autonomy.” 
(JHUCER1)  
“Yeah, that just takes away all 
autonomy.” (GHSIRB3) 
“I’d feel like the option 2 I don’t 
get no respect. Option 3 is I get 
some respect.” (JHUHTN1 
M1) 
“It’s the most formalized way 
to respect people’s autonomy 






“I’m a full disclosure kind of 
guy. They need to know 
they’re in a study and they 
need to know why they’re 
doing things, like writing 
down for the doctor because 
they need to know it’s not 
part of normal treatment.” 
(JHUIRB CM3) 
 
“I don’t think it’s right that you 
don’t know that you’re part 
of a study…you should 
know what’s being done to 
you.” (GHSMIG1 F1) 
 
“It’s a big deal if that do a 
study behind my back…it is 
sneaky in a way.” 
(JHUHTN1 M1) 
“Not informing people that they 
have the option to opt-out is 
the major issue here if in fact 
some people would have that 
option and it’s just a question 
of saying, “If you don’t want 
to do this you don’t have to.”” 
(JHUIRB1) 
 
“I don’t really care for that 
one…My husband … would 
go and not question his doctor 
at all, whatever the doctor 
would tell him, that’s what he 
would do…He would not 
understand any of that stuff 
…if you gave him the option 
[to opt-out] I think he would 
understand it more.” 
(GHSHTN1 F8) 
“It seems reasonable because they 
are informed of this particular 
study, and then they’re also 
told that they can opt-out.” 
(GHSCER2) 
 
“That’s more informative than the 
other one. The person does 
have the option to opt-out…the 
doctor does tell the patient 
right up front.” (GHSMIG2 F5) 
 
“I feel better about this one than 
the second one because of the 
openness about it.” 
(GHSHTN1 M6) 
“On the information scale there 
appears to be more 
information…So I think that 
gives patients more of a 
sense … of being able to 
control this process.” 
(JHUIRB 3) 
 
“I think the subjects have the 
opportunity to understand 
that they’re part of research 
and understand what that 
means for this particular 
study.” (JHUCER2) 
 
“You feel better when you have 
more information about 





“It sort of takes that 
[voluntariness] off the table.  
I mean … you could argue 
that they’re volunteering 
because they’ve been told 
that this is going on and you 
have the option to go to 
another system.  But not 
everybody has that option of 
mobility.  So people who are 
“I think in some ways, we have 
to – you could argue we 
almost have to bend over 
backwards to allow people to 
opt-out as opposed to making 
it harder for them to opt-out in 
terms of the issue of 
voluntariness.” (JHUIRB2) 
 
“The patient might feel like 
“I think that it is important… that 
they don't have to expend too 
much energy if [they want to 
opt-out]... But I’m in favor of 
making them expend some 
energy to get out of trial as 
opposed to just making it a 
pure choice between yes or no 
… given the low risk of this 
study and the possible benefit, 
“Well, I think it has the best 
chance of maximizing the 
patient’s voluntary informed 
choice.  So I think there are a 
lot of barriers to getting an 
authentic voluntary consent, 
even with this approach, but 
without this approach, I 





sort of captive in this 
particular system … [so] I 
don’t really think there’s the 
same level of voluntariness 
there.” (JHUIRB2) 
 
“I think if they want to do a 
study, they need your 
permission at all 
times…They’re basically 
saying they [patients] don’t 
have a choice.” (JHUMIG1 
F3) 
they’re railroaded. The doctor 
said I have to be in this, so 
then they would just – they 
wouldn’t know they had a 
choice. [The patient might] 
feel betrayed, sort of, that 
they’re thrown into a study.” 
(GHSHTN1 F3) 
it's okay to assume a default 
position that's efficient.” 
(GHSCER1) 
 
“The other two [models 1 and 2], 
the patients are generally 
saying, “Oh, okay.” But this 
you’re starting to get the 
patient to be more directly 
involved in that decision.” 
(GHSHTN2 M13) 
 
“It’s like opt-in versus opt-out, 
I always want to opt-in…it 
shouldn’t be harder for 
















Variable Category n n n 
Gender 
Female 11 16 27 
Male 5 6 11 
Race 
Caucasian 6 22 27 
African American 10 0 10 
Other* 0 1 1 
Ethnicity Hispanic 0 1 1 
Age 
< 39 1 2 3 
40-59 12 12 24 
> 60 3 8 11 
Education Level 
Less than High School 1 0 1 
High School Diploma/GED 4 10 14 
Some College 1 3 4 
College Degree 4 5 9 
Graduate Level Degree 4 3 7 
Other 2 1 3 
Previous Experience 
Participating in 
Research as a 
Patient or Healthy 
Volunteer 
Yes 11 5 16 
No 5 17 22 
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Paper 2: Rethinking the Balance of Self-Determination Interests with 
Interests in Achieving High Quality Health Care  
Abstract 
As the number of quality improvement and comparative effectiveness activities 
continues to increase, questions have emerged regarding whether it is always necessary to 
obtain prospective written informed consent from individuals participating in these 
activities. Determining whether consent is necessary requires balancing interests 
individuals likely have in being able to decide whether or not to participate with other 
interests individuals and societies likely have in being able to access high quality health 
care. This paper aims to further clarify when it is morally permissible to waive or alter 
informed consent requirements for quality improvement and comparative effectiveness 
activities by employing Madison Powers and Ruth Faden’s theory of well-being and its 
relationship to self-determination interests. This paper argues that in order to justify 
waiving or altering consent requirements, it is important that quality improvement or 
comparative effectiveness research activities address issues of relevance to the setting or 
settings in which they are conducted and that those settings have a plan in place to 
implement the results from those activities. This paper further argues that there are 
certain features of these types of activities that impact the likelihood that the decision to 
participate will engage important self-determination interests that individuals have. These 
features include the health benefits and risks of harm to individuals enrolled, the burden 
imposed on participants, and whether the activity limits the ability of individuals to 
participate in health care decisions that engage meaningful preferences that they have.  




having access to high quality medical care, when it is likely that the results from the 
activity will be used to improve care and it is unlikely that an activity will impact 
important self-determination interests that individuals have, individuals likely do not 
have overriding interests in the decision to participate in those activities and as a result, 
waiving or altering informed consent requirements is morally permissible. Drawing on 
this analysis, this paper delineates a number of recommendations regarding morally 
permissible alternatives to prospective informed consent for quality improvement and 
comparative effectiveness activities.   
 
Background and Introduction 
Increasingly, there is a growing recognition of the lack of high quality evidence to 
support many clinical and health care policy decisions. In response, there have been 
efforts to systematically gather evidence from ordinary or slightly modified clinical 
encounters to better learn what does or does not work in ongoing clinical practice 
(Institute of Medicine 2007; Selby and Krumholz 2013). Two areas that embody this 
learning from standard or slightly modified clinical practice, and that will serve as the 
focus of this analysis, are quality improvement (QI) and comparative effectiveness 
research (CER). QI has been defined as “systematic, data-guided activities designed to 
bring about immediate improvements in health care delivery in particular settings” (Lynn 
et al. 2007) while CER has been defined as “the conduct and synthesis of research 
comparing the benefits and harms of different interventions and strategies to prevent, 
diagnose, treat and monitor health conditions in “real world” settings” (Federal 




definitions suggest, many QI and CER activities
2
 are distinct from earlier phase clinical 
research in that they are designed to systematically implement or compare different, 
widely-used, non-experimental therapies, diagnostics, or processes of delivering care in 
order to determine which is most beneficial. 
Scholars generally agree that engaging in QI and CER is valuable as it furthers 
interests that societies and individuals have in high quality health care and therefore, it is 
important to ensure that these sorts of activities are conducted. Some scholars have also 
recognized that informed consent requirements can sometimes create practical barriers to 
the efficient implementation of these activities (Van Staa et al. 2012). This is because 
informed consent requirements are resource intensive, time consuming, and sometimes 
impractical (Dubler et al. 2007; Manson and O’Neill 2007, 116; Lynn et al. 2007; Lo and 
Groman 2003; Peddicord 2010). In addition, engaging in informed consent may result in 
selection bias, thereby threatening the validity and thus the social value of certain 
activities (Miller 2008; Largent, Joffe, and Miller 2011; Tu et al. 2004).  As a result of 
these considerations and because many QI and CER activities require large sample sizes 
to detect small but clinically meaningful differences in clinical outcomes, several scholars 
have argued that traditional informed consent procedures are ill suited and not morally 
required for at least some subset of QI and CER activities (Baily et al. 2006; Dubler et al 
2007; Faden et al. 2013b; Miller and Emanuel 2008; Largent, Joffe, and Miller 2011; Lo 
and Groman 2003; Lynn et al. 2007; Peddicord 2010; Sabin et al. 2008; Selker et al. 
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 The word “activity” will be used throughout this paper instead of “research” or “practice.” This is because 
there is some discussion regarding whether the labels of “research” and “practice” are really that useful for 
making decisions regarding the necessity of oversight and informed consent (Faden et al. 2013a) as well as 
some discussion regarding if and when quality improvement efforts should be considered research 
(Casarett, Karlawish, and Sugarman 2000; Harrington 2007; Lynn et al. 2007). Attempting to address these 




2011). To justify this view, many of these scholars also point out that most QI and CER 
activities are designed to generate information on widely-used, non-experimental 
interventions and generally do not significantly alter patients’ medical care. Nevertheless, 
scholars also recognize that it is important to demonstrate respect for the moral status of 
individuals participating in these activities.  
How to balance these different considerations is a matter of some debate. This 
paper aims to further clarify when it is morally permissible to waive or alter informed 
consent requirements for QI and CER activities. To accomplish this aim, this paper will 
employ Madison Powers and Ruth Faden’s theory of well-being and its relationship to 
self-determination to further claims made in the literature about the moral permissibility 
of waiving or altering informed consent requirements for at least some subset of QI or 
CER activities. This paper will also incorporate current thinking from a recently 
developed framework for learning health care systems (Faden et al. 2013a). 
Although it has not previously been applied in this context, Power and Faden’s 
theory is helpful in justifying why all liberty interests are not deserving of equivalent 
levels of policy protection as well as why it is that certain features of an activity and of 
the health care system in which that activity is being implemented are important to 
consider when making decisions about the moral permissibility of limiting, in some way, 
the ability of an individual to make a choice regarding his or her participation in that QI 
or CER activity. After describing the relevance of Powers and Faden’s theory, this paper 
will review those features of an activity and the health care system in which it is 
implemented that are important to consider when making decisions about the moral 




moral significance of these features is not unique to QI and CER activities, this paper will 
explore their relevance within these contexts. Based on this analysis, this paper will 
discuss when it is permissible to waive or alter informed consent requirements for QI and 
CER activities.   
 
Demonstrating Respect for the Moral Status of Individuals Enrolled in QI and CER 
Activities 
It is often asserted that informing individuals about research activities that they 
may be enrolled in, and engaging them in decisions about participating in those activities, 
is important because these actions demonstrate respect for the moral status or moral 
standing of those individuals.
 3 
 Although there is some disagreement regarding what 
exactly confers this special moral status on persons, it is generally recognized that there is 
something unique about humans that makes it such that their interests matter morally in 
this way (Dillon 2010; Jaworska and Tannenbaum 2013). Furthermore, it is generally 
accepted that the centrally important demonstration of respect for moral status in research 
with human subjects is respect for the autonomy of competent individuals.  
Nevertheless, although informing individuals about a research activity or 
activities, ensuring that they understand that information, and allowing them to 
voluntarily decide whether to participate are often discussed together, these are distinct 
components of demonstrating respect for autonomy. Additionally, it is important to 
recognize that respect for autonomy is a component of respect more broadly. In the 
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 I have elected to use the terms “moral status” or “moral standing”, which I am using as synonyms, in part 
to avoid controversies that accompany terms such as “moral worth” or “human dignity”. Attempting to 
defend or resolve controversies about exactly what is unique about human beings that confers this special 




context of QI or CER,  other components of respect could include engaging individuals 
impacted by QI and CER activities in other decisions related to those activities,
4
 
informing individuals who receive their care at an institution about that institution’s 
commitment to regularly engaging in QI and CER activities to improve health care 
quality, and informing individuals about institutional policies as they relate to the rights 
and protection of individuals who may be enrolled in those activities (Baily et al. 2007; 
Faden et al. 2013b; Largent, Joffe, and Miller 2011; Lo and Groman 2003). Finally, 
respect can also be demonstrated by ensuring that there is adequate oversight of QI and 
CER activities so that individuals are protected from disproportionate risks of harm.
5
 All 
of these components can, in certain situations, play an important role in demonstrating 
respect for individuals who are eligible to participate in QI and CER activities. However, 
what this paper aims to demonstrate is that not all of these components of respect are 
morally required in all situations.  Specifically, this paper will argue that treating people 
with respect does not always require that those individuals be given a robust way to affect 
the course of events with regard to their participation in QI and CER activities. Yet, in 
situations where the ability of individuals to control their participation in QI and CER 
activities is limited, implementing policies related to the other components of respect 
discussed above becomes even more critical. 
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 For instance, individuals can be engaged in policy discussions about the acceptability of waivers of or 
alternatives to prospective informed consent, in priority setting discussions for QI and CER activities, or in 
discussions surrounding the design and implementation of these activities. 
5
 In addition to being required by the principle of beneficence, protecting individuals can arguably also be 
considered to be a form of demonstrating respect for potential research participants. In its explication of 
what is required to fulfill the principle of respect for persons, the Belmont Report asserts that “persons with 
diminished autonomy are entitled to protection” (National Commission 1978). However, even for 
competent individuals, requiring that QI and CER activities receive ethical oversight is still arguably partly 
required out of respect for persons as it would be disrespectful of the moral status of those individuals to 




As will be further described in the next section, whether it is necessary to give 
people the ability to control their participation in a QI or CER activity and the amount of 
control people ought to have depends on the features of that activity and features of the 
institution or health care system in which the activity is implemented. Since individuals 
seeking care at a health care institution are all interdependent members of a health care 
community, it is permissible at times to place limits on the choices available to those 
individuals in order to further interests that those individuals and others within their 
health care system have in being able to access high quality health care (Dickert 2009). 
The following section employs a theory developed by Madison Powers and Ruth Faden 
to demonstrate why it may be morally permissible to limit the ability of individuals to 
make autonomous choices regarding their inclusion in certain QI and CER activities.   
 
Features of QI and CER Activities that are Relevant to the Acceptability of Waiving or 
Altering Informed Consent Requirements  
The starting point for this discussion is an understanding of the moral importance 
of interests that individuals have. Specifically, although it is generally important to 
respect the interests of competent individuals, not all individual interests are of equal 
moral significance. Rejecting this view would require one to adopt the position that all 
interests that individuals have are worthy of the same level of respect from others, which 
is inconsistent with many moral theories as well as many current public policies. 
Justifying why it is that not all individual interests or aims are of equal moral 
significance, TM Scanlon explains that  “[m]any rationale aims are quite specific and 




helping a friend out of some difficulty. Other aims take the form of what Joseph Raz has 
called “comprehensive goals” – plans or intentions that shape a large part of one’s life. 
Success in these more comprehensive goals has a larger effect on a person’s life than 
success in more limited aims, and consequently…. make a greater contribution to well-
being” (1998, 121-122). 
More recently, Madison Powers and Ruth Faden, focusing specifically on public 
policies and liberty interests, further described why it is that not all liberty interests that 
individuals have deserve of equal policy protections. Since the theory proposed by 
Powers and Faden is best suited for questions about appropriate public policy options, 
this paper will apply this theory to develop arguments regarding the moral permissibility 
of waiving or altering consent requirements for QI and CER activities.  Similar to TM 
Scanlon, Powers and Faden argue that one reason why respecting the autonomous choice 
of competent individuals is often considered to be an important component of respecting 
the moral status of those individuals is because being able to exercise self-determination 
is a critical element of well-being.
6
 These scholars assert that “[w]hat matters is that our 
lives be shaped at least in part by our choices, informed by our own values and interests” 
(Powers and Faden 2006, 28). Given this, individuals place a high value on making 
decisions that may impact important interests that they have and the ability to make these 
decisions plays a central role in an individual’s well-being (Miller and Wertheimer 2010, 
83; Powers and Faden 2006, 26-29). Since the experiences people have participating in 
certain QI and CER activities can, at times, affect these interests, in those situations it is 
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 Autonomy and self-determination are related but distinct terms. Autonomy refers to the ability of a 
competent individual to self-govern. Individuals can and do exercise autonomy in many situations. Some of 
those situations have an important impact on an individual’s self-determination, meaning her ability to 
shape her life in ways that are important to her, whereas other situations in which an individual might 




important to allow “competent individuals to decide whether participation in research is 
consistent with their interests” (Wendler and Grady 2008).   
However, not all decisions regarding participation in QI and CER activities 
impact these interests that individuals have in important or significant ways. Recognizing 
that not all choices individuals make are of equal moral significance, Powers, Faden, and 
Saghai further claim, using John Stuart Mill’s theory as the basis of their moral argument, 
that “it is a mistake to suppose that all liberties of all sorts are on a moral par. They are 
not appropriately viewed as being on a moral par in the sense that not all stand in an 
equally privileged position at the front end of a balancing process when liberties conflict 
with other competing interests” (2012). Instead, it is most important to “protect the kinds 
of choices that structure the contours of one’s life in their most fundamentally defining 
ways” (2012).   Not all interests that individuals have are of equal moral worth and 
therefore, “they do not all merit the same level of protection in public policy” (Faden and 
Powers 2011). Since participating in some QI or CER activities will have only a very 
limited impact on an individual’s interests or rational aims, participation in those 
activities is unlikely to have a significant impact on an individual’s well-being. 
Nevertheless, Powers, Faden, and Saghai also argue that “[l]iberty interests matter 
in any case as concerns that trigger the need for justification, even if they do not loom so 
large as ones that figure centrally in the value of a self-determining life” (2012). 
Essentially what these scholars are arguing is that those choices that engage interests 
individuals have in the course of their lives or their health – interests that Faden and 
colleagues have called “autonomy interests” in the passage referenced below and that will 




policy protections than those choices that do not engage individual interests in this way. 
However, all liberties are of some moral importance and should not be infringed upon 
without sufficient justification.  
In a more recent article, Faden and colleagues make a similar argument. 
Specifically, these scholars state:  
Respecting autonomy is primarily about allowing persons to shape the 
basic course of their lives in line with their values and independent of 
the control of others. Not all health care decisions are likely to be 
attached to a significant autonomy interest of individual patients, and 
deference of the wrong sort can constitute a moral failure to take 
adequate care of patients rather than an instance of showing respect.  
 
In interpreting the obligation to respect autonomy in learning health 
care contexts,
7
 we should assess both whether a learning activity 
unduly limits the choices of patients and the value of those choices to 
patients. Many decisions in health care—such as how often simple 
laboratory tests should be repeated during a hospitalization or whether 
medications should be dispensed by one qualified professional or 
another—are not likely to engage values of central importance to the 
patient. Learning activities that relate to such decisions can be 
undertaken by health professionals and institutional officials without a 
violation of obligations to respect the rights or dignity of patients 
(Faden et al. 2013a). 
 
Arguments made by other scholars in favor of waiving or altering consent 
requirements for some QI and CER activities and even the current regulations governing 
informed consent in human research are consistent with the view that interests in 
controlling participation are more important to protect in some types of activities than in 
others, especially when balanced against other interests health care consumers have in 
receiving high quality medical care (45CFR46.116(d); Baily et al. 2006; Dubler et al 
2007; Faden et al. 2013b; Miller and Emanuel 2008; Largent, Joffe, and Miller 2011; Lo 
and Groman 2003; Lynn et al. 2007; Peddicord 2010; Sabin et al. 2008; Selker et al. 
2011). The importance of protecting these liberties depends on certain features of QI and 
                                                          
7
 This paper discusses the relevance of whether the QI or CER activity is conducted in the context of a 




CER activities including the potential benefits of the QI or CER activity to the 
participant, the risk that a participant will experience harm as a result of participating in 
an activity, the level of burden imposed on participants, and whether the decision to 
participate in the activity engages meaningful preferences that an individual has.
8
  
This paper will discuss each of these features, including relevant arguments made 
by other scholars, and will demonstrate that what these features have in common is the 
impact they have on the likelihood that the decision to participate in a QI or CER activity 
engages important self-determination interests an individual has.
9
 As a result of the 
influence these features have on these individual self-determination interests, these 
features also impact the moral importance of participants being able to control their 
participation in certain QI and CER activities. However, as was discussed by Powers and 
Faden, in addition to understanding the impact of choice on self-determination and 
ultimately well-being, it is also important to ensure that there is a sufficient justification 
for limiting choice. This paper will argue that an important piece of the justification for 
waiving or altering informed consent requirements relates to the value of a particular QI 
or CER activity to the health care system or systems in which it is implemented and the 
likelihood that the information generated will be used to improve clinical care. Given the 
important role these later features have in the justification for waiving or altering consent 
requirements, they will be discussed first, followed by the features of QI and CER 
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 Although the regulations governing the practice of informed consent for human subjects do allow for 
waivers of informed consent when risks of harm to individuals are minimal and it is not practical or 
possible to do the research if informed consent is required, this paper asserts that there are additional 
features of the study design and study setting that are important to consider when making decisions about 
the moral permissibility of waiving consent requirements. Because the current regulations do not account 
for these additional features, they may not appropriately balance interests individuals have in controlling 
their participation with other interests in having access to high quality medical care.  
9
 It is important to note that none of these features on its own can be used to determine the moral 
permissibility of waiving or alternating informed consent requirements. Rather, it is necessary to examine 




activities that impact the likelihood that the decision to participate engages important 
self-determination interests.  
 
Ability of the Health Care System to Use the Results from a QI or CER Activity to 
Improve Care 
As mentioned earlier, QI and CER activities are intended to further interests 
patients have in being able to access a health care system that is designed to deliver high 
quality medical care. To achieve such a goal, there must be a high likelihood that the 
results from QI and CER activities will actually succeed in improving health care quality. 
The likelihood that QI and CER activities will advance health care quality is furthered 
when these activities are designed to address issues of significance in the setting or 
settings in which they are conducted and when those settings are able to routinely 
translate the findings into practice. Therefore, these features are an important component 
of the justification for waiving or altering informed consent requirements. Further, it is 
important to note that both of these features are critical. Although ensuring that QI and 
CER activities address issues of particular importance in the setting or settings in which 
they are conducted increases the likelihood that the information generated will be 
relevant in that particular setting, generating the information is not sufficient to change 
medical practice and, in turn, to deliver on the goal of achieving optimal clinical 
outcomes.  
In order for the information generated to have a positive impact on medical care, 
there must be a plan in place that describes how that information will be used in clinical 




demonstrates to patients that the QI and CER activities in which they are involved will 
likely be helpful in promoting important interests that those patients have in their health 
and demonstrates a commitment on the part of the institution or system to improving the 
quality of care provided to patients. Unfortunately, it is often the case that it takes many 
years for the results of clinical research to change practice, if it happens at all. When the 
results from activities are not efficiently implemented, it becomes more difficult to justify 
limiting the ability of patients to make a voluntary decision regarding their participation 
in those activities especially in cases where participating in the activity may result in a 
setback in other interests that participants have. This is because part of the justification 
for limiting individual choice regarding participation is to allow activities to be conducted 
efficiently so that the results are available and used to improve medical care sooner and 
this justification is only relevant in situations where there is some actionable and efficient 
plan for using the results of the activity to improve care.
10
 Additionally, when there are 
plans or policies in place for implementing the findings, it is important to inform patients 
both about them as well as about how information generated from other QI and CER 
activities has led to advancements in medical care within the health care system so that 
patients are aware of how these activities promote their interests. As mentioned earlier, 
providing information about these sorts of policies is important to demonstrating respect 
for the moral status of individuals being enrolled in these activities.  
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 An actionable plan to implement findings would entail more than just a plan to disseminate results. 
Developing a plan might entail speaking to leadership at the institution(s) in which the activity is being 
conducted to understand whether it will be possible to change systems level policies based on the results of 
the activity or considering whether it would be possible to integrate the findings from the activity into 
electronic health record systems so that it is available to medical staff. If the activity is just a first step 
toward addressing a larger problem, the plan should indicate next steps and how the results from the 




Since QI and CER activities are generally concerned with the comparative 
benefits and harms of widely-used and/or evidence-based interventions, it is reasonable to 
expect the results of these activities will be more readily integrated into clinical care than 
the results from early phase clinical research, which generally requires further 
development, testing, and approval before the outcome will have an impact on clinical 
care. Several scholars have argued that a defining feature of QI activities is the high 
likelihood that the results from these sorts of activities will impact clinical practice in a 
particular setting within a short amount of time because QI projects are designed to 
address problems relevant to a particular setting and often incorporate features of that 
setting in to the design (Baily et al. 2006; Dubler et al. 2007; Lynn et al. 2007). However, 
it is important to recognize that these design features are not necessarily unique to the 
field of QI. CER activities can incorporate these design features as well and different 
health care settings are developing plans and policies for implementing the results of 
these types of activities. For instance, some health care settings have the capability to 
change physician “best of care” order sets, which are a component of care provider order 
entry systems, based on current evidence (Ozidas et al. 2006). This means that if 
evidence generated through CER activities demonstrate that one intervention is more 
effective than another for patients or certain subgroups of patients, this information can 
be translated in to these physician order sets. Additionally, there have been increasing 
calls for health care systems in the United States to become learning health care systems, 
where the defining features of a learning health care system are that there are the 
continuous efforts to learn from usual or slightly modified medical care and that there are 




(Institute of Medicine 2007).  Since a critical component of achieving a learning health 
care system is the ability to use findings from activities to improve clinical practice, it is 
reasonable to expect that efforts will be made to identify additional mechanisms by which 
to routinely and efficiently implement the results from these activities into clinical care.   
 
Impact on the Likelihood that Patients will Experience Optimal Clinical Outcomes 
It is widely recognized in the research ethics literature and in the federal 
regulations that it is important to consider the potential health benefits to participants in 
research or learning activities (Emanuel, Wendler, and Grady 2000; National 
Commission 1978). Understanding whether individuals enrolled in a QI or CER activity 
are likely to experience a health benefit as a result of their enrollment is important 
because being healthy is often critical to achieving other goals an individual has set for 
him or herself. Therefore, if being in a QI or CER activity is likely to further interests 
individuals have in their own health or, at the very least, is unlikely to have a negative 
impact on individual health outcomes when compared with standard clinical care, then 
waiving or altering consent in those situations is more likely to be morally permissible 
than it is in situations where there is less certainty regarding how being in the activity will 
impact health outcomes for patients.   
Again, because QI and CER activities are generally designed to compare or 
systematically implement widely-used, non-experimental practices or interventions, the 
health outcomes experienced by individuals in these activities will often not differ from 
those experienced by patients as part of standard clinical care. Bernard Lo and Michelle 




those enrolled. These scholars provide an example of a QI project designed to improve 
the “use of aspirin, -blockers, and statins after myocardial infarction,” all of which have 
previously been shown to improve outcomes for patients but are still currently 
underutilized (2003). As part of the activity, physicians of patients who experienced a 
myocardial infarction but who were not given these drugs will be sent a letter to remind 
them to provide these drugs to the patient if appropriate. Lo and Groman argue that there 
is a high likelihood that patients of physicians involved in this activity will experience 
improved health outcomes as a result of this activity being implemented (2003). 
Nevertheless, it is often the case that how likely it is that an activity of this sort will 
improve outcomes for participants depends on the quality of the evidence upon which the 
existing knowledge or guidelines are based and the degree to which monitoring or other 
aspects of care delivery are modified as is discussed in greater detail below.  
QI and CER activities that are unlikely to impact the health benefits experienced 
by patients include observational QI or CER activities since these activities have no 
impact on the medical care that a patient receives (Faden et al. 2013b; Miller 2008). 
While arguably more controversial, some QI and CER activities that involve the 
manipulation of medical care, such as, but not limited to, the random assignment of 
patients to different treatment arms, may also have no impact on patients’ health benefits 
since it is not always the case that manipulating medical care results in increased 
uncertainty regarding health outcomes (Faden et al. 2013b).  Instead, if an activity is 
comparing two or more widely-used, non-experimental interventions where there is no 
evidence that one of the interventions will result in better clinical outcomes and where 




activity that would likely have resulted in better outcomes, there is no reason to believe 
that patients enrolled in that activity will have worse outcomes than patients receiving 
care outside of that activity.  
However, there are cases where QI or CER activities are designed to 
systematically implement or compare interventions that are not based on existing 
evidence. For instance, a CER activity may compare a widely-used intervention that is 
consistent with standard care to an intervention that is being used “off-label” and in such 
a way that is not widely practiced in standard care. In this situation, although the 
intervention being used “off-label” may work well for another clinical indication, the 
evidence demonstrating that the intervention is effective for the indication for which it is 
being used in the CER activity is limited. In these situations, the impact that the activity 
will have on health outcomes experienced by patients is more uncertain; consequently, 
there is a greater likelihood compared to other types of QI and CER activities that 
individuals will experience a worse clinical outcome than they would have experienced in 
standard clinical care. As a result, the decision to participate in QI and CER activities of 
this sort likely engages important self-determination interests that people have and 
therefore, in these situations, it is critical to ensure that liberty interests are preserved.  
 
Risks of Personal Harm, Risks to Privacy, and Risks of Group Harm 
In addition to benefits, there is also general agreement in the literature and in 
current regulations that the risk of harm to participants is an important criterion to 
consider when evaluating a QI or CER activity in general as well as when making 




According to Tom Beauchamp and James Childress, the term risk of harm “refers to a 
possible future harm, where harm is defined as a setback of interests, particularly in life, 
health, and welfare” (2009, 221). This definition is very broad and, as is discussed in 
further detail below, as written encompasses burdens as well, which are conceptually 
distinct from harms. However, this definition is beneficial in demonstrating the 
relationship between risks of harm, burdens, and individual self-determination interests.  
Beauchamp and Childress further add that when adjectives such as “minimal” or “high” 
are used before “risk”, they are generally referring to the probability that harm will occur 
although sometimes they are also used to refer to the severity or magnitude of the harm.
11
 
Risks of harm in research include physical risks of bodily harm, psychological risks 
related to stress or depression, social risks if the activity’s findings or participation in the 
activity could results in social stigma or employment or insurance discrimination, as well 
as economic risks if individuals have to bear any of the financial costs associated with 
participation (Levine 1978, 2-5).
12
Although all risks of harm are morally significant, not 
all risks are of equal moral importance. When making decisions about the permissibility 
of waiving or altering informed consent requirements, it is necessary to consider the 
different sources, types, and risks of harm that exist as well as whether it is likely that 
those harms will engage important individual self-determination interests.  
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 The Belmont Report uses similar definitions (National Commission, 1978). 
12
 For some activities, the additional costs to the participants are knowable at the time that an individual is 
enrolled in the study. For instance, if an activity is comparing two different interventions and one costs the 
patient more than the other, than individuals who receive the more expensive intervention will have to pay 
more than individuals who receive the less expensive intervention. In other activities, there may be some 
uncertainty regarding whether patients will experience additional costs. For instance, an activity may 
implement a systems level intervention designed to increase monitoring of patients experiencing a certain 
health condition. If, as part of the additional monitoring, patients have to return to the hospital for 
additional office visits, there may be costs associated with these visits, such as finding child care services, 
that are not recognized by those implementing the activity. This paper considers both of these to be a form 




Considering different sources and types of additional risk of harm in QI and CER 
activities: Some risks of harm that individuals experience as part of QI or CER activities 
are no different from the risks those individuals would have experienced as part of 
standard clinical care, while others are specific to a particular activity. When evaluating 
the significance of the risks imposed on individuals, some scholars suggest first 
differentiating risks associated with standard clinical care for a person with a certain 
health condition from those risks that are not. This is because, according to Charles 
Weijer, risks associated with standard clinical care are “justified by their potential to 
benefit the subject” (Weijer 2000). Since most individuals have an interest in promoting 
their own health, individuals will generally accept the risks associated with standard 
clinical care because these risks should be offset by the prospect of direct health 
benefits.
13
 Additionally, there are already accepted mechanisms for consent to treatment 
within the context of standard clinical care and as part of these processes, patients already 
agree to the risks associated with treatment.
14
    Risks of harm not associated with 
standard clinical care are often not offset by direct health benefits to the individual. 
Instead, participants accept these risks to further other interests that they have in ensuring 
that they, along with other patients, receive high quality medical care in the future.
15
 
While important, interests in obtaining high quality health care in the future may not 
carry the same weight for an individual as interests in avoiding risks of harm that are not 
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 Nevertheless, it is important to acknowledge that standard clinical care is not risk free. There are many 
practices that are part of standard clinical care that are not based on high quality evidence or that are 
overutilized such that the risks associated with those practices may not be offset by direct health benefits to 
patients (Kass, Faden, Goodman et al. 2013).  
14
 It is also important to note that different types of consent are used in the clinical context depending on 
features of the medical treatment and that there are some parts of clinical care, such as when a patient is 
undergoing surgery, when medical practitioners do seek consent more formally.  
15
 This is similar to an idea raised by Charles Weijer who argues that the risks are justified by their potential 




offset by more immediate health benefits. As a result, these risks of harm are of greater 
importance when making decisions about the moral permissibility of waiving or altering 
prospective informed consent requirements.  
In QI and CER activities, risks of harm beyond those associated with standard 
clinical care can occur (1) when sensitive and personal information about an individual is 
being used in ways that are not consistent with standard clinical care, (2) when 
participation in a study increases the likelihood that a certain group will experience social 
stigma compared to standard clinical care (Faden et al. 2013b), (3) when participants are 
provided with less than standard clinical care (Dubler et al. 2007; Lo and Groman 2003) 
or when interventions that are not evidence-based and/or consistent with standard clinical 
practice are used (Miller and Emanuel 2008; Lo and Groman 2003; Sabin et al. 2008; 
Selker et al. 2011), (4) when one of the interventions being compared is associated with 
greater risks of harm than other standard of care interventions (Morris and Nelson 2007; 
Largent, Joffe, and Miller 2011; Truog et al. 1999), or (5) when participants are asked to 
do extra things that are not consistent with standard clinical practice and that may cause 
them harm (Morris and Nelson 2007).   The final three potential sources of additional 
risks occur when a QI or CER activity involves some form of manipulation of medical 
care or when an activity imposes additional burden on participants. It is important to note 
that some activities may involve several different sources of additional non-clinical risks. 
In those situations, the combined risk of harm of the different components needs to be 
considered when making determinations about the level of risk (Weijer 2000; Weijer and 





The nature of the risks of harm imposed on participants:  Although each of the 
potential sources and types of additional risks of harm are important to consider, not all 
risks will impact an individual’s health or his or her ability to accomplish other life goals 
in significant ways. This is either because it is very unlikely that the harm will occur or 
because the harm itself is relatively benign. Recognizing that not all risks are of equal 
moral importance, there is general agreement in the literature and in the federal 
regulations that waivers of prospective informed consent are more acceptable when an 
activity involves only minimal risk to individual participants (45CFR46.116(d); Baily et 
al. 2006; Dubler et al. 2007; Lynn et al. 2007; Miller and Emanuel 2008; Lo and Groman 
2003; Selker et al. 2011) as well as only minimal risk of group harms (Faden et al. 
2013b). According to the federal regulations, minimal risk “means that the probability 
and magnitude of harm or discomfort anticipated in the research are not greater in and of 
themselves than those ordinarily encountered in daily life or during the performance of 
routine physical or psychological examinations or tests” (45CFR46.102). Unfortunately, 
this definition has resulted in considerable disagreement regarding what counts as 
minimal risk in part because the terms used in the definition lack clarity.
 
Part of the 
confusion comes from difficulties with defining what constitutes ordinary daily life and 
whether that should differ for different sets of individuals based on the setting in which 
they live, their age, or their health status (Kopelman 2000; Resnik 2005).
16
  
As a result of this ambiguity and confusion, although there is general agreement 
that it is important to distinguish minimal risk from greater than minimal risk activities, 
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 David Resnik suggests that the definition of minimal risk should be shortened to the following: minimal 
risks are “the risks associated with routine physical or psychological exams.” (2005) However, this does 
not completely resolve the confusion in part because standards of clinical care are always changing and, 
more importantly, because what is routine for a person with a certain health condition may not be routine 




people differ in exactly where they believe that line should be drawn.  Unfortunately, 
attempting to address this ambiguity is beyond the scope of this paper. Instead, for the 
reasons described previously, this paper adopts the view that the risks of harm that are 
most important to consider are those that are not associated with the routine clinical care 
for an individual with a certain health condition and that these risks should be considered 
to be minimal risk only when they will not significantly impact other interests individuals 
have in their overall health and general life course.
 17
  In order for it to be morally 
permissible to waive or alter informed consent requirements, the QI or CER activity must 
be under the minimal risk threshold, in terms of the risks involved that are beyond those 
posed by standard clinical care. However, this does not mean that waivers or alternatives 
are permissible for all activities that present only minimal additional risks to participants. 
Instead, the permissibility of waiving or altering informed consent also depends on the 
other characteristics of the activity and the institution in which the activity is being 
conducted. 
Based on this analysis, a few additional points can be made. The first point is that 
for observational QI or CER activities that do not impose additional burdens on 
participants, as long as there are adequate confidentiality protection measures in place 
and severe repercussions for any breaches of confidentiality, the risks of harm to 
participants will generally fall below the minimal risk threshold.
18
 Therefore, in these 
situations, it is unlikely that the decision to participate will engage important self-
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 Even if readers disagree with this definition of minimal risk, they may still agree with the general points 
described below.  
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 The second point is that not all activities that involve some sort 
of manipulation of medical care, such as but not limited to the random assignment of 
individuals to different interventions, impose more than minimal additional risks of harm 
beyond those associated with standard clinical care.  Morris and Nelson argue that 
activities that involve random assignment do not increase or only minimally increase 
risks of harm to participants when the following five criteria are met: “1) genuine clinical 
equipoise exists; 2) all of the treatment options included in the research study fall within 
the current standard of care; 3) there is no currently available treatment with a more 
favorable risk-benefit profile than the treatments included in the research study; 4) the 
nontherapeutic components of the research are safely under the minimal risk threshold; 
and 5) the research protocol provides sufficient latitude for treating physicians to 
individualize care when appropriate” (2007). Expanding on Morris and Nelson’s fourth 
criteria, Faden and colleagues argue that activities that meet these criteria and that impose 
some additional burden on participants can still be considered to be minimal risk 
activities as long as the additional burden imposes no or only minor additional risks of 
harm to participants (Faden et al. 2013b). In situations where activities meet these 
criteria, there is a lower likelihood that the activity will have a significant impact on 
important self-determination interests that an individual has related to his or her health or 
general course of life and therefore, it is not as important to ensure that individuals are 
given the opportunity to decide whether to participate. Since many QI and CER activities 
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 Franklin Miller further adds that in cases where an activity relies exclusively on personal health 
information and involves no interventions, as long as confidentiality is adequately protected, there is “no 
interference with [an individual’s] freedom or the course of their lives.” As a result, being afforded the 
liberty to decide whether to participate in these sorts of activities is less important than being afforded the 
liberty to decide whether to participate in other sorts of activities “especially when balanced against the 





that do involve manipulating medical care only involve widely-used and/or evidence-
based interventions, it is reasonable to expect that many will fall under this minimal risk 
threshold. 
 
Burden to Individuals Participating in the Activity 
A burden can be defined here as anything extra that an individual is asked to do 
for the sake of the activity beyond what that individual would have been asked to do as 
part of standard clinical practice. As previously mentioned, it is important to recognize 
that burdens are conceptually distinct from risks of harm and that not all burdens placed 
on participants will increase the risk that those individuals will experience a physical, 
psychological, social, or economic harm. For instance, asking participants to complete 
additional questionnaires will not increase risk of harm as long as the questionnaires are 
not about a subject that is upsetting to participants and include no personal sensitive 
information (Faden et al. 2013b). Moreover, if as part of an activity, participants are 
asked to return to their doctors’ offices for extra visits, as long as those visits do not 
involve additional procedures that impose risk and that are not consistent with standard 
clinical care and as long as individuals are compensated for the direct and indirect costs 
associated with those visits, they do not impose additional risks of harm on that 
individual. Nevertheless, these extra tasks may result in setbacks to important interests 
that participants have, to a greater or lesser extent, and therefore, it is necessary to 
consider whether an activity imposes additional burdens on individuals regardless of 




It is also important to recognize the huge variation that exists in the types of 
burdens that QI and CER activities might impose on participants and that different 
burdens will have more or less of an impact on an individual’s self-determination 
interests. Returning to the types of burdens described above, filling out a questionnaire, 
especially if it is during an already scheduled appointment, is very unlikely to impact 
other interests an individual has in his or her health or general life course. Alternatively, 
if the questionnaire was administered more frequently and not during already scheduled 
appointments, as would be the case if a QI or CER activity included a monthly phone 
questionnaire to collect additional data on patient reported outcomes, then the impact that 
additional burden may have on individual interests starts to increase. Nevertheless, this 
additional burden is still unlikely to have a significant impact on important interests that 
individuals have since individuals can simply choose to not take the call or complete the 
questionnaire (assuming that they appreciate that they have this option). However, other 
burdens such as returning to a clinic for extra blood pressure measurements, keeping a 
daily diary, for instance of foods consumed or of migraine symptoms, or wearing a 
twenty-four hour blood pressure monitor may have a more significant impact on self-
determination interests. As a result, in these situations, it becomes more important to 
ensure that individuals recognize that these additional tasks are for the purposes of a QI 
or CER activity.  
Although many scholars writing about QI and CER activities agree that it is 
important to consider the additional burdens imposed on participants when making 
decisions about the necessity of informed consent, scholars differ in terms of whether 




where patients experience no additional burden beyond what they would have 
experienced as part of routine clinical care, as is the case with QI or CER activities 
relying exclusively on routinely collected health information, or whether they believe that 
some minor additional burdens can be acceptable. For instance, Dubler and colleagues 
argue that waivers of informed consent should only be allowable for QI activities that do 
not impose any additional burden on participants (2007) whereas Ruth Faden and 
colleagues as well as Emily Largent and colleagues assert that waivers may also be 
acceptable in situations where activities impose only minor additional burdens compared 
to standard clinical care (Faden et al. 2013b; Largent, Joffe, and Miller 2011).
 
What is 
interesting is that both of the latter sets of scholars believe that health care should be 
delivered within the context of a learning health care system where these QI and CER 
activities are routinely conducted such that there is a demonstrable commitment on the 
part of the institution to improving clinical care and where there are mechanisms by 
which to translate the results from an activity. Further, both sets of scholars assert that 
patients should be broadly informed of an institution’s policies regarding QI and CER 
activities, which, as discussed earlier, can be an important component of demonstrating 
respect for the moral standing of individuals. In these situations, these scholars 
presumably feel that demonstrating respect in these ways is sufficient given the limited 
impact minor additional burdens have on individuals and given the commitment on the 
part of the institution to implement the results of the activity. 
This paper argues that when no additional burdens are imposed on individuals, 
waivers of or alternatives to prospective informed consent are more likely to be morally 




when a QI or CER activity imposes only minor additional burdens that are unlikely to 
impact important self-determination interests that individuals have, waiving or altering 
informed consent requirements can still be permissible. In order for waiving consent to be 
permissible, there must be a plan in place to efficiently implement the results from the 
activity such that it is likely that the activity will promote other interests individuals have 
in receiving high quality health care and patients must be informed about their 
institution’s policies regarding QI and CER activities so that they understand how their 
interests are protected. Examples of minor additional burdens include completing an extra 
questionnaire at an already scheduled appointment, completing health related quality of 
life surveys administered over the phone, or having one’s blood pressure taken both at the 
beginning and at the end of a physical exam instead of just at the beginning. However, in 
cases where QI or CER activities impose minor burdens of this sort but where there is no 
plan in place for efficiently implementing the results, it is important that individuals be 
informed about those burdens and also that doing these additional tasks is voluntary. The 
reason for this is that although these additional burdens are unlikely to impact important 
self-determination interests, they may still be an inconvenience and in cases where there 
is no plan to implement the results, it is uncertain whether those inconveniences will be 
offset by furthering other interests individuals have in having access to high quality care. 
Nevertheless, in instances where it is relatively easy for individuals to simply not 
complete the extra tasks asked of them, such as completing additional questionnaires or 
surveys, while those in charge of the activity should inform individuals about these 
minor, additional tasks, they should not be morally required to get written authorization 




Finally, in cases where QI or CER activities impose greater than minor additional 
burdens, since these additional burdens may impact important self-determination interests 
that a person has, it is important that it is disclosed to a patient that these additional tasks 
are for the purposes of a QI or CER activity and that completing them is voluntary 
regardless of whether the institution has a plan in place for implementing the results. 
Examples of this type of burden would include additional office visits that are not part of 
standard clinical care or other tasks that may interfere with an individual’s life like 
wearing a 24 hour blood pressure monitor for the purposes of the activity or recording 
certain information on a daily basis, such as in a food diary, that are not normally 




Likelihood that the Activity Impacts Medical Decisions that Engage Meaningful 
Preferences  
In addition to benefits, risks of harms, and burdens, it is important to consider 
whether a QI or CER activity limits the ability of patients and physicians to make 
medical decisions that engage meaningful preferences that patients have.  Although 
individuals may have preferences about whether to participate in QI or CER activities in 
general, this section is focused on preferences individuals have with regard to their 
medical treatment. QI and CER activities can only impact these sorts of preferences when 
these activities manipulate medical care in some way. However, just because an activity 
involves the manipulation of medical care, it does not follow that that activity necessarily 
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 Several scholars have noted that individuals may be more willing to do the extra tasks for the purposes of 
a QI or CER activity if those individuals are informed about the activity and the rationale for asking them 
to complete the additional tasks (Lo and Groman 2003). For instance, in the case of a food diary, if people 
understand the importance of the activity, they may keep more accurate records than they otherwise might 




limits patient preferences regarding medical treatment in meaningful ways. One reason 
for this is that there are certain decisions regarding the way patients are treated that 
institutions, rather than individual patients and doctors, routinely make and, arguably, are 
in the best position to make. Additionally, even in cases where patients and their doctors 
are in the best position to make an individual-level treatment decision, not all QI and 
CER activities that involve the manipulation of medical care infringe on these decisions 
in significant ways. 
 
Activities that Involve Health Systems-Level Interventions:  Some QI and CER 
activities are designed to determine the effect of a health systems or practice-level 
intervention, such as policy changes or changes to the process of delivering care, on 
patient outcomes. Patients may have reasoned preferences about the implementation of 
these interventions within their health care setting and these interventions may impact 
important interests individuals have in their health. However, according to Julius Sim and 
Angus Dawson, one factor that distinguishes health systems or practice-level 
interventions from patient-level interventions is that during the course of receiving 
medical care, individual patients are not normally consulted before these types of 
interventions are implemented and this “reflects an acceptance that such measures are 
legitimately decided at a higher level and that the same degree of consent is not expected 
for community-level interventions as it is for individual treatment decisions” (2012).  For 
instance, a health care institution would not ask patients for permission prior to changing 




also would not ask patients for permission prior to implementing a new set of hand 
washing guidelines designed to decrease the risk of nosocomial infections.  
There are several potential reasons why this has become an accepted norm in 
clinical practice. One reason is that asking individual patients for their permission prior to 
implementing different health systems-level interventions would be inefficient and costly. 
Additionally, because systems-level interventions apply to large population of patients, 
allowing individual patients to make decisions about these interventions is often 
impractical. However, arguably the most important justification for this practice is that 
when making decisions about the implementation of such interventions, the institution 
must make trade-offs among a number of different considerations including, for instance, 
what is in the best interest of the patient population, the evidence supporting the 
intervention, cost concerns, and the feasibility of implementing the intervention.  Because 
it would be extremely difficult or impossible to inform all patients about these different 
considerations, it structurally has never been the practice to allow individual patients to 
have a say in making these decisions. As a result, since institutions are in the best 
position to weigh these different considerations, patients must entrust institutions with the 
authority to make decisions regarding the implementation of systems-level interventions. 
For these reasons, if a QI or CER activity involves the systematic implementation or 
comparison of different health systems-level interventions or practices, it is not as 
important, morally speaking, that the patient be involved in decisions regarding the 
implementation of those interventions or practices. Therefore, it is not as important, 
morally speaking, to allow individuals to decide whether or not to participate in that 




burdens or may negatively impact the ability of a patient to experience an optimal clinical 
outcome, it is important to have strong institutional ethical oversight of that activity. 
Additionally, in situations where the activity imposes greater than minor additional 
burden on individuals for the purposes of collecting additional information for the 
activity, it is still important that patients be informed about those burdens and that 
completing them is voluntary. 
 
Activities that Involve Patient-Level Interventions: Unlike health systems or practice-
level interventions, patients and their physicians are generally in the best position to 
decide which considerations are most important and to weigh those different 
considerations when making patient-level treatment decisions. Even when there is 
uncertainty regarding which of several patient-level interventions is likely to result in the 
best clinical outcome for patients, individuals still may have other reasons for preferring 
one of the interventions over others, some of which are more meaningful than others. QI 
or CER activities that limit the ability of patients and clinicians to make treatment 
decisions based on patient preferences include activities where: 
1. individuals or groups of individuals are randomly assigned to different patient-
level interventions (Miller 2010, 388; Lo and Groman 2003),
21 
 
2. individuals are asked to stop taking a medication that they are familiar with and 
switch to a different medication, or 
3. the activity limits the number of treatment options patients have, compared with 
standard clinical care.  
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 Whether the activity involves randomization at the level of a cluster or at the individual level is irrelevant 




The difficulty is that although not all preferences individuals have are of equal 
moral significance, it is generally not possible to distinguish preferences that are 
meaningful for an individual from those that are not.
22
 While it is clear that preferences 
based on superficial characteristics such as name or color of a specific treatment do not 
have any impact on important self-determination interests and that other preferences such 
as those based on risks or burdens clearly do, there are many instances where the choice 
between two interventions may engage preferences that are meaningful for some 
individuals but not others. For instance, consider a study comparing taking a medication 
in the morning to taking that same medication at night (NIH Collaboratory 2013). Many 
patients will not have a strong preference regarding when they take their medication 
while others might prefer to take the medication in the morning because that is when 
those individuals take other medications and they may be concerned that they will forget 
to take their medication in the evening.  Although a preference for taking one’s 
medication in the morning is not as important as a preference for surgery instead of 
chemotherapy, it is arguably still important for individuals to know if they are being 
asked to take the medication at a certain time for the purposes of a QI or CER activity 
instead of for purely medical reasons. Because individuals form preferences for a variety 
of reasons, many of which may not be known to the investigators conducting a QI or 
CER activity, some individuals may reasonably have meaningful preferences about 
treatment decisions that other patients see as trivial. Since individual patients and doctors 
are in the best position to understand individual patient preferences, when a QI or CER 
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 Truog and colleagues suggest that the “reasonable person” standard should be used to differentiate 
ethically relevant preferences from those that are less important. However, these scholars also admit that 





activity limits patient-level treatment decisions in some way, it is important for patients to 
understand how their options are being limited and why. Furthermore, it is important for 
patients to have an opportunity to select another treatment option with their clinicians 
from the range of options that would have been available to them if there is a reason for 
the patient to prefer an alternative treatment.  
However, some activities that involve manipulation of individual treatment 
decisions only infringe on preferences in a very limited way. For instance, when it is easy 
for the patient and clinician to override the random choice and select another treatment 
from the choices that would otherwise have been available to the patient, the impact 
randomization has on patient preferences regarding medical treatment is minimal.
23
 
Demonstrating this point, Sabin and colleagues provide a hypothetical example of a 
cluster randomized study where patients diagnosed with a certain condition at one health 
plan are prescribed one medication (Drug A) and patients with the same medical 
condition at a different health plan are prescribed a different medication (Drug B). Both 
medications are approved by the United States Food and Drug Administration and 
widely-used and physicians are free to override the cluster randomization if they feel that 
one of the medications is better for a particular patient or if the patient has a reason to 
prefer another medication. Based on a literature review and interview data, Sabin and 
colleagues reason that because physicians in the trial are only asked to prescribe the 
favored therapy unless the physician or the patient has a reason to prefer the alternative, 
“[t]here is nothing in this chain of steps that is inherently different from ordinary practice. 
With regard to the prescribing of A or B, there is no “experiment” being done and 
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 Of course, allowing patients and physicians to relatively easily override the random assignment will 
impact the internal validity of the study. However, this issue is not the focus of this paper and therefore, 




nothing requiring informed consent beyond what is ordinarily required in clinical 
practice” (2008). 
Presumably, there is nothing inherently different because both of the medications 
are commonly used and because doctors are free to override the random assignment if 
there is a reason for the patient to prefer a different medication. Since it is extremely easy 
to override the random assignment, enrollment in that activity would not significantly 
infringe on meaningful preferences, assuming that patients are given enough information 
about other treatment options to understand how medication selection may impact 
meaningful preferences that they might have.
24
 Therefore, in these situations, it is not as 
important to allow the individual to decide whether or not to participate in the activity.  
 
Discussion: Recommendations Regarding the Moral Permissibility of Limiting an 
Individual’s Ability to Decide Whether to Participate in a QI or CER Activity  
The ability of QI and CER activities to provide needed information on the relative 
benefits and harms of interventions and practices in order to improve the quality of health 
care delivered to patients is furthered when there is near universal participation in these 
activities (Faden et al. 2013a; Lynn et al. 2007). This is because generating robust 
evidence of effectiveness, and especially comparative effectiveness, often requires large 
sample sizes in order to detect small but clinically meaningful differences in outcomes 
and because high participation rates allow the research to be completed faster. 
Additionally, near universal participation decreases the risk of selection bias and 
improves the generalizability of the results. Being able to achieve near universal 
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 Arguably, this information should also be provided as part of standard clinical care. However, an in-




participation and to implement these activities as efficiently as possible has led to an 
interest in the availability of waivers of or alternatives to prospective informed consent, at 
least in some circumstances. These reasons combined with the fact that QI or CER 
activities often do not involve manipulating medical care and when they do, they often 
involve widely-used and/or evidence-based interventions or practices raises the question 
of whether it may be morally permissible to implement alternatives to current informed 
consent requirements for at least some subset of QI and CER activities.   
The goal of this paper was to demonstrate that the moral importance of allowing 
individuals to decide whether or not to participate in a QI or CER activity, and thus the 
importance of engaging in full prospective informed consent, depends on a number of 
features of that activity as well as of the health care system in which it is being 
implemented. These include the ability of the health care system to implement the 
findings from the activity, the health benefits and risks of harm to individuals enrolled, 
the burden imposed on participants, and whether the activity limits the ability of 
individuals to participate in individual-level treatment decisions that may engage 
meaningful preferences.  The first feature is an important component of the justification 
for waiving or altering informed consent requirements. The remaining features are 
important because each influences the likelihood that the decision to participate in the 
activity engages important self-determination interests that individuals have.  If, after 
considering these features, it is clear that the decision to participate does not engage 
important interests and preferences that individuals have in their health or general life 
course and if the system or institution in which the activity is implemented has a plan to 




implementing waivers of or alternatives to prospective informed consent in order to 
improve the ability of those activities to efficiently generate evidence to improve clinical 
care is morally permissible. Alternatively, if the decision to participate does engage 
important interests and preferences, it is necessary to ensure that individuals are able to 
decide whether participating is consistent with the interests and preferences that they 
have. The reason for this is that infringing on the autonomy of individuals by not 
allowing them to make informed choices about participation in these activities can have a 
negative impact on the overall well-being of those individuals.  
Based on this line of reasoning, it is possible to draw the following conclusions 
about the moral permissibility of waiving or altering prospective informed consent 
requirements for certain kinds of QI and CER activities.  
 
1. Prospective informed consent should always be required for QI and CER 
activities that involve the manipulation of individual-level treatment decisions and 
that impose greater than minimal risks of harm or burdens beyond those 
associated with standard care or that involve interventions that are associated 
with significant uncertainty regarding the health benefits to participants: 
When a QI or CER activity involves manipulating individual-level treatment 
decisions, the activity may limit the ability of patients and physicians to make choices 
based on meaningful preferences that patients have. Because of this, individuals should 
be given some authority to resist participation if they feel that participation is not aligned 
with their interests and preferences. If the activity also imposes greater than minimal 




the case when experimental interventions are being tested) or if there is significant 
uncertainty regarding the impact participation will have on patient health outcomes, 
prospective informed consent should be obtained from individuals prior to enrolling 
them. It is also necessary to obtain prospective informed consent when a QI or CER 
activity imposes greater than minor additional burdens on participants. In these situations 
infringing on the autonomy of individuals is likely to have a negative impact on the well-
being of those individuals since decisions regarding participation are likely to impact 
important self-determination interests that they have.  
 
2. For QI or CER activities that involve manipulating individual-level treatment 
decisions and that impose only minimal additional risks or minor additional 
burdens compared to standard clinical care and involve only interventions that 
are widely-used and/or evidence-based, it is sometimes permissible to alter 
informed consent requirements by setting up defaults to encourage patient 
participation:  
Even if a QI or CER activity that involves the manipulation of individuals-level 
treatment decisions only involves widely-used and/or evidence-based interventions, is 
unlikely to negatively impact health outcomes experienced by patients, and does not 
involve greater than minimal additional risks or burdens, it is still important that 
individuals be given some authority to resist participating. In these situations, it is 
necessary to allow patients, in consultation with their clinicians, to consider the different 




treatment options to be limited in order to help generate evidence of the effectiveness of 
those interventions.   
Nevertheless, there are some design features of these sorts of activities that can 
decrease the likelihood that treatment decisions will be constrained in ways that may 
engage meaningful preferences. First, since the decision to switch treatments once a 
patient has found a treatment plan with which he or she is satisfied will often engage 
meaningful preferences, activities that only enroll individuals who are treatment naïve are 
less likely to infringe on meaningful preferences than activities that enroll individuals 
who currently have treatment plans in place. Additionally, for activities that involve 
random assignment of individuals or groups of individuals to different treatments, if, as 
part of an activity, clinicians are given the authority to override the random assignment at 
any time if their patient has a reason to prefer a different treatment, if the patient requires 
a different dose of the treatment, or if the patient and physician believe that the patient 
would benefit from an add-on therapy, then the activity only limits the ability of patients 
and clinicians to make decisions that might engage meaningful preferences in a very 
limited way. However, even in these situations, it is important that patients be informed 
about the potential treatment options that would have been available to them as part of 
standard clinical care as well as the main risks of harm associated with those different 
options because this information is necessary in order for patients to understand if and 
how the choice among treatments might engage meaningful preferences that they have.
25
 
As part of this disclosure, patients should also be aware of how the activity limits their 
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 However, it is not the case that patients need to be informed of every potential risk associated with each 
treatment option. Instead, Wendler and Grady argue that it is appropriate for those conducting the activity 
to rely on existing and appropriate clinical standards to determine what information should be disclosed to 
patients about the risks of widely-used, evidence-based therapies being studied in minimal risk activities 




treatment options. Further, even in situations where QI or CER activities incorporate the 
design features described in this paragraph, patients should have some authority to resist 
participating in those activities. 
However, this does not necessarily mean that patients should be asked for their 
authorization prior to being enrolled. Instead, for activities where (1) all interventions are 
widely-used and/or evidence-based, (2) none of the of the interventions involves a 
significantly greater risk of harm or is significantly more burdensome than other 
interventions available as part of standard clinical care, and (3) the design features 
described in the previous paragraph are incorporated into the activity, it is morally 
permissible to set up defaults to encourage patient participation, as long as there is a plan 
in place to efficiently implement the findings from those activities. The reason for this is 
again because the decision to participate in activities that meet these criteria is unlikely to 
engage important self-determination interests. Given this, instead of engaging in 
prospective informed consent, it is morally permissible to ask individuals to opt out of the 
activity if they would prefer not to participate. When opt out models are used, the 
presumption is that individuals should participate and that if individuals do not want to 
participate, it is acceptable for them to have to exert some effort to remove themselves 
from the activity. The moral permissibility of opt out models hinges on how easy it is for 
an individual to resist participating (Blumenthal-Barby and Burroughs 2012). Building on 
the concept of resistibility developed by Ruth Faden and Tom Beauchamp (1986, 
260,341-343, and 367-368), Yashar Saghai asserts that “resistibility is a criterion for 
testing the degree to which an influence is controlling.” Saghai further explains that an 




influence (Saghai 2012, 48-49).  In situations where opt out approaches are used, it is 
important to ensure that it is not excessively difficult for individuals to refuse to 
participate.  
 
3. Waivers or alternatives to informed consent are generally morally permissible 
when QI or CER activities involve manipulating medical care through the 
implementation of a health care system or practice-level intervention. However, 
individuals should be informed about greater than minor additional burdens and 
ethical oversight is needed if the activity imposes greater than minimal additional 
risks of harms or burdens or if it could negatively impact the ability of patients to 
experience optimal clinical outcomes: 
Since institutions, rather than individual patients and physicians, are generally 
given the authority to make decisions regarding the implementation or manipulation of 
health systems-level interventions, individuals have no choice but to entrust the 
institution with the authority to weigh the possible risks, benefits, and burdens of these 
types of interventions and to make appropriate choices regarding their use. Therefore, 
when a QI or CER activity involves a systems-level intervention, not informing patients 
about the activity and allowing them to make a voluntary decision regarding participation 
is morally permissible unless the activity imposes greater than minor additional burdens 
on individuals for the purposes of activity-related data collection.
 26
 When a QI or CER 
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 It is also important to note that in cases where an activity involves retrospective analysis of existing data 
or where the activity involves the implementation of a health systems-level intervention, it is often more 
difficult to obtain prospective informed consent from participants. This feasibility concern also serves to 
help justify waiving informed consent requirements. However, although feasibility concerns can help to 
justify waiving or altering informed consent requirements, it is not the case that feasibility concerns are 




activity involving systems-level interventions does impose greater than minor additional 
burdens for the purposes of additional data collection, individuals should be informed 
about those burdens and should be given the opportunity to make a voluntary decision 
about completing them. If a QI or CER activity relies on routinely collected information, 
it is necessary to ensure that proper confidentiality protections are in place and that there 
are severe repercussions if confidentiality is breached.  Also, in situations where the 
activity may negatively impact health outcomes for patients or poses greater than 
minimal risk, it is important that that activity receives additional ethical oversight beyond 
the oversight associated with standard clinical care. 
Moreover, to justify conducting QI and CER activities of this sort without patient 
informed consent there should be a plan in place for efficiently implementing the results 
of the activity, especially if minor additional burdens are imposed on participants. 
Additionally, to demonstrate respect for individuals, it is important that institutions 
regularly inform patients that these sorts of activities are conducted without consent. As 
part of this process of informing patients, institutions should describe why these activities 
are being done, how patients’ interests and preferences are protected, and how the results 
from these activities will be used to improve clinical practice.
27
 
On a related note, it is important to point out that it is generally already widely 
accepted that consent should not be required for many QI activities. One of the 
predominant arguments in favor of this practice is that these activities should be 
considered “a normal part of health care operations” whereas other activities, including 
CER activities, are outside of normal health care operations (Baily et al. 2006; Dubler et 
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 As mentioned earlier, institutions could also considering engaging individuals impacted by QI and CER 




al. 2007; Lynn et al. 2007). This criterion relates to the justification for waiving or 
altering informed consent requirements. Specifically, QI activities are often designed to 
address important issues in the health care system in which they are conducted and there 
are often mechanisms in place for using the information generated from these activities to 
improve medical care or, stated differently, to further interests patients have in being able 
to access high quality medical care (Kass et al. 2013). However, also relevant is that QI 
activities often involve health systems or practice-level interventions instead of 
individual-level treatment decisions, often impose only minimal additional risks and 
burden on those enrolled, and often are unlikely to negatively impact the health outcomes 
of patients. It is for these reasons that it is generally morally permissible to waive 
informed consent requirements for QI activities.  
 
4. Waivers or alternatives to informed consent are generally morally permissible 
when QI or CER activities have no impact on the medical care patients receive 
and impose no or only minimal risks of harm and no or only minor additional 
burdens:  
In these situations, interests individuals have in high quality of health care are 
more important, morally speaking, than the ability to make a decision regarding 
participation and therefore, infringing on the autonomy of individuals is justified. As a 
result, in these situations it is morally permissible to limit the ability of individuals to 
decide whether or not to participate. The kinds of QI or CER activities that fit this 
description are observational activities that either rely exclusively on routinely collected 




completing a short survey while in the waiting room for a regularly scheduled 
appointment. In order to be considered minimal risk, those in charge of the activity need 
to ensure that there are confidentiality protections in place and that there are severe 
repercussions if confidentiality is breached. Also, if, in order to conduct an activity, there 
is a need to access particularly sensitive information, such that breaches of confidentiality 
will result in severe harms to individuals, then informing individuals about the activity 
and asking them for their authorization prior to enrolling them should be required. 
Nevertheless, it is still important that the institution has mechanisms in place for 
translating the results of these activities in to clinical practice and that patients are 
informed of the institution’s policies regarding these types of activities as described 
above.  It is also important that institutions ensure that these activities receive ethical 
oversight.  
 
Conclusions and Next Steps 
This paper makes several recommendations about when it is morally permissible 
to waive or alter prospective informed consent requirements based on an analysis of 
when the decision to participate in QI and CER activities engages important self-
determination interests. Nevertheless, there is still some additional normative and 
empirical work that should be done to build on this initial set of recommendations. For 
instance, one issue that was not discussed in this paper as it is beyond the paper’s scope is 
whether and how the level of trust a community has in health care institutions or in 
clinical research should factor in to decisions about the moral permissibility of waiving or 




plays in the proper functioning of the medical and research enterprises, future work 
should consider whether obtaining prospective informed consent is more significant, 
morally, in situations where there is already a lack of trust. Additionally, since it has been 
argued that choice has intrinsic value regardless of whether it leads to better outcomes or 
impacts well-being (Scanlon 1986, 189), one issue that deserves further attention is 
whether allowing waivers of or alternatives to prospective informed consent to be used in 
these additional situations would cause individuals to feel wronged. This paper adopts the 
view that if waivers or alternatives are only used in situations in which decisions 
regarding participation are unlikely to impact individual self-determination interests, it is 
reasonable to expect that individuals will not feel as wronged as they may feel if their 
ability to decide whether to participate in other types of research were restricted. This 
paper also suggests that when consent requirements are waived or altered, it is important 
to demonstrate respect for individuals in other ways. While this is not meant to suggest 
that demonstrating respect in these other ways can replace the importance of choice, 
doing so many still help to alleviate feelings of being wronged.  However, additional 
empirical work on this topic is needed in order to support this normative claim. 
Future work should also focus on delineating what non-clinical risks of harm 
should reasonably fall under the minimal risk threshold as well as which burdens are so 
minor that they are unlikely to impact interests individuals have with regard to their 
health or general life course. It would be useful to engage in a closer examination of the 
different risks and burdens associated with previously implemented QI and CER 
activities to determine whether there are specific criteria that could be developed that 




if using opt out approaches is more efficient than traditional informed consent and results 
in higher participation in QI and CER activities since both considerations are important 
parts of the justification in favor of adopting these approaches. Finally, although it is 
already generally accepted that many QI activities do not require prospective informed 
consent, future work is needed to understand the social and political feasibility of 
implementing the morally permissible alternatives to informed consent described in this 
paper for CER activities (Faden et al. 2013b; Whicher 2013).  
Despite these outstanding issues, this paper builds on the small but growing body 
of literature devoted to understanding if the current regulations governing the practice of 
informed consent in the United States appropriately balance concerns about respect for 
the self-determination interests of individuals with interests in improving the quality of 
health care delivered to patients. The arguments in this paper suggest that there are 
additional situations in which it is morally permissible to waive or alter prospective 
informed consent requirements for QI and CER activities. Ensuring that the regulations 
appropriately balance these different considerations is critical as imposing overly 
protective consent requirements can prevent or delay the development of evidence 
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Paper 3: Simplified Disclosure Statements and Opt-Out Approaches as 
Policy Alternatives to Prospective Informed Consent for Low-Risk CER 
Trials 
Introduction  
There is a growing body of literature arguing for the importance of conducting 
randomized comparative effectiveness research (CER) trials of widely-used interventions 
in order to improve health care quality (Mullins et al. 2010; Tunis et al. 2003). Related, 
there has been increasing federal support for CER efforts, and, as such, the number of 
CER trials is likely to increase going forward (Patient Protection and Affordable Care 
Act 2010; Selby et al. 2012). Moreover, for the first time in forty years, there have been 
efforts to reform the U.S. federal human subjects research regulations (45CFR46).  One 
piece of the proposed changes aims to further ensure that the level of protection required 
for research projects is commensurate with the level of risk to individuals participating in 
those projects (Department of Health and Human Services 2011; Emanuel and Menikoff 
2011). While the proposed changes do not explicitly discuss streamlined oversight and 
consent options for CER, scholars have suggested that it may sometimes be appropriate 
to waive or alter consent requirements for this type of research (Kass et al. 2012). 
Related, it has been suggested elsewhere that under certain conditions, randomized trials 
pose no more than minimal risk to participants (Morris and Nelson 2007). Indeed, several 
scholars have questioned the appropriateness of always requiring that prospective 
informed consent be obtained from individuals eligible for randomized trials comparing 
widely-used, clinically indicated interventions (Faden et al. 2013; Selker et al. 2011; 




As CER trials are deliberately and increasingly integrated into ongoing clinical 
care, current consent requirements become challenging because of their length and 
complexity (Van Staa et al. 2012). Also, consent requirements are resource intensive, 
introduce selection bias, and can result in lower participation rates, while CER trials 
generally require large sample sizes to detect small but clinically meaningful differences 
between interventions. Such features of informed consent, of course, are relevant to all 
research and are not themselves sufficient for altering consent requirements, which are 
intended to provide protection to those who enter research and to demonstrate respect for 
autonomy. Instead, these considerations must be weighed against the importance of this 
protection and of exercising autonomy in different types of situations (Whicher 2013a).  
 
Constructing Viable Alternatives to Prospective Informed Consent  
Current regulations already allow waivers of consent for certain types of research 
studies, including observational studies relying on existing data. This reflects a view that 
when autonomy interests and the need for protection are thought to be more limited, it 
may be acceptable to allow commitments to improving clinical care to take precedence. 
However, there are several notable differences between observational studies and 
randomized CER trials that make supporting waivers for the latter more challenging. 
First, observational research does not alter patient care in any way.  Second, obtaining 
consent may be more difficult in observational research than in randomized CER trials, 
since observational research is often retrospective while randomized trials are conducted 




that is, more likely to feel violated or treated unfairly-- if they are enrolled in randomized 
trials without their consent (Lo and Groman 2003).    
Nevertheless, not all randomized trials are the same. Different features of a trial’s 
design or setting may affect whether the decision to participate engages significant 
autonomy interests and, as a result, how wronged individuals might feel if consent 
requirements are altered. Specifically, it has been suggested that individuals may feel less 
wronged if it is easy for physicians to over-ride the randomization, if all of the 
interventions being compared are widely-used and evidence-based and none of the 
interventions is significantly riskier than the others, and if the evidence generated is likely 
to be used to improve care (Whicher 2013a).  Moreover, and importantly, there are 
several options that one might consider for disclosure and authorization of clinical 
research besides completely waiving consent requirements or engaging in full prospective 
informed consent. These other options may more appropriately balance the ability to 
generate robust comparative effectiveness evidence with the desire to respect individuals’ 
interests and preferences. Alternatives can differ from prospective informed consent in 
the amount of information disclosed, the amount of control afforded to individuals over 
the decision to participate, and the format in which information is delivered and decisions 
documented. 
Notably, scholars have questioned the current requirement to disclose more 
information in CER trials about clinically indicated interventions than would be provided 
as part of standard clinical care (Van Staa et al. 2012). Instead, scholars have asserted that 
while patients should be informed about the research, it is appropriate to rely on “existing 




clinically indicated procedures” (Wendler and Grady 2008). Additionally, our own 
preliminary qualitative research suggests that many patients, comparative effectiveness 
researchers, and institutional review board members would support such an approach 
(Whicher 2013b).
 
Several patients in our study also commented that disclosing 
information that is not routinely provided in clinical care could scare or overwhelm 
individuals. 
Another option for low-risk CER trials is the use of “opt-out” rather than “opt-in” 
approaches.  Again, in our own work, many participants felt that opt-out approaches were 
acceptable if individuals were informed about both the trial and the opt-out option and 
opting-out was relatively easy. Under these conditions, the opt-out alternative arguably 
gives patients a sufficient amount of control over their participation while signaling the 
low-risk nature of the research as well as its importance. There is also some limited 
evidence from within clinical research (Berry et al. 2012; Rogers et al. 1998) and even 
stronger evidence from outside that context that opt-out approaches result in higher 
recruitment and participation rates (Jayaraman et al. 2003; Johnson and Goldstein 2004; 
Madrian and Shea 2001). Moreover, there is evidence that opt-out procedures can be 
readily integrated in standard care (Haukoos et al. 2010).  
 
Moving Towards Policy Change  
Either disclosing the same level and types of risk/benefit information as is given 
in standard care or using opt-out mechanisms could be considered as a possible 
alternative to full, prospective consent for low-risk CER trials of widely-used, clinically 




be more effective than either one alone at increasing the efficiency of conducting these 
trials and integrating them into clinical practice. Furthermore, because some degree of 
choice is preserved, these alternatives are less likely to result in individuals feeling 
wronged compared to complete waivers of consent. However, implementing these 
alternatives requires regulatory change.  To work towards such change, several key next 
steps must occur.  
First, to justify these changes, it is necessary to continue to build the case for the 
importance of CER by demonstrating its utility in improving health care quality. This will 
require ensuring that evidence generated from CER trials will be efficiently implemented 
in clinical care. Second, additional discussions are needed to determine what information 
should be disclosed to eligible individuals, including further defining appropriate clinical 
standards for disclosure. These discussions should also focus on determining effective 
mechanisms for disclosing information and documenting decisions. Third, it is necessary 
to gather additional information regarding stakeholders’ perceptions of the acceptability 
of using opt-out approaches (PCORI 2013). Fourth, additional work is needed to further 
define what kinds of research should qualify for these alternatives. Finally, it is important 
to conduct demonstration projects examining whether these approaches result in patients 
feeling sufficiently respected, actually improve efficiency, and are easier to integrate into 
clinical care to ensure that making policy changes to the informed consent regulations 
would have the desired positive effects.  
Given the recent focus on improving care quality through research, and also on 
reforming the U.S. human subjects research regulations, it is an important time to re-




morally desirable outcomes that they were designed to achieve. Respecting autonomy 
interests and protecting individuals is important.  Simplified disclosure statements and 
opt-out approaches may satisfy what is required in fulfilling these commitments in the 
context of low-risk CER trials of widely-used interventions, and may more appropriately 




Berry JG, Ryan P, Gold MS. A randomised controlled trial to compare opt-in and opt-out 
parental consent for childhood vaccine safety surveillance using data linkage. J Medical 
Ethics 2012; 38(10):619-625.  
 
Department of Health and Human Services. Human subjects research protections: 
enhancing protections for research subjects and reducing burden, delay, and ambiguity 
for investigators. Fed Regist 2011;76:44512-44531. 
 
Emanuel EJ, Menikoff J. Reforming the Regulations Governing Research with Human 
Subjects. N Engl J Med 2011; 365(12):1145-1150.  
 
Faden R, Kass N, Whicher D, Stewart W, Tunis S. Ethics and Informed Consent for 
Comparative Effectiveness Research with Prospective Electronic Clinical Data. Medical 
Care 2013; 51(8 Suppl 3): S53-7. 
 
Haukoos JS, Hopkins E, Conroy AA, et al. Routine opt-Out Rapid HIV Screening and 
Detection of HIV Infection in Emergency Department Patients. JAMA 2010; 304(3): 
284- 292.  
 
Jayaraman GC, Preiksaitis JK, Larke B. Mandatory reporting of HI infection and opt-out 
prenatal screening for HIV infection: effect on testing rates. Canadian Medical 
Association Journal 2003; 168(6): 679-682.  
 
Johnson EJ, Goldstein DG. Defaults and Donation Decisions. Transplantation 2004; 
78(12):1713-1716.  
 
Junghans C, Feder G, Hemingway H, Timmis A, Jones M. Recruiting patients to medical 






Kass N, Faden R, Tunis S. Addressing Low-Risk Comparative Effectiveness Research in 
Proposed Changes to US Federal Regulations Governing Research. JAMA 2012; 
307(15): 1589-1590. 
 
Lo B, Groman M. Oversight of Quality Improvement: Focusing on Benefits and Risks. 
Arch Intern Med 2003; 163(12):1481-1486.  
 
Madrian BC, Shea DF. The Power of Suggestion: Inertia in 401(k) Participation and 
Savings Behavior. The Quarterly Journal of Economics 2001; 116(4):1149-1187. 
 
Morris MC, Nelson RM. Randomized, controlled trials as minimal risk: An ethical 
analysis. Crit Care Med 2007; 35(3): 940-944. 
 
Mullins CD, WhicherD, Reese ES, Tunis S. Generating Evidence for Comparative 
Effectiveness Research Using More Pragmatic Randomized Controlled Trials. 
Pharmacoeconomics 2010; 28(10): 969-976. 
PCORI: Patient Centered Outcomes Research Institute. Stakeholder Views of 
Streamlined Informed Consent options for CER Studies. Available at: 
http://pcori.org/pfaawards/stakeholder-views-of-streamlined-informed-consent-options-
for-cer-studies/?state=MD&priority=&project_year=#map. Accessed October 24, 2013. 
 
Patient Protection and Affordable Care Act, Pub L No. 111-148, 124 Stat 727, §6301.  
 
Rogers CG, Tyson JE, Kennedy KA, Broyles RS, Hickman JF. Conventional consent 
with opting in versus simplified consent with opting out: An exploratory trial for studies 
that do not increase patient risk. JPediatr 1998; 132(4): 606-611.  
 
Selby JV, Beal AC, Frank L. The Patient-Centered Outcomes Research Institute (PCORI) 
National Priorities for Research and Initial Research Agenda. JAMA 2012; 307(15): 
1583-1584. 
 
Selker H, Grossmann C, Adams A, Goldmann D, Dezii C, Meyer G, Roger V, Savitz L, 
Platt R. The Common Rule and Continuous Improvement in Health Care: A Learning 
Health System Perspective. Institute of Medicine; October 2011.  
 
Truog RD, Robinson W, Randolph A, Morris A. Is informed consent always necessary 
for randomized, controlled trials? N Engl J Med 1999 Mar 11;340(10):804-807.  
 
Tunis ST, Stryer DB, Clancy CM. Practical Clinical Trials: Increasing the Value of 
Clinical Research for Decision Making in Clinical and Health Policy. JAMA 2003; 
290(12):1624-1632. 
United States Department of Health, Education, and Welfare, Code of Federal 





Van Staa TP, Goldacre B, Gulliford M et al. Pragmatic Randomized Trials Using Routine 
Electronic Health Records. BMJ 2012; 344:e55. 
 
Wendler D, Grady C. What Should Research Participants Understand to Understand they 
are Participants in Research? Bioethics 2008; 22(4): 203-208. 
 
Whicher D. Rethinking the Balance of Autonomy Interests with Interests in Achieving 
High Quality Health Care. Unpublished Dissertation Work 2013a. 
 
Whicher D. Stakeholders’ Views of Alternatives to Prospective Informed Consent for 







Appendix 1: Johns Hopkins Bloomberg School of Public Health IRB Approval Notice 
















Appendix 2: Geisinger Health System IRB Approval Notice 




























Appendix 4: Extended Methods Section for Aim 1 Qualitative Study Exploring 
Stakeholders’ Views of the Acceptability of Different Models of Consent, Disclosure, 
and Authorization 
 
This study explored stakeholders’ views on the acceptability of implementing 
alternatives to prospective informed consent for pragmatic randomized controlled trials 
(PCTs) comparing drugs that are widely-used in clinical practice and similar in terms of 
their route of administration as well as their side effect profiles.  To do so, this study 
conducted a series of 8 focus groups with patients and 18 semi-structured interviews with 
Institutional Review Board (IRB) members and researchers between July, 2012 and June, 
2013. Qualitative methods were used because qualitative approaches are appropriate 
when little information exists about a given topic as well as when a research project aims 
to understand people’s perspectives or attitudes and the reasons for these views 
(Sugarman and Sulmasy, 2010, 193-195). Focus groups were used to explore patient 
perspectives because informed consent is not a topic that many patients are familiar with 
and therefore, having other people with whom to discuss this topic could help to spur 
discussion. IRB members and researchers, on the other hand, have more experience 
discussing human subjects research and informed consent and may be more comfortable 
expressing their thoughts without their colleagues present. This study was approved by 
the Johns Hopkins Bloomberg School of Public Health IRB as well as the Geisinger 
Health System IRB. 
 
IV. Development of Materials for the Interviews and Focus Groups 
Materials used for the interviews and focus groups included the following: 




descriptions of the migraine and hypertension case studies (described in greater detail 
below), descriptions of four different models of consent, disclosure, and authorization 
(also described in greater detail below), and participant surveys. The in-depth interview 
and focus group guides contained the following: a set of introductory questions, 
background information on comparative effectiveness research (CER) and the case 
studies, a set of discussion questions about the case studies, and a set of questions 
designed to elicit participants’ perceptions of the different models of consent, disclosure, 
and authorization. Each of these domains is described in greater detail below.  All of the 
materials were developed by the student investigator (DW) and were reviewed and 
revised by a second member of the study team (NK).  
Prior to beginning the study, all project materials were pilot tested. To pilot test 
the focus group materials, a student investigator (DW) conducted 3 pilot interviews with 
hypertension patients and 2 pilot interviews with migraine patients from the Johns 
Hopkins Community Physicians (JHCP) network who met the eligibility criteria for this 
study, as described below. To pilot test the interview materials, the student investigator 
conducted 2 pilot interviews with researchers from Johns Hopkins Health System (JHS) 
and 3 individuals who previously served on an IRB at JHS. All but one of the pilot 
interviews was conducted in person; the other was conducted by phone. Pilot interviews 
were recorded but not transcribed. The student investigator took structured notes during 
the interview and directly following the interview. All project materials were updated 




(1) changing the description of the process of randomization in the case study 
information provided to patients from “flipping a coin” to “a computer selects” 
because patients felt that the “flipping a coin” language seemed unprofessional;  
(2) adding details to the description of the case studies because IRB members felt that 
it was distracting that additional information was provided when the case study 
was being verbally described by the student investigator (DW) that was not 
available in the case study information sheet; and 
(3) creating a PowerPoint presentation for the focus groups because one pilot 
participant suggested that it would be useful to have a visual to accompany the 
focus group discussion. The PowerPoint described the main points of the 
background information provided and listed the various discussion questions that 
participants were asked to talk about.  
 
Additionally, minor changes were made to the language in the descriptions of the case 
studies, the descriptions of the different models of consent, disclosure, and authorization, 
and the in-depth interview and focus group guides to further clarify the information 
provided.  Revised materials were submitted to the IRB and approved prior to the start of 
the study.  
 
V. Study Sites and Study Sample 
Focus groups and interviews were conducted at two locations: Johns Hopkins 
Health System (JHS) and Geisinger Health System (GHS). These two sites were selected 
because they differ in ways that may impact individual views on the appropriateness of 




academic institution located in rural Pennsylvania that serves a predominantly Caucasian 
patient population. Additionally, GHS  has a strong commitment to “developing and 
refining an innovation infrastructure that can adapt to new evidence efficiently, and 
rapidly translate that evidence into care delivery, and focus on patient benefit in a setting 
where many (or most) patients would be excluded from randomized trials because of age, 
comorbidities, and other limiting factors” (Paulus et al, 2008). JHS is situated within a 
large academic medical center located largely in an urban setting- Baltimore, Maryland 
and serves a racially diverse patient population. Although there is significant ongoing 
research within this institution, JHS arguably does not have internal and direct feedback 
loops for researchers’ findings to be integrated into the health system’s clinical guidelines 
and formularies.   
 
a. Patient Focus Groups 
As described in greater detail below, during the focus groups and interviews, two 
hypothetical case studies developed for this project were presented. The first case study 
described a PCT comparing widely-used drugs used to treat migraines and the second 
case described a PCT comparing widely-used drugs used to treat hypertension. Since 
individuals who have been diagnosed with a given health condition generally have more 
knowledge of that condition and the treatments for that condition and it was thought that 
knowledge made the topics discussed during the focus group more relevant, only 
individuals who had been diagnosed with either migraines or hypertension were eligible 
to participate in the focus groups. Specifically, 4 of the 8 focus groups (2 at each site) 




at each site) were attended by individuals who had been diagnosed with hypertension 
(table A.1). To be eligible, individuals also had to be over the age of 18 and had to have 
been receiving their health care within the health care system where the focus group was 
taking place for at least 1 year to ensure that they had some familiarity with the system.  
 
Table A.1: Focus Group Composition 
Focus Group Institution Composition Case 
A Geisinger Adults diagnosed with hypertension Hypertension study 
B Geisinger  Adults diagnosed with hypertension Hypertension study 
C Geisinger Adults diagnosed with migraine Migraine study 
D Geisinger Adults diagnosed with migraine Migraine study 
E Johns Hopkins Adults diagnosed with hypertension Hypertension study 
F Johns Hopkins Adults diagnosed with hypertension Hypertension study 
G Johns Hopkins Adults diagnosed with migraine Migraine study 
H Johns Hopkins Adults diagnosed with migraine Migraine study 
 
 
At GHS, a random sample of 100 migraine patients and 100 hypertension patients 
who met the eligibility criteria and who lived within a short distance of the health care 
facility in Danville, PA were identified through Geisinger’s electronic medical record 
system. This sample of patients was then mailed an invitation letter from the staff at GHS 
after approval from the patient’s primary care physician had been obtained. The letter 
informed individuals about how to opt out of the study and also informed them that if 
they did not opt out, they would receive a follow-up telephone call to inquire about their 
interest in participating in the study. The phone survey unit at GHS then called 
individuals who did not opt out until a sufficient number of individuals had been 
recruited to the focus groups. Of the 200 eligible individuals who were mailed an 
invitation letter about this study, 21 individuals opted out (6 migraine patients and 21 
hypertension patients) and 156 were called by the calling center in order to identify a 




hypertension patients). Of those, 34 individuals (16 migraine patients and 18 
hypertension patients) signed up to participant in one of the four focus groups and a total 
of 22 individuals ended up actually participating.  
Due to a combination of resource constraints and JHS not having the built-in 
infrastructure for research recruitment that GHS has, it was not possible to use this same 
method to recruit participants from JHS. Instead, to identify individuals who were willing 
and eligible to participate at JHS, recruitment posters were hung in exam rooms and 
waiting rooms at two clinics within the JHCP network.  JHCP is a network of health care 
clinics located throughout the state of Maryland. Individuals were recruited from either 
the Wyman Park clinic or the Canton Crossing clinic, which are both located in 
Baltimore, MD, in order to ensure that it was a short distance for individuals to attend the 
focus groups.  The recruitment posters contained information on the purpose of the study, 
the eligibility criteria, the amount of compensation given to participants, and contact 
information. Patients who were interested in participating and who believed they were 
eligible were asked to contact the student investigator by phone or email. The student 
investigator then described the research study in more detail to those who called and 
screened individuals to verify that they met the eligibility criteria. A total of 21 
individuals from JHCP (10 migraine patients and 11 hypertension patients) called the 
recruitment phone number after seeing the recruitment flyer posted in their clinic. Of 
those, 16 ended up participating in one of the four focus groups (8 migraine patients and 
8 hypertension patients). The others did not participate because they were ineligible, 





All focus group participants with given a $60.00 VISA gift card to compensate 
them for their time. 
 
b. IRB Member and Research Interviews 
IRB members from both institutions were eligible if they were either an IRB chair 
or if they had been an IRB member for 1 year or longer.  This was to ensure that 
participants had experience dealing with issues of research oversight and informed 
consent for different types of research. IRB community members were also eligible to 
participate as these individuals provide both considerable IRB experience as well as the 
perspective of a non-scientist.  Researchers were eligible to participate if they had 
experience conducting a CER project and/or if they were identified by their colleagues as 
having expertise in the field of CER.  The investigators determined if individuals had 
experience conducting an RCT by reviewing their peer reviewed publications as well as 
their biographical sketches, if available. 
At GHS, once eligible individuals were identified by the study investigators, a 
purposefully-selected sub-sample of those individuals was sent an introductory email by 
an investigator from GHS. Specifically, IRB chairs were invited to participate first as 
well as researchers who had more experience conducting CER studies. This email 
provided a brief explanation of the study, mentioned that an investigator from Johns 
Hopkins would contact them by email and provide additional details, and provided 
instructions regarding how to opt out of the study. A week later, an invitation email was 
sent from the student investigator (DW) at Johns Hopkins to all individuals who did not 




investigator would follow-up regarding scheduling an interview. The email also provided 
clear instructions on how to opt out of the study. If invited individuals did not respond or 
opt out within a week, they were contacted by telephone to seek their willingness to 
schedule an interview.  Additional individuals were recruited from the list of eligible IRB 
chairs and longstanding members and researchers using this same recruitment method 
until data saturation were reached. A total of 7 researchers were invited to participant and 
of those, 5 were interviewed. Additionally, 5 IRB chairs or longstanding members and 3 
IRB community members were invited to participate and of those, 3 chairs or 
longstanding members agreed to participate and were interviewed. No IRB community 
members agreed to be part of this study. Also, one of the researcher interviews was later 
dropped from the data analysis because the participant did not speak English very well 
and it was not clear that she understood the concepts or materials. This participant did not 
present any new themes or information that was not already discussed in other interviews. 
A similar process was followed to recruit participants from JHS. Again, a 
purposefully-chosen sub-sample of individuals was selected from the list of eligible 
individuals. Again, IRB chairs were invited to participate first as well as researchers who 
had more experience conducting CER studies. Researchers were sent an invitation letter 
that explained the study and indicated that the investigator would follow-up regarding 
scheduling an interview. The email also provided clear instructions on how to opt out of 
the study. The email was sent by a student investigator at JHS (DW) and was co-signed 
by an academic comparative effectiveness researcher from JHS as it was felt that 
researchers may be more responsive if they were aware that one of their colleagues 




were contacted by telephone to see if they were willing to schedule an interview.  Eligible 
IRB members were sent an introductory email from the director of human subjects 
research operations. This email provided a brief explanation of the study and mentioned 
that the student investigator (DW) would be following up with additional details. Shortly 
after, an invitation email, which provided a more detailed explanation of the study and 
also provided information about how to opt out, was sent from the student investigator 
(DW). If individuals did not respond within a week, they received a follow-up telephone 
call. Participants were recruited using this same recruitment method until data saturation 
was reached. A total of 7 researchers were sent invitation emails inquiring about their 
willingness to participate in this study. Of those, 4 were interviewed. Additionally, a total 
of 8 IRB chairs or longstanding members and 6 IRB community members were invited to 
participate and of those, 3 chairs and 3 community members were interviewed. 
 
VI. Focus Group and Interview Structure 
At the beginning of each focus group and interview, oral informed consent was 
obtained from participants. All focus groups were conducted in-person by the student 
investigator from Johns Hopkins (DW). A note-taker was also present at each of the 
focus groups. Each of the interviews was conducted by the same student investigator 
(DW). Interviews with professionals from GHS were conducted by phone. A majority of 
the interviews with professionals from JHS were conducted in-person with the exception 
of one, which was conducted by phone. All focus group and interview discussions were 
recorded and later transcribed. The interviews and focus groups all followed the same 




to supplement the information that was provided to focus group participants. No 
PowerPoint presentation was used during the interviews.  
 
a. Introductory Questions 
At the beginning of each focus group and interview, participants were asked 
several introductory questions. Patient participants were asked to introduce themselves, 
and to discuss how long they had had either migraines or hypertension, whether they had 
ever been asked to participate in a medical research study, what they believe the term 
‘medical research’ meant, and whether they thought it was important to conduct more 
research about treatments for migraines or hypertension. IRB members and researchers 
were asked a series of close-ended questions about their professional experience and their 
perceptions of the current regulations governing the practice of informed consent.  The 
purpose of the introductory questions was to get the participants comfortable talking 
about medical research and informed consent and to obtain some background 
information.  
 
b. Discussion of a Hypothetical Case Study 
Following these introductory questions, participants were given a brief description 
of CER and were then read one of two hypothetical case studies developed for this 
project. Both case studies described a PCT designed to compare two FDA approved and 
widely-used drugs that are both taken orally and that are similar in terms of their side 
effect profiles. Participants were told why doing the hypothetical trial was important and 




for the study, that individuals enrolled in the study would receive one of the drugs 
through a process of random assignment, and that there would be some minimal 
additional burdens imposed on individuals enrolled in the hypothetical trial. Focus group 
and interview participants were also told how being enrolled in the study was different 
from receiving clinical care outside of the study.  
One of the hypothetical case studies described a trial comparing anti-hypertension 
drugs to each other, and the other described a trial comparing drugs taken by patients to 
relieve migraine pain. Patients in focus groups reviewed the case study that related to the 
health condition that they had (either migraines or hypertension) whereas researchers and 
IRB members were assigned to one of the two cases such that about half of the 
interviewees reviewed the migraine case and the other half reviewed the hypertension 
case. These two disease areas were selected for several reasons. First, both conditions are 
highly prevalent in the United States and therefore pose a significant public health 
burden. In addition, for both conditions, there are a diverse set of therapies (both generic 
and brand name) that are prescribed to patients and there is a lack of information 
regarding the comparative effectiveness of these different therapies. There are also 
significant variations in the costs of the therapies. However, these conditions are also of 
interest because they differ from one another in notable ways. While migraines are a 
symptomatic condition, hypertension is a silent disease. In addition, while migraines are 
an acute, episodic condition, hypertension is a chronic condition. Therefore, although 
these conditions are amenable to the implementation of a PCT, they differ in ways that 




differences may also affect their views about participation in a randomized trial and, in 
turn, about appropriate models of consent, disclosure, or authorization. 
The two case studies were the same except for slight differences in the additional 
burdens imposed on study participants. In both of the case studies, participants in the 
hypothetical study would be asked to complete short surveys after they saw their doctor. 
The surveys would ask questions about patients’ use of and level of satisfaction with the 
drug they were prescribed. In addition, in the hypertension case, participants would be 
asked to return to the clinic two additional times beyond what is usually done as part of 
standard clinical care to have their blood pressure checked by a nurse.  In the migraine 
case, participants would be asked to write down information about the next three 
migraines they experienced after being prescribed a drug. The information requested 
includes the time when the individual first felt migraine pain and how bad that pain was, 
the time when the individual took the medication he or she was prescribed, how bad the 
migraine pain was 15 minutes, 30 minutes, 1 hour, and 2 hours after taking the drug, and 
whether the migraine returned within 24 hours of it going away. The purpose of 
reviewing these two case studies was to facilitate discussion and to provide a more 
concrete example to which study participants could react. 
After reviewing the hypothetical case studies with participants, the student 
investigator (DW) asked several discussion questions about the case. Specifically, focus 
group and interview participants were asked to discuss any risks of harm to patients who 
might enroll in the hypothetical case study trial and any benefits to patients who might 
enroll.  Focus group and interview participants were also asked about any social benefits 




interview participants only (IRB members and researchers) were asked whether they 
were aware of any trials like the one described in the case study. These questions were 
asked because of a view that respondents' perceptions of the risks and benefits as well as 
their perceptions of the number of trials like the ones described in the case study might 
relate to their views on the acceptability of the different models of consent, disclosure, 
and authorization for these particular case studies.  
 
c. Discussion of Four Different Models of Consent, Disclosure, and 
Authorization 
After the discussion of the hypothetical case study, participants were told about 
four different models of consent, disclosure, and authorization (table A.2) and were asked 
to consider the acceptability of each model as a way of enrolling individuals in the 
hypothetical case studies. Specifically, participants were read a description of each model 
and were told what some people may view as the pros and cons of it. The reason for 
providing some information on what people may see as the pros and cons of each model 
was so participants had some knowledge of the trade-offs involved in choosing between 
the different models. After being read each description, participants were asked their 
initial reactions to the model as well as if they had any questions about the model. Most 
interviewees and all focus group participants were also told that a major difference 
between models 2 and 3 versus model 4 is the amount of information provided to eligible 
individuals. With models 2 and 3, patients who are eligible for one of the hypothetical 
case studies are told about the study and what study participation entails. The amount of 




part of standard clinical care, meaning patients are told about the main risks and are given 
additional information when they pick up the drug at the pharmacy. With model 4, 
patients are also provided with information on the study and what study participation 
entails. However, when this model is used, the amount of information provided is typical 
of a standard informed consent form meaning individuals are told about all of the risks 
associated with a drug as well as what the alternatives to study participation are.  
 
 







 Individuals in a health care system are informed broadly that the system 
engages in CER of widely-used interventions and that sometimes patients are 
enrolled in these studies if they already need that general type of medicine.  
 Patients who might have been given either of the drugs in the study anyways 
might automatically be enrolled in these studies if they are eligible.  
 Patients are also informed how rights and interests are protected. 
Model 2: Study 
specific disclosure 
with no routine 
option to opt out  
 Patients are told that their health care system does a lot of medical research 
studies to compare widely-used drugs to each other to figure out which drugs 
work best.  
 If a patient is eligible for one of these studies, that patient is told about the 
study and then enrolled.  
 Patients can opt-out of the study, although they are not told this explicitly.  
Model 3: Study 
specific disclosure 
with an explicit 
option to opt out  
 Patients are told that their health care system does a lot of medical research 
studies to compare widely-used drugs to each other to figure out which drugs 
work best.  
 If a patient is eligible for one of these studies, that patient is told about the 
study and is also told that if he or she does not want to be part of the study, he 
or she can opt-out.  
 If a patient does not opt-out, he or she is enrolled in the study.  
Model 4: 
Prospective 
informed consent  
 Patients are told that their health care system does a lot of medical research 
studies to compare widely-used drugs to each other to figure out which drugs 
work best.  
 If a patient is eligible for one of these studies, that patient is told about the 
study and then asked if they would like to be a part of the study before being 
enrolled.  
  
After being told about all four models and providing their initial reactions, 
participants were asked a series of discussion questions about each of the models. 





(1) Please discuss whether or not you think this is an acceptable way of telling people 
about the medical research study we just discussed. 
(2) Please discuss what you think the benefits of using this approach are, if any. 
(3) Please discuss any concerns you have about this approach, if any. 
Patients were also asked to discuss how they would feel if their health care system used 
the different models to tell them about the hypothetical medical research study described 
in the case. Following this discussion, participants were asked to discuss which model 
they felt was the best way of telling patients about the medical research study described 
in the case.  
At the very end of the focus groups and interviews, participants were asked to 
complete short surveys. The patient surveys contained demographic questions as well as 
questions about several topics including past experience participating in research and 
perceptions of the importance of research. The survey also contained the 4 item “Trust in 
Medical Researchers” scale, which was validated in a national survey (Hall et al, 2006). 
The IRB member and research surveys also contained some demographic questions as 
well as questions about the participant’s experience conducting human subjects research 
and his or her past experience participating in research.  
The materials used during the interviews and focus groups were very similar. The 
only difference was that patients were provided with more information on key concepts 
such as medical research, CER, randomization, and selection bias. Additionally, at the 
end of the interviews, IRB members and researchers were asked four additional 




perceptions of the acceptability of the models would change in response to several 
variations on the case study:   
(1) The case study trial compared drugs that are administered differently 
(2) The case study trial compared drugs that had very different side effect profiles 
(3) The case study trial compared drugs that differently in terms of costs, even if 
patient in the trial would not be expected to pay for the drugs 
(4) The case study trial placed an even greater burden on participants 
 
VII. Data Management and Analysis 
Following each focus group or interview, the student investigator typed up her 
notes from the interview. She also noted key themes, any issues that arose, and ways to 
improve future focus groups or interviews. Additionally, the audio recording was sent out 
for transcription. When transcripts were received, all identifiable information was 
redacted from those transcripts. Transcripts were then checked against the audio 
recording and any mistakes were corrected. During this review, important or significant 
quotes were highlighted and additional themes were noted. Then, focus groups and 
interview transcripts were read more carefully and a coding scheme was developed. Once 
the coding scheme was finalized, all transcripts were read again and coded. Following 
this, a second coder used the coding scheme to independently code three transcripts (1 
focus group transcript, 1 interview transcript from an interview with a researcher, and 1 
interview transcript from an interview with an IRB member). The student investigator 
(DW) then checked the coded transcripts for consistency. Because there was a high level 




changes were made to the organization of the coding scheme. The coded transcripts were 
then reviewed a final time and summary documents that described the main themes from 
each of the focus groups and interviews were developed. The student investigator (DW) 
also noted how many interviewees discussed each specific code. For the focus group 
data, the student investigator noted how many focus groups discussed a certain theme, 
since recording numbers of participants would suggest false precision. Finally, major 
patterns were identified in the data. 
Quantitative data from the surveys participants were asked to complete at the end 
of the interviews and focus groups were entered into excel, double checked to ensure 
accurate data entry, and analyzed to understand background characteristics of participants 
as well as some of their views on research. 
Data reported in this dissertation relate to parts of this project that have to do with 
participants’ perceptions of the different models of consent, disclosure, and authorization 
for the hypothetical case studies. Data on patients’ perceptions of the importance of 
research, how patients prefer medical decisions to be made, and whether there is any 
relationship between these variables and the model of consent, disclosure, and 
authorization an individual prefers will be reported in a subsequent paper. Additionally, 
data on how interviewees’ opinions changed in response to the variations on the 
hypothetical case studies is not reported on in this dissertation but it will be described in a 
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Appendix 5a: Participant Consent Form: Johns Hopkins/Geisinger Comparative 
Effectiveness Researchers 
JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH 
AND GEISINGER HEALTH SYSTEM 
 
ORAL CONSENT SCRIPT FOR IN-DEPTH INTERVIEWS 
 
[Johns Hopkins OR Geisinger] Health System Comparative Effectiveness 
Researchers 
 
Study Title:  Rethinking Informed Consent for Pragmatic Comparative 
Effectiveness Trials 
Principal Investigator:  Dr. Nancy Kass (Johns Hopkins) 
       Dr. Steven Steinhubl (Geisinger) 
 
What you should know about this study 
 
 You are being asked to join a research study. 
 This consent form explains the research study and your part in the study.   
 Please review it carefully and take as much time as you need.  
 You are a volunteer.  You can choose not to take part and if you join, you may 
quit at any time. There will be no penalty if you decide to quit the study.   
 
Purpose of research project 
 
This research project is being done to learn what people think are acceptable strategies 
for informed consent, disclosure, and authorization for randomized comparative 
effectiveness trials.  
 
If you join this project, I will ask you to participate in an approximately one hour and a 
half long interview. During the interview, we will talk about one or two examples of 
medical research studies.  Both of these are examples of what is often called 
"comparative effectiveness research".  That is, in each example, the research we talk 
about will be comparing two different drugs to see which drug works better.  One 
example will be about migraine medications and the other example will be about 
hypertension medications.  The goal of our interview will be to talk through different 
approaches to informed consent, disclosure, and authorization that could be used for these 
hypothetical medical research studies. 
 
We want to know what you think of the different approaches to informed consent, 
disclosure, and authorization that could be used for the medical research study described 





Why you are being asked to participate 
 
You are being asked to participate because as a comparative effectiveness researcher, you 
have a lot of experience with speaking to people about medical research studies and 




If you join this research study, you will be asked to participate in an interview. The 
interview will last approximately one hour and a half. At the beginning of the interview, 
you will be asked a couple of questions about your professional experience. You will also 
be asked a couple of questions about your opinions of the current regulations governing 
the practice of informed consent. Then you will be asked to talk about one or two 
examples of medical research studies. One of the medical research studies is designed to 
understand which of two drugs is best for patients with hypertension.  The other medical 
research study is designed to understand which of two drugs is best for patients with 
migraines. Last, you will be asked questions about your opinions of a number of different 
models of informed consent, disclosure, and authorization that could be used for the 
example medical research studies. During the final 5 minutes of the interview, you will 
be asked to complete a short survey about your professional experience.  
 
I would like to record this interview so that I can capture all that you say without having 
to take a lot of notes during the interview.  All recordings will be erased as soon as they 




This is a very low risk project.  You do not have to answer any questions you would 
prefer not to answer.  In this project, we are not asking you questions directly about 
yourself but rather we seek your professional opinion about how to explain comparative 




There is no direct benefit to you from being in this study. However, we do hope that the 
results will help improve the way medical researchers tell people about medical research 
studies and ask them to participate.  
 
Protecting data confidentiality 
 
All research projects carry some risk that information about you may become known to 
people outside of a study. There is a risk that someone may find out that you participated 
in this project.  We will do everything we can to prevent that from happening.   
 
We will not include any identifying information, such as your name, in any notes or 




based on this research project.  The recording and transcript of the interview will be 
stored on a password-protected computer.  Only the members of the research team will 
have access to this information, and they will not be allowed to share it with anyone else.   
 
Who do I call if I have questions or problems? 
 
 Call the principal investigator, Nancy Kass, at (410) 614-5579 if you have 
questions or complaints related to this study. 
 
 Call or contact  
 
o For Johns Hopkins: the Johns Hopkins Bloomberg School of Public 
Health IRB Office if you have questions about your rights as a study 
participant. Contact the IRB if you feel you have not been treated fairly or 
if you have other concerns. The IRB contact information is: 
 
Address: Johns Hopkins Bloomberg School of Public Health 
615  Wolfe Street, Suite E1100 
Baltimore, MD 21205 
 
Telephone: 1-410-955-3193 
Toll Free:  1-888-262-3242 
Fax:  410-502-0584 
E-mail:irboffice@jhsph.edu 
 
o For Geisinger: the Human Research Protection Program staff of the 
Geisinger Institutional Review Board (which is a group of people who 
review the research to protect your rights) at (570) 271-8663. 
 
What does your voluntary permission mean? 
 
Your oral permission means: 
 
 You have been informed about this study’s purpose, procedures, possible benefits 
and risks. 
 You have been given the chance to ask questions. 
 You have voluntarily agreed to be in this study.  
 
PERMISSION TO PROCEED 
 







Appendix 5b: Participant Consent Form: Johns Hopkins/Geisinger Institutional 
Review Board Member 
JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH 
AND GEISINGER HEALTH SYSTEM 
 
ORAL CONSENT SCRIPT FOR IN-DEPTH INTERVIEWS 
 
[Johns Hopkins OR Geisinger] Health System Institutional Review Board Members 
 
Study Title:  Rethinking Informed Consent for Pragmatic Comparative 
Effectiveness Trials 
Principal Investigator:  Dr. Nancy Kass (Johns Hopkins) 
       Dr. Steven Steinhubl (Geisinger) 
 
What you should know about this study 
 
 You are being asked to join a research study. 
 This consent form explains the research study and your part in the study.   
 Please review it carefully and take as much time as you need.  
 You are a volunteer.  You can choose not to take part and if you join, you may 
quit at any time. There will be no penalty if you decide to quit the study.   
 
Purpose of research project 
 
This research project is being done to learn what people think are acceptable strategies 
for informed consent, disclosure, and authorization for randomized comparative 
effectiveness trials.  
 
If you join this project, I will ask you to participate in an approximately one hour and a 
half long interview. During the interview, we will talk about one or two examples of 
medical research studies.  Both of these are examples of what is often called 
"comparative effectiveness research".  That is, in each example, the research we talk 
about will be comparing two different drugs to see which drug works better.  One 
example will be about migraine medications and the other example will be about 
hypertension medications.  The goal of our interview will be to talk through different 
approaches to informed consent, disclosure, and authorization that could be used for these 
hypothetical medical research studies. 
 
We want to know what you think of the different approaches to informed consent, 
disclosure, and authorization that could be used for the medical research study described 





Why you are being asked to participate 
 
You are being asked to participate because as an Institutional Review Board member, you 
have a lot of experience thinking about how to protect and respect individuals who are 




If you join this research study, you will be asked you to participate in an interview. The 
interview will last approximately one and a half hours. At the beginning of the interview, 
you will be asked a couple of questions about your professional experience. You will also 
be asked a couple of questions about your opinions of the current regulations governing 
the practice of informed consent. Then you will be asked to talk about one or two 
examples of medical research studies. One of the medical research studies is designed to 
understand which of two drugs is best for patients with hypertension.  The other medical 
research study is designed to understand which of two drugs is best for patients with 
migraines. Last, you will be asked questions about your opinions of a number of different 
models of informed consent, disclosure, and authorization that could be used for the 
example medical research studies.  During the final 5 minutes of the interview, you will 
be asked to complete a short survey about your professional experience. 
 
I would like to record this interview so that I can capture all that you say without having 
to take a lot of notes during the interview. All recordings will be erased as soon as they 




This is a very low risk project.  You do not have to answer any questions you would 
prefer not to answer.  In this project, we are not asking you questions directly about 
yourself but rather we seek your professional opinion about how to explain comparative 




There is no direct benefit to you from being in this study. However, we do hope that the 
results will help improve the way medical researchers tell people about medical research 
studies and ask them to participate.  
 
Protecting data confidentiality 
 
All research projects carry some risk that information about you may become known to 
people outside of a study. There is a risk that someone may find out that you participated 
in this project.  We will do everything we can to prevent that from happening.   
 
We will not include any identifying information, such as your name, in any notes or 




based on this research project.  The recording and transcript of the interview will be 
stored on a password-protected computer.  Only the members of the research team will 
have access to this information, and they will not be allowed to share it with anyone else.   
 
Who do I call if I have questions or problems? 
 
 Call the principal investigator, Nancy Kass, at (410) 614-5579 if you have 
questions or complaints related to this study. 
 
 Call or contact  
 
o For Johns Hopkins: the Johns Hopkins Bloomberg School of Public 
Health IRB Office if you have questions about your rights as a study 
participant. Contact the IRB if you feel you have not been treated fairly or 
if you have other concerns. The IRB contact information is: 
 
Address: Johns Hopkins Bloomberg School of Public Health 
616  Wolfe Street, Suite E1100 
Baltimore, MD 21205 
 
Telephone: 1-410-955-3193 
Toll Free:  1-888-262-3242 
Fax:  410-502-0584 
E-mail:irboffice@jhsph.edu 
 
o For Geisinger: the Human Research Protection Program staff of the 
Geisinger Institutional Review Board (which is a group of people who 
review the research to protect your rights) at (570) 271-8663. 
 
What does your voluntary permission mean? 
 
Your oral permission means: 
 
 You have been informed about this study’s purpose, procedures, possible benefits 
and risks. 
 You have been given the chance to ask questions. 
 You have voluntarily agreed to be in this study.  
 
PERMISSION TO PROCEED 
 






Appendix 5c: Participant Consent Form: Johns Hopkins/Geisinger Patients with 
Hypertension 
JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH 
AND GEISINGER HEALTH SYSTEM 
 
ORAL CONSENT SCRIPT FOR FOCUS GROUPS 
 
[Johns Hopkins OR Geisinger Health System] Patients with Hypertension 
 
Study Title:  Rethinking Informed Consent for Pragmatic Comparative 
Effectiveness Trials 
Principal Investigator:  Dr. Nancy Kass (Johns Hopkins) 
       Dr. Steven Steinhubl (Geisinger) 
 
What you should know about this study 
 
 You are being asked to join a research study. 
 This consent form explains the research study and your part in the study.   
 Please read it carefully and take as much time as you need.  
 You are a volunteer.  You can choose not to take part and if you join, you may 
quit at any time. There will be no penalty if you decide to quit the study.   
 
Purpose of research project 
 
This research project is being done to figure out the best ways to tell people about 
medical research studies. 
  
Today, we are asking you to be part of a 2-3 hour focus group.  During the focus group, 
we will talk about an example of a medical research study. The goal of the medical 
research study example will be to figure out which of two drugs works better for people 
with high blood pressure. What we want to talk to you about today is different options for 
telling people about the high blood pressure study.   
 
We want to know what you think of the different ways of telling people about the 
medical research study described in the example.   
 
Why you are being asked to participate 
 
Since the example is about a research study related to high blood pressure, we think the 
best people to give us advice on how to talk to patients about it are also people with high 
blood pressure.  So we only want people to be part of this group today who have been 
receiving medical care at [Johns Hopkins OR Geisinger] Health System for high blood 







If you join this research study today, you will be asked to be part of a focus group. The 
focus group will last 2-3 hours. During the focus group, you will be asked to talk about 
an example of a medical research study that is designed to understand which of two drugs 
is best for patients with high blood pressure.  The group will then discuss a number of 
different ways to tell people with high blood pressure about the medical research study 
example described.  
 
At the end of the focus group, you will be asked to complete a short survey with some 
questions about yourself. The survey will also ask you what you think about medical 
research.  
 
You should also know that this focus group discussion will be recorded so that we can 
keep track of the comments you make without having to take too many notes today. All 




This is a very low risk project.  You do not have to answer any questions you would 




There is no direct benefit to you from being in this study. However, we do hope that the 





You will be given a $60 gift card for being part of the group today. This money is meant 
to cover your travel costs and the 2-3 hours you will spend in the focus group discussion. 
You will be paid at the end of the focus group. If you have to leave early, your payment 
will be given to you at the time you leave the focus group.  
 
Protecting data confidentiality 
 
All research projects carry some risk that information about you may become known to 
people outside of a study. There is a risk that someone may find out that you are in this 
project and that you have high blood pressure.  We will do everything we can to prevent 
that from happening.   
 
We will not include any identifying information, such as your name, in any notes or 
transcripts from the focus group.  You will not be named in any reports that are written 




password-protected computer.  Only the members of the research team will have access 
to this information, and they will not be allowed to share it with anyone else.   
 
The other members of the focus group will be asked not to discuss who else was part of 
the focus group. 
 
Protecting subject privacy during data collection 
 
To help protect everyone's privacy, only two people from the research team will be in the 
room during the focus group.  
 
What happens if you leave the focus group early?   
 
If you leave the focus group early, there will be no negative consequences to you. You 
will be given your payment for participation at the time you leave the focus group. 
 
Who do I call if I have questions or problems? 
 
 Call the principal investigator, Nancy Kass, at (410) 614-5579 if you have 
questions or complaints related to this study. 
 
 Call or contact  
 
o For Johns Hopkins: the Johns Hopkins Bloomberg School of Public 
Health IRB Office if you have questions about your rights as a study 
participant. Contact the IRB if you feel you have not been treated fairly or 
if you have other concerns. The IRB contact information is: 
 
Address: Johns Hopkins Bloomberg School of Public Health 
617  Wolfe Street, Suite E1100 
Baltimore, MD 21205 
 
Telephone: 1-410-955-3193 
Toll Free:  1-888-262-3242 
Fax:  410-502-0584 
E-mail:irboffice@jhsph.edu 
 
o For Geisinger: the Human Research Protection Program staff of the 
Geisinger Institutional Review Board (which is a group of people who 
review the research to protect your rights) at (570) 271-8663. 
 
What does your voluntary permission mean? 
 
Your oral permission means: 





 You have been given the chance to ask questions. 
 You have voluntarily agreed to be in this study.  
 
PERMISSION TO PROCEED 




Appendix 5d: Participant Consent Form: Johns Hopkins/Geisinger Patients with 
Migraines 
JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH 
AND GEISINGER HEALTH SYSTEM 
 
ORAL CONSENT SCRIPT FOR FOCUS GROUPS 
 
[Johns Hopkins OR Geisinger] Health System Patients with Migraines 
 
Study Title:  Rethinking Informed Consent for Pragmatic Comparative 
Effectiveness Trials 
Principal Investigator:  Dr. Nancy Kass (Johns Hopkins) 
       Dr. Steven Steinhubl (Geisinger) 
 
What you should know about this study 
 
 You are being asked to join a research study. 
 This consent form explains the research study and your part in the study.   
 Please read it carefully and take as much time as you need.  
 You are a volunteer.  You can choose not to take part and if you join, you may 
quit at any time. There will be no penalty if you decide to quit the study.   
 
Purpose of research project 
 
This research project is being done to figure out the best ways to tell people about 
medical research studies. 
  
Today, we are asking you to be part of a 2-3 hour focus group.  During the focus group, 
we will talk about an example of a medical research study. The goal of the medical 
research study example will be to figure out which of two drugs works better for people 
with migraines. What we want to talk to you about today is different options for telling 
people about the migraine study.   
 
We want to know what you think of the different ways of telling people about the 
medical research study described in the example.   
 
Why you are being asked to participate 
 
Since the example is about a research study related to migraines, we think the best people 
to give us advice on how to talk to patients about it are also people with migraines.  So 
we only want people to be part of this group today who have been receiving medical care 
at [Johns Hopkins OR Geisinger] Health System for migraines. There will be between 6 







If you join this study today, you will be asked to be part of a focus group. The focus 
group will last 2-3 hours. During the focus group, you will be asked to talk about an 
example of a medical research study that is designed to understand which of two drugs is 
best for patients with migraines.  The group will then discuss a number of different ways 
to tell people with migraines about the medical research study example described.  
 
At the end of the focus group, you will be asked to complete a short survey with some 
questions about yourself. The survey will also ask you what you think about medical 
research.  
 
You should also know that this focus group discussion will be recorded so that we can 
keep track of the comments you make without having to take too many notes today. All 




This is a very low risk project.  You do not have to answer any questions you would 




There is no direct benefit to you from being in this study. However, we do hope that the 





You will be given a $60 gift card for being part of the group today. This money is meant 
to cover your travel costs and the 2-3 hours you will spend in the focus group discussion. 
You will be paid at the end of the focus group. If you have to leave early, your payment 





Protecting data confidentiality 
 
All research projects carry some risk that information about you may become known to 
people outside of a study. There is a risk that someone may find out that you are in this 
project and that you have migraines.  We will do everything we can to prevent that from 
happening.   
 
We will not include any identifying information, such as your name, in any notes or 
transcripts from the focus group.  You will not be named in any reports that are written 
from this project.  The recording and transcript of the focus group will be stored on a 
password-protected computer.  Only the members of the research team will have access 
to this information, and they will not be allowed to share it with anyone else.   
 
The other members of the focus group will be asked not to discuss who else was part of 
the focus group. 
 
Protecting subject privacy during data collection 
 
To help protect everyone's privacy, only two people from the research team will be in the 
room during the focus group.  
 
What happens if you leave the focus group early?   
 
If you leave the focus group early, there will be no negative consequences to you. You 
will be given your payment for participation at the time you leave the focus group. 
 
Who do I call if I have questions or problems? 
 
 Call the principal investigator, Nancy Kass, at (410) 614-5579 if you have 
questions or complaints related to this study. 
 
 Call or contact  
 
o For Johns Hopkins: the Johns Hopkins Bloomberg School of Public 
Health IRB Office if you have questions about your rights as a study 
participant. Contact the IRB if you feel you have not been treated fairly or 
if you have other concerns. The IRB contact information is: 
 
Address: Johns Hopkins Bloomberg School of Public Health 
618  Wolfe Street, Suite E1100 
Baltimore, MD 21205 
 
Telephone: 1-410-955-3193 
Toll Free:  1-888-262-3242 






o For Geisinger: the Human Research Protection Program staff of the 
Geisinger Institutional Review Board (which is a group of people who 
review the research to protect your rights) at (570) 271-8663. 
 
What does your voluntary permission mean? 
 
Your oral permission means: 
 You have been informed about this study’s purpose, procedures, possible benefits 
and risks. 
 You have been given the chance to ask questions. 
 You have voluntarily agreed to be in this study.  
 
PERMISSION TO PROCEED 




Appendix 6a: In-Depth Interview Guide: Comparative Effectiveness Researchers 
and Institutional Review Board Members 
 Thank you for volunteering to help with this project. I appreciate your willingness to 
share your time and ideas.   
 
 The goal of this project is to understand the best methods for describing to patients 
and asking patients to participate in comparative effectiveness trials comparing 
widely available drugs in order to understand which drugs work best.  
 
 Just as a reminder, what you say here is confidential – your name will not be used in 
any of our write-ups  
 
 So before we begin, is it alright with you if I record this discussion?   
 
 Do you have any questions before we begin? 
 
Close Ended Questions 
 I would like to begin by asking a number of closed ended questions about your 
professional experience. [Not all questions were asked of all interviewees. Relevant 
questions were asked based on the expertise of the interviewee.] 
 
1. How long have you been employed at [Johns Hopkins or Geisinger]? 
 
2. How long have you been a member of the IRB? 
 
3. Are you currently involved in the conduct of a prospective randomized control 
trial?  
 
4. Have you ever been involved in the conduct of a prospective randomized control 
trial? 
 
5. Do you have experience seeking informed consent for randomized control trials? 
 
a. Probe: What did you or do you think of the process? 
 
6. Can you think of any recent IRB applications where the IRB had a difficult time 
deciding whether the application qualified for a waiver or alteration of informed 
consent or where the IRB wanted to implement a waiver and the regulatory 
people wouldn’t allow them to? 
 
a. Probe: Why did the IRB have a difficult time deciding? 
 
7. How well do you think the current informed consent regulations do at protecting 




a. Probe: What changes, if any, do you think should be made to improve the 
current regulations? 
 
Explanation of the First Case Study 
 
 Today I would like to discuss a certain subset of comparative effectiveness trials 
 That is ones that are:  
o conducted in routine clinical settings 
o compare two or more FDA approved and widely used drugs,  
 where there is considerable disagreement about which of the drugs 
work best, and  
 where there are not significant differences in how the drugs are 
administered or the side effects associated with the drugs.  
o And ones where patients are randomly assigned to treatment arms 
 So that we have a more concrete example to discuss, I would like to go through a 
specific case study that describes a trial that meets this description 
 Please turn to the first handout and feel free to take notes as we review it together. 
 
1. Do you have questions before I start reading the case study? 
 
[Read through one of the two case studies] 
 
Case Study Discussion Questions 
 
1. Are you aware of any trials like the one described in the case study meaning a 
trial that compares similar and widely used therapies to one another in a routine 
clinical setting that are currently ongoing? *Note: the study doesn’t have to be 
about blood pressure or migraine drugs 
 
2. Can you describe what you believe are the risks of harm to people who participate 
in the kind of clinical trial described in the case study? 
 
3. Can you describe what you believe are the benefits to patients who participate in 
the kind of clinical trial as well as the benefits to patients more broadly? 
 
Explanation of consent, disclosure, and authorization models 
 
 I would now like to discuss a number of different ways that patients could be 
informed about the trial described in the case study.  
 
 As you are aware, prospective informed consent is generally required for all clinical 
trials involving individual randomization of patients.  
 
 However, what I am interested in getting your perspective on is whether there are 
alternative, less burdensome models of consent, disclosure, or authorization (and I 




comparing similar and widely used drugs to each other in the context of routine 
clinical care such as the trial described in the case.  
 
 Again, you have a document that describes the different models as well as what some 
people view as the pros and cons of those different models that I would like to go 
through together 
 
 Feel free to take notes and I will pause after each section for feedback 
 
1. Do you have any questions or comments before we begin? 
 
[Read second handout] 
 
Perceptions of the Different Models 
 
 I would now like to ask you some questions to understand what you think of the 
different models. For the sake of this project I would like to know what you think 
is acceptable and not what the current human subjects regulations require.  
 
We will first start by discussing the first model: broad authorization [review models 
briefly].  
  
1. Thinking about the case, please describe whether or not you think this is an 
acceptable method. 
a. Probe participants on why they think this is acceptable or not 
i. Can you tell me about why you think this is acceptable? 
ii. Can you tell me about why you don’t think is acceptable? 
b. If participants are discussing randomization, probe on why randomization 
is relevant.  
c. If participants point out other aspects of the study as being problematic, 
probe on why they think that part of the case study is problematic.   
 
2. Describe what you think the benefits of using this approach are 
 
3. Describe any concerns you have about this method 
a. Probe: Tell me about how important these concerns are to you  
 
Now let’s turn to the second model: disclosure with no option to opt out. 
 
1. Again, thinking about the trial described in the case, please describe whether or 
not you think this is an acceptable method. 
a. Probe participants on why they think this is acceptable or not 
i. Can you tell me about why you think this is acceptable? 
ii. Can you tell me about why you don’t think is acceptable? 
b. If participants are discussing randomization, probe on why randomization 




c. If participants point out other aspects of the study as being problematic, 
probe on why they think that part of the case study is problematic  
 
2. Describe what you think the benefits of using this approach are 
 
3. Describe any concerns you have about this method 
a. Probe: Tell me about how important these concerns are to you  
 
Great – now let’s discuss the third way of telling patients. The only difference between 
this models and the way we just discussed is that if this model were used, patients would 
be able to tell a nurse that they would not like to be part of the trial. 
 
1. Given this, please discuss how your opinions change if patients were able to tell 
someone involved in the trial that they would not like to be part of the study.   
 
Finally, we will discuss informed consent. 
 
1. Thinking about the case, please describe what you think are the benefits of using 
this approach  
 
2. Discuss whether you think this approach is better or worse than the other 
approaches we described 
 
Okay great. So…  
 
1. Given our discussion today, please discuss what you think is the best way of 
telling patients about the example medical research study comparing drugs used 
to treat [migraine or hypertension]. 
 
Just a couple more questions. 
 Can you describe how your opinions regarding the acceptability of the models 
would change if the case study trial were comparing 2 different drugs that are 
administered differently? 
 Can you describe how your opinions would change if the therapies being 
compared had very different side effect profiles? 
 Can you describe how your opinions would change if one of the therapies was 
much more costly than the other therapy even if patients in the trial would not be 
expected to pay for the therapies? 
 Can you describe how your opinion would change if patients were required to 





Appendix 6b: Focus Group Guide: Patients with Hypertension or Migraines 
 Thank you for volunteering to help with this project. I appreciate your willingness to 
share your time and ideas.   
 
 The goal of this project is to understand what the best ways are for telling patients 
about medical research studies. During this group discussion, I’m going to tell you 
about a particular type of medical research.  I’m then going to ask your advice on 
how to explain this research to people, and how much explaining is needed.  
 
 The focus group will last 3 hours. During this time, I’m hoping we can have a real 
discussion, meaning that I hope you’ll talk to each other at least as much as you talk 
to me.    Feel free to disagree with what others have said or give another opinion: the 
more different ideas I hear, the more information I will have to work with.  But also 
please be respectful of other members of the group.  
 
 I will let you know when we are near the end of our time.  If you have to go to the 
bathroom, just slip out quietly and come back as quickly as you can. 
 
 At the very end of the discussion, I will ask you to complete a short survey where you 
will be asked to answer several questions about yourself and where you will be asked 
to provide any final thoughts you have based on today’s discussion. Once you have 
handed in your survey, you will receive a $60 visa gift card to show our appreciation 
for your participation in this focus group. 
 
 Just as a reminder, what you say here is confidential – your name will not be used in 
any of our write-ups  
 
 I also want to ask that none of you states your last name during the focus group 
discussion. You may even choose to not to use your real name during the focus group 
if you wish. If you prefer not to use your real name, feel free to make up another 
name that you would like people to use during the focus group. 
 
 Also, once we leave the focus group, I would like to ask that you do not repeat what 
anyone else said during the focus group or tell other people who was part of this focus 
group with you. 
 
 If you have any questions about this focus group or the project after we leave, you 
can me at 978-407-7265 or write me an email at dwhicher@jhsph.edu. 
 
 So before we begin, is it alright with you if I record this discussion? 
 







I would now like to ask you a couple of introductory questions.  
1. Please introduce yourself and tell us your first name. If you would prefer not to 
use your real name, feel free to make up another name that you would like people 
to use. 
 
2. Can each of you please share how long you have had [high blood pressure or 
migraines] for? 
 
3. Has anyone ever talked with you about being part of a medical research study –
either related to your [high blood pressure or migraines] or to something else?  
 
4. Please describe what the term ‘medical research’ means to you. 
 
5. Please discuss whether you think more research about treatments for [migraine or 
high blood pressure] is important? 
 
Explanation of the Case Example 
 Today I want to talk to you about a particular type of research study for [high blood 
pressure or migraine] that might be done.  
 
 Some research studies test brand new drugs to see if they work at all and might 
include a placebo.  But the kind of study I want to talk to you about is different. 
Today we will be talking about medical research studies that compare drugs that 
doctors use all the time to treat patients with [high blood pressure or migraines] 
because they know that these drugs work. However, the reason they want to do a 
medical research study is because they do not know which one works the best.  
 
 So we are talking about medical research studies where people in the study get 1 of 2 
drugs that are given to patients with [high blood pressure or migraines] all the time by 
doctors. This means that none of the patients in the study will get a placebo. 
 
 To begin the discussion, I am going to read you an example of a medical research 
study that fits this description that medical researchers might do to figure out what the 
best drug is to treat [high blood pressure or migraine]. Please note, this is a 
hypothetical research study – [Johns Hopkins or Geisinger] is not actually doing this. 
 
 You have received a handout that describes the important points about this medical 
research study. Feel free to take notes on that sheet of paper while I read through the 
case with you and feel free to stop me at any point if you have questions. I will start 
by describing why this study might be done. I will then describe what would happen 
to patients who are in the study and finally, how being in the study is different from 
just getting ordinary clinical care without being in a study. 
 







[Read hypertension or migraine case] 
 
Case Example Discussion Questions 
 
1. Please describe whether you think that the results from this medical research 
study will be useful for patients like you and your doctor. 
 
2. Can you tell me about whether there are any risks of harm or bad things that could 
happen to patients if they are a part of the medical research study? 
 
3. Can you tell me about whether there are any benefits or good things that could 
happen to patients if they are a part of the medical research study? 
 
4. Can you tell me about whether there are any benefits or good things that could 
happen for other patients with [migraine or high blood pressure] at [Johns 
Hopkins or Geisinger] as a result of this medical research study being done? 
 
 
Explanation of consent, disclosure, and authorization models 
 
 Now that we have gone through the case study, I want to talk to you about a few 
different ways that doctors or medical researchers could tell patients about medical 
research studies going on in their clinics or hospitals.  
 
 Today we will talk about 4 different ways that patients might be told about medical 
research studies like the one in the case example we just talked about.  
 
 After we go through all 4, I will ask you what you think about these different ways of 
telling patients about the medical research study described in the case example.  
 
 The next document in your folder describes the different ways patients might be told. 
Let’s go through this document together. 
 
1. Are there any questions before we begin? 
 
[Read through hand out on models of consent, disclosure, and authorization] 
 
1. Are there any questions on any of the information we have discussed so far? 
 
 Now I just want to quickly talk about how these models relate to the case study we 
talked about and what normally happens when patients go to see their doctor.  
 
 When you go to your doctor’s office for an appointment, you are not generally asked 




doctor’s office, it is assumed that you are agreeing to allow the doctor to give you a 
check-up and to give you basic medical care if needed.  
 
 Remember, the example medical research study we discussed is like what happens 
when you go to your doctor’s office because many patients who receive a drug to 
treat their [migraines or high blood pressure] are given one of the two drugs that 
patients who are part of the medical research study get.  
 
 However, it is different from what happens when you go to your doctor’s office 
because patients in this medical research project are assigned one drug or the other 
based on a random assignment, meaning their treatment is chosen by a computer. 
Also, information about how well the drugs work at [relieving pain or reducing blood 
pressure] will be collected by medical researchers from patients who are part of the 
medical research study to help them figure out which drug is best.  
 
Perceptions of the Different Models 
Okay, now, given all the information we talked about today, I would like to understand 
your opinions about each of the 4 different ways patients might be told about medical 
research studies.   
 
We will first start by discussing the first way of telling patients about medical research 
studies that is listed on your handout called “Broad Authorization” where patients are 
told that [Johns Hopkins or Geisinger] does a lot of studies like the one we discussed and 
patients are not told about every one. 
  
4. Please discuss whether or not you think this is an acceptable way of telling people 
about the medical research study we just discussed. 
a. Probe participants on why they think this is acceptable or not 
b. If participant is discussing randomization, probe on why randomization is 
so problematic.  
c. If participants point out other aspects of the study as being problematic, 
probe on why they think that part of the case study is problematic.   
d. If participants describe changing the way care is delivered as being 
problematic, ask what are the kinds of changes that a doctor can make that 
you would not need to be told about? 
 
5. Please discuss how you would feel if [Johns Hopkins or Geisinger] used this way 
of telling you about the medical research study we discussed earlier. 
 
6. Please discuss what you think the benefits of using this approach are 
 
7. Please discuss any concerns you have about this method 
a. Probe: Tell me about how important these concerns are to you  
 
8. There are some medical research studies where nothing happens to patients. 




Please discuss if you think this is an acceptable way of telling patients about 
medical research studies where researchers were only looking at information in 
people’s medical records.  
 
 
Now let’s turn to the second model which involves telling patients about a specific 
medical research study, such as the one we discussed, without giving them a way to 
choose not to be part of the medical research study. Remember the key points about this 
way of telling people are on your handout. 
 
4. Please discuss whether or not you think this is an acceptable way of telling people 
about the medical research study we just discussed. 
a. Probe participants on why they think this is acceptable or not 
b. If participants are discussing randomization, probe on why randomization 
is so problematic.  
c. If participants point out other aspects of the study as being problematic, 
probe on why they think that part of the case study is problematic  
 
5. Please discuss how you would feel if [John Hopkins or Geisinger] used this way 
of telling you about the medical research study we discussed earlier. 
 
6. Please discuss what you think the benefits of using this approach are 
 
7. Please discuss any concerns you have about this method 
a. Probe: Tell me about how important these concerns are to you  
 
Great – now let’s discuss the third way of telling patients. The only difference between 
this way of telling patients and the way we just discussed is that if this way of telling 
patients were used, patients would be able to tell a nurse that they would not like to be 
part of the medical research study. 
8. Given this, please discuss how your opinions would change if patients were able 
to tell someone involved in the medical research study that they would not like to 
be part of the study.   
 
Finally, we will discuss the last way of telling people about medical research studies that 
is listed on your handout. This where patients are told about the medical research study 
and are allowed to choose whether or not to participate.  
 
3. Describe what you think are the benefits of using this way of telling people about 
and asking them to be part of the medical research study we just discussed. 
 
4. Please discuss how you would feel if [Johns Hopkins or Geisinger] used this way 
of telling you about the medical research study we discussed earlier 
 
5. Discuss whether or not you think this way of telling people is better or worse than 





Okay great. I just have one final question.  
1. Given our discussion today, please discuss what you think is the best way of 
telling patients about the example medical research study comparing drugs used 
to treat [migraine or hypertension]. 
 
We have come to the end of our discussion. I have reserved the last 15 minutes to allow 
you time to complete a short survey. Please select the answer to these questions that you 
feel best describes your feelings about these topics – there is no right or wrong answer – I 
am most interested in your own opinions. At the end of the survey you will be given the 
opportunity to provide any final thoughts you have based on today’s discussion. Please 
remember that you do not have to answer any questions that make you uncomfortable.   
 
Thank you for participating - your opinions and ideas are very valuable. Once we leave 
the focus group, I would like to ask that you do not repeat any of the focus group 






Appendix 7a: Case Studies: Hypertension Case Study Description 
*This was the version of the case study provided to patients. The version provided to 
researchers and IRB members had less explanation of key concepts such as 
randomization.  
 
The High Blood Pressure Medical Research Study: 





 Right now, there are many different drugs that are used to lower blood pressure for 
patients who have high blood pressure if diet and lifestyle changes are not enough. 
Some doctors start their patients on one of these drugs and some doctors start their 
patients on another. 
 
 Even though all the drugs lower blood pressure and all of them are safe, doctors are 
not sure which one works the best at lowering blood pressure and reducing the chance 
that a patient will have a heart attack or a stroke. This is because not a lot of research 
has been done that compares these drugs to one another. 
 
 Medical research studies that compare these drugs to each other can help us figure out 
which drug is the best at lowering blood pressure and reducing the chance that a 
person will have a heart attack or stroke. Therefore, [Johns Hopkins or Geisinger] 




How would the medical research study work? 
 
 Patients at [Johns Hopkins or Geisinger] with high blood pressure who need to start 
taking a drug to lower their blood pressure will be prescribed one of the two most 
commonly used drugs based on a random assignment.  
 
 This means that a computer program will select one of the two drugs in the study and 
the patient’s doctor will prescribe that drug to the patient. Therefore, patients in the 
study have an equal chance of being prescribed either of the two drugs.  
 
 The two drugs that are being studied are ones that patients would likely have been 
prescribed even if they were not in the medical research study. This means that 
patients in the medical research study are getting the same drugs as many patients 





 Also, a patient can only be in the medical research study if that patient’s doctor 
determines that both drugs in the study are appropriate for treating the patient’s high 
blood pressure. 
 
 Once patients are prescribed one of the drugs, they will see their doctor one week 
after they have started to take the drug, one month after they have started to take the 
drug, six months after, and 1 year after. This is the same number of times that patients 
would normally see their doctor even if they were not in the study.  
 
 During these doctors’ appointments, the patient’s doctor will take the patient’s blood 
pressure. The doctor will also ask the patient how he or she is doing and if there have 
been any side effects. If the drug is not working or if the patient does not like the 
drug, the patient’s doctor can switch the patient to a different drug or can change the 
amount of the drug the patient takes. 
 
 Patients will also be asked to complete a short survey after they see their doctor. 
Patients not in the study are not asked to complete this survey.  The survey will ask: 
o what the patient likes or does not like about the drug  
o how often the patient took the drug  
o what time of day the patient usually took the drug, and  
o when the last time the patient took the drug was  
 
 In addition, for the purposes of this medical research study, patients will be asked to 
return to the clinic 2 extra times to have their blood pressure read by a nurse. 
 
 A copy of the extra blood pressure measurements and the patient’s survey responses 
will be given to the patient’s doctor so that the doctor can use this information to help 
figure out how well the drug is working for the patient. 
 
 Medical researchers will compare the blood pressure measurements and survey 
results of patients in the medical research study who are taking one drug to the blood 
pressure measurements and survey results of patients taking the other drug. Medical 
researchers will also look at patients' medical records to see if any patients had a heart 
attack or stroke within 3 years of getting the drug. 
 
 
How is that different from what would have happened to patients as part of ordinary 
clinical care?  
 
 Patients in the medical research study are given a drug based on a random 
assignment.  If a patient just went to his doctor, the patient’s doctor would select the 
drug for the patient that that doctor likes best. 
 
 It is important to remember that even if a patient were not in the medical research 




patients in the medical research study to treat the patient’s high blood pressure 
because each is a very safe drug that is used a lot to treat high blood pressure. 
 
 Patients in the medical research study will see their doctor just as often as patients not 
in the medical research study.  In addition, patients in the medical research study will 
be asked to go to the clinic 2 extra times to have their blood pressure read by a nurse. 
 
 Patients in the medical research study will be treated the same way as other patients 
when they see their doctor. The only difference is that doctors of patients in the 
medical research study will have more information to help them figure out how well 
the drug is working because patients in the medical research study will be asked to 
complete a survey and will have their blood pressure read 2 additional times. 
 
 After they see their doctor, patients in the medical research study will be asked to 
complete a short survey. Patients are not asked to complete surveys as part of 
ordinary clinical care.  
 
 Medical researchers will look at the medical records of patients in the medical 
research study, which does not happen as part of ordinary clinical care. 
 
 Patients who are part of the medical research study will be helping to figure out 
which drug is best for patients with high blood pressure. Understanding which drug is 






Appendix 7b: Case Studies: Migraine Case Study Description 
*This was the version of the case study provided to patients. The version provided to 
researchers and IRB members had less explanation of key concepts such as 
randomization.  
 
The Migraine Medical Research Study: 





 Right now, there are many different drugs that are used to treat migraines. Some 
doctors start their patients on one of these drugs and some doctors start their patients 
on another. 
 
 Even though they all relieve migraines and all of them are safe, doctors are not sure 
which one works the best. This is because not a lot of research has been done that 
compares these drugs to one another.  
 
 Medical research studies that compare one of the drugs to another can help us figure 
out which drug is the best for treating migraines. Therefore, [Johns Hopkins or 
Geisinger] would like to do a study to compare two drugs that are often used to treat 
migraines.   
 
How would the medical research study work? 
 
 Patients at [Johns Hopkins or Geisinger] with migraines who need to start taking a 
drug to treat their migraines will be prescribed one of the two most commonly used 
drugs based on a random assignment. 
  
 This means that a computer program will select one of the two drugs in the study and 
the patient’s doctor will prescribe that drug to the patient. Therefore, patients in the 
study have an equal chance of being prescribed either of the two drugs.  
 
 The two drugs that are being studied are ones that patients would likely have been 
prescribed even if they were not in the medical research study. This means that 
patients in the medical research study are getting the same drugs as many patients 
who are not in the medical research study. 
 
 Also, a patient can only be in the medical research study if that patient’s doctor 
determines that both drugs in the study are appropriate for treating the patient’s 
migraines. 
 
 Once patients get a drug, they will be asked to write down the following information 




o The time they first felt migraine pain and how bad the migraine pain was 
o The time when they took the drug they were prescribed 
o How bad the migraine pain was 15 minutes, 30 minutes, 1 hour, and 2 
hours after taking the drug 
o If the migraine pain returned within 24 hours of it going away  
 
 Patients will give this information to their doctor at their next appointment.  
 
 During the next doctor’s appointment, the patient’s doctor will review this 
information with the patient and will ask the patient if he or she has had any side 
effects. The doctor will then provide the patient with information on how well the 
drug seems to be working compared to how well it can be expected to work. If the 
drug is not working or if the patient does not like the drug, the patient’s doctor can 
switch the patient to a different drug or change the amount of the drug the patient 
takes. 
 
 Patients will be asked to complete a short survey after they see their doctor. Patients 
not in the study are not asked to complete this survey. The survey will ask: 
o What the patient likes or does not like about the drug 
o How many times the patient has taken the drug since it was prescribed 
o If the patient takes the drug every time they experience migraine pain 
A copy of the patient’s survey responses will be given to the patient’s doctor so the 
doctor can use the information to help figure out how well the drug is working. 
 
 Medical researchers will compare the survey responses and information written down 
by patients who are taking one drug in the medical research study to the survey 
responses and information written down by patients taking the other drug. Medical 
researchers will also look at patients' medical records to see if the patients had any 
side effects or switched drugs. 
 
How is that different from what would have happened to patients as part of ordinary 
clinical care? 
 
 Patients in the medical research study are given a drug based on a random 
assignment.  If a patient just went to his doctor, the patient’s doctor would select the 
drug for the patient that he or she likes best.  
 
 It is important to remember that even if a patient were not in the medical research 
study, it is very likely that his or her doctor would select one of the drugs given to 
patients in the medical research study to treat the patient’s migraines because each is 
a very safe drug that is used a lot to treat migraines.  
 
 Patients in the medical research study are asked to write down information about how 
fast the drug relieved their migraine pain. Patients are not asked to write down this 





 Patients in the medical research study are treated the same way as other patients when 
they see their doctor. The only difference is that doctors of patients in the medical 
research study will have more information to help them figure out how well the drug 
is working because patients in the medical research study will be asked to write down 
information about each migraine they experience and to complete a survey. 
 
 After they see their doctor, patients in the medical research study will be asked to 
complete a short survey. Patients are not asked to complete surveys as part of 
ordinary clinical care. 
 
 Medical researchers will look at the medical records of patients in the medical 
research study as well as the information they recorded in the survey and at home, 
which does not happen as part of ordinary clinical care. 
 
 Patients who are part of the medical research study will be helping to figure out 
which drug is best for patients with migraines. Understanding which drug is best is 





Appendix 8: Description of the Models of Consent, Disclosure, and Authorization 
 
Ways of Telling Patients about Medical Research Studies: 
Information Sheet 
 
1. Broad Authorization: Patients are told that [Johns Hopkins or Geisinger] does a lot 
of medical research studies to compare widely used drugs to each other to figure out 
which drugs work best. Patients who might have been given either of the drugs in 
the study anyway might automatically be enrolled in these studies if they are 
eligible.  
 
How it would work. 
 When this way of telling patients is used, patients are told that medical research 
studies like the study described in the case example that compare safe and widely 
used drugs to each other are done all the time at [Johns Hopkins or Geisinger] and 
patients are sometimes included in studies when they need that general type of 
medicine.   
 
 This means that patients are not told every time a study comparing safe and widely 
used drugs is done.   
 
 This is so that [Johns Hopkins or Geisinger] can quickly do these medical research 
studies and use the information to improve the care they provide to patients. 
 
 If patients want to find out more about medical research studies that [Johns Hopkins 
or Geisinger] is doing, they can call a research office to get more information. 
 
Why some people like this. 
 This way of telling patients takes the least amount of time, which means that more 
busy doctors and nurses will participate. If more doctors and nurses participate, more 
of their patients will also be part of the study meaning the study can potentially be 
completed in a shorter amount of time 
 
 This also means that there will likely be many different kinds of patients who are part 
of the medical research study which would allow researchers to see which drug works 
best for all different types of patients. This is important because sometimes one drug 
can be the best for a patient with certain traits while another drug can be best for a 
patient with different traits.  
 
 This way of telling patients costs the least amount of money. 
 
Why some people DO NOT like this. 
 Patients will not know every time they are part of a medical research study.  
 
 Patients will not always be able to say whether or not they want to be part of a 





 Patients may be asked to do extra things like [write down information about their 
migraines or go see their doctor two extra times] that they would not normally have to 
do even though they were not asked if they wanted to be part of the medical research 
study. 
 
2. Disclosure with No Routine Option to Opt Out: Patients are told that [Johns 
Hopkins or Geisinger] does a lot of medical research studies to compare widely used 
drugs to each other to figure out which drugs work best. Patients who might have 
been given either of the drugs in the study anyway are also told about each study 
they are eligible for. Patients might then automatically be enrolled in these studies if 
they are eligible. 
 
How it would work. 
 Patients at [Johns Hopkins or Geisinger] are told that sometimes medical research 
studies comparing safe and widely used drugs to each other are done to figure out 
which drug is best.  
 
 Patients are also given more information about each medical research study they 
could be a part of. Patients are told that everyone who is part of the medical research 
study will get the same kind of medical treatments as patients not in the study. 
 
 After patients are told about the medical research study, they are told that in order to 
help [Johns Hopkins or Geisinger] figure out which drug is best, they will be enrolled 
in the study. 
 
 If, after being told about the study, a patient says that he or she does not want to be a 
part of it, that patient will not be included in the study.  
 
Why some people like this. 
 Patients will be told about each medical research study that [Johns Hopkins or 
Geisinger] is doing that they could be included in. 
 
 This way of telling patients takes less time than the other two ways described next, 
which means that more busy doctors and nurses will participate. If more doctors and 
nurses participate, more of their patients will also be part of the study meaning the 
study can potentially be completed in a shorter amount of time 
 
 This also means that there will likely be many different kinds of patients who are part 
of the medical research study which would allow researchers to see which drug works 
best for all different types of patients. This is important because sometimes one drug 
can be the best for a patient with certain traits while another drug can be best for a 
patient with different traits.  
 





Why some people DO NOT like this. 
 Patients will not be told that they do not have to be in the study.  
 
 Patients may be asked to do extra things like [write down information about their 
migraines or go see their doctor two extra times] that they would not normally have to 
do even though they were not asked if they wanted to be part of the medical research 
study. 
3. Disclosure with an Option to Opt Out: Patients are told that [Johns Hopkins or 
Geisinger] does a lot of medical research studies to compare widely used drugs to 
each other to figure out which drugs work best. Patients who might have been given 
either of the drugs in the study anyway are also told about each study they are 
eligible for. Patients might then be enrolled in these studies but are told that if they 
do not want to be part of the medical research study, they don’t have to. 
 
How it would work. 
 Patients at [Johns Hopkins or Geisinger] are told that sometimes medical research 
studies comparing safe and widely used drugs to each other are done to figure out 
which drug is best.  
 
 Patients are also given more information about each medical research study they 
could be a part of. Patients are told that everyone who is part of the medical research 
study will get the same kind of medical treatments as patients not in the study. 
 
 After patients are told about the medical research study, they are told that in order to 
help [Johns Hopkins or Geisinger] figure out which drug is best, they will be enrolled 
in the study. 
 
 Patients are also told that if they do not want to be part of the medical research study, 
they can talk to a study nurse at the front desk or talk to their own doctor and they 
will not be included in the medical research study. 
 
Why some people like this. 
 Patients will be told about each medical research study that [Johns Hopkins or 
Geisinger] is doing that they could be a part of. 
 
 Patients are able to choose whether or not to be in the medical research study. 
 
 This way of telling patients takes less time and costs less money than the way of 
telling patients described next.  
 
Why some people DO NOT like this. 
 Patients have to tell someone if they do not want to be part of the medical research 
study instead of being asked if they would like to be a part of it. 
 
 Some patients may choose not to be part of the medical research study even though 





 Some patients may choose not to be part of the medical research study even though it 
is very likely that nothing bad will happen to them if they are in the study. 
 
 If some patients choose not to be part of the medical research study, there will not be 
any information about which drug is best for those patients and it may also take 
longer to figure out which drug is best overall. 
 
 
4. Prospective Informed Consent: Patients are told that [Johns Hopkins or Geisinger] 
does a lot of medical research studies to compare widely used drugs to each other to 
figure out which drugs work best. Patients are also told about each study they are 
eligible for. Patients who might have been given either of the drugs in the study 
anyway are then asked if they would like to be a part of the study before they are 
enrolled. 
 
How it would work. 
 Patients at [Johns Hopkins or Geisinger] are told that sometimes medical research 
studies comparing safe and widely used drugs to each other are done to figure out 
which drug is best.  
 
 Patients are also given more information about each medical research study they 
could be a part of. Patients are told that everyone who is part of the medical research 
study will get the same kind of medical treatment as patients not in the study. 
 
 Patients are asked whether or not they would like to be part of the medical research 
study. 
 
 If patients would like to be a part of the medical research study, they are enrolled in 
it. 
 
Why some people like this. 
 Patients will be told about each medical research study that [Johns Hopkins or 
Geisinger] is doing that they could be a part of. 
 
 Patients are asked whether or not they would like to be part of the medical research 
study. 
 
Why some people DO NOT like this. 
 This way of telling people takes the most time and costs the most money.  
 
 Many patients may choose not to be part of the medical research study even though 





 Some patients may choose not to be part of the medical research study even though it 
is very likely that nothing bad will happen to them if they are in the medical research 
study. 
 
 If some patients choose not to be part of the medical research study, there will not be 
any information about which drug is best for those patients and it will take longer to 





Appendix 9a: Survey for Researchers and Institutional Review Board 
Chairs/Longstanding Members 
 
Please answer the following questions. 
 
1. What is your gender?    
 Male    
 Female 
 
2. What is your age? 






 80 or over 
 




4. What is your race? (You may select more than one) 
 American Indian or Alaska Native 
 Asian  
 Black or African American 
 Native Hawaiian or Other Pacific Islander 
 White or Caucasian 
 Other 
 
5. How long have you been employed at [Johns Hopkins or Geisinger]? 
 Less than 1 year 
 1-3 years 
 4-6 years  
 7-10 years 
 Greater than 10 years 
 
6. [Only asked on IRB member survey] How long have you been a member of the 
[Johns Hopkins or Geisinger] IRB? 
 1-3 years 
 4-6 years  
 7-10 years 













 Other ________________________________________ 
 
9. Have you ever been involved with the conduct of a medical research study as a 




10. Are you currently involved in the conduct of a medical research study as a principal 




11. If you answered “yes” to the last question, approximately what proportion of your 







12. How many prospective randomized control trials enrolling over 100 patients have you 




 3 or more 
 
13. Have you ever been asked to participate in a medical research study as a patient or as 












15. Would you be willing to be a patient participant in the medical research study or 
studies we discussed? 
 Yes 
 No 
 Don’t know 
 
16. Thinking about the medical research study we discussed today, please place a check 
mark next to the different ways that you think it is acceptable for doctors or medical 
researchers to tell people about the medical research study. You may select more than 
one answer.  
 
 1. Patients are told that [Johns Hopkins or Geisinger] does a lot of medical 
research studies to compare widely used drugs to each other to figure out which 
drugs work best. Patients who might have been given either of the drugs in the 
study anyway might automatically be enrolled in these studies if they are eligible.  
 
 2. Patients who might have been given either of the drugs in the study anyway are 
told about each study they are eligible for. Patients then might be automatically 
enrolled in these studies if they are eligible. 
 
 3. Patients who might have been given either of the drugs in the study anyway are 
told about each study they are eligible for. Patients are then enrolled in these 
studies if they are eligible but are told that if they do not want to be part of the 
medical research study, they don’t have to. 
 
 4. Patients are told about each study they are eligible for. Patients who might have 
been given either of the drugs in the study anyway are then asked if they would 
like to be a part of the study before they are enrolled. 
 
17. Thinking about our discussion today and your own feelings, please state why you 
think the models you selected are appropriate and why the models you did not select 
are not appropriate in the space below. If you need more room, you can write on the 








Appendix 9b: Survey for Institutional Review Board Community Members 
 
Please answer the following questions. 
 
1. What is your gender?    
 Male    
 Female 
 
2. What is your age? 






 80 or over 
 




4. What is your race? (You may select more than one) 
 American Indian or Alaska Native 
 Asian  
 Black or African American 
 Native Hawaiian or Other Pacific Islander 
 White or Caucasian 
 Other 
 
5. How long have you been a member of the [Johns Hopkins or Geisinger] IRB? 
 1-3 years 
 4-6 years  
 7-10 years 
 Greater than 10 years 
 
6. Please select the statement that best describes how you would like you and your 
doctor to make decisions about how to treat your medical condition. 
 I prefer to make the decision about which treatment I will receive 
 I prefer to make the final decision about my treatment after seriously considering 
my doctor’s opinion 
 I prefer that my doctor and I share responsibility for deciding which treatment is 
best for me 
 I prefer that my doctor makes the final decision about which treatment will be 
used but seriously considers my opinion 




7. Have you ever been asked to participate in a medical research study as a patient or as 









9. Would you be willing to be a patient participant in the medical research study or 
studies we discussed? 
 Yes 
 No 
 Don’t know 
 
10. How important do you think it is to do more medical research to see how well drugs 
for [high blood pressure or migraine] work for patients? 
 Very important 
 Important 
 Somewhat important 
 Not important 
 Don’t know 
 
11. How important do you think it is for people to participate in medical research studies? 
 Very important 
 Important 
 Somewhat important 
 Not important 
 Don’t know 
 
For the following four items, please check the box next to the response that best 
reflects your view. 
12. How much do you trust doctors to always provide the best medical care available? 
 A great deal 
 Some  
 Very little 
 Not at all 
 
13. Doctors who do medical research tell their patients everything that patients need to 
know about being in a research study. 







 Strongly disagree 
14. Medical researchers treat people like “guinea pigs”. 




 Strongly disagree 
 
15. I trust doctors who do medical research. 




 Strongly disagree 
 
16. Thinking about the medical research study we discussed today, please place a check 
mark next to the different ways that you think it is acceptable for doctors or medical 
researchers to tell people about the medical research study. You may select more than 
one answer.  
 
 1. Patients are told that [Johns Hopkins or Geisinger] does a lot of medical 
research studies to compare widely used drugs to each other to figure out which 
drugs work best. Patients who might have been given either of the drugs in the 
study anyway might automatically be enrolled in these studies if they are eligible.  
 
 2. Patients who might have been given either of the drugs in the study anyway are 
told about each study they are eligible for. Patients then might be automatically 
enrolled in these studies if they are eligible. 
 
 3. Patients who might have been given either of the drugs in the study anyway are 
told about each study they are eligible for. Patients are then enrolled in these 
studies if they are eligible but are told that if they do not want to be part of the 
medical research study, they don’t have to. 
 
 4. Patients are told about each study they are eligible for. Patients who might have 
been given either of the drugs in the study anyway are then asked if they would 
like to be a part of the study before they are enrolled. 
 
17. Thinking about our discussion today and your own feelings, please state why you 
think the models you selected are appropriate and why the models you did not select 
are not appropriate in the space below. If you need more room, you can write on the 








Appendix 9c: Survey for Patients with Hypertension or Migraines 
 
Please answer the following questions. 
 
1. What is your gender?    
 Male    
 Female 
 
2. What is your age? 






 80 or over 
 
3. What is the highest level of education you have completed? 
 Less than high school 
 High school diploma or GED  
 Some college 
 College degree 
 Graduate level degree 
 Other ______________________  
 




5. What is your race? (You may select more than one) 
 American Indian or Alaska Native 
 Asian  
 Black or African American 
 Native Hawaiian or Other Pacific Islander 
 White or Caucasian 
 Other 
 
6. In general, how would you rate your health? 
 Excellent 








7. Please select the statement that best describes how you would like you and your 
doctor to make decisions about how to treat your medical condition. 
 I prefer to make the decision about which treatment I will receive 
 I prefer to make the final decision about my treatment after seriously considering 
my doctor’s opinion 
 I prefer that my doctor and I share responsibility for deciding which treatment is 
best for me 
 I prefer that my doctor makes the final decision about which treatment will be 
used but seriously considers my opinion 
 I prefer to leave all decisions regarding treatment to my doctor. 
 
8. Have you ever been asked to participate in a medical research study as a patient or as 













 Don’t know 
 
11. How important do you think it is to do more medical research to see how well drugs 
for [migraines or high blood pressure] work for patients? 
 Very important 
 Important 
 Somewhat important 
 Not important 
 Don’t know 
 
12. How important do you think it is for people to participate in medical research studies? 
 Very important 
 Important 
 Somewhat important 
 Not important 







For the following four items, please check the box next to the response that best 
reflects your view. 
 
13. How much do you trust doctors to always provide the best medical care available? 
 A great deal 
 Some  
 Very little 
 Not at all 
 
14. Doctors who do medical research tell their patients everything that patients need to 
know about being in a research study. 




 Strongly disagree 
 
15. Medical researchers treat people like “guinea pigs”. 




 Strongly disagree 
 
16. I trust doctors who do medical research. 









17. Thinking about the medical research study we discussed today, please place a check 
mark next to the different ways that you think it is acceptable for doctors or medical 
researchers to tell people about the medical research study. You may select more than 
one answer.  
 
 1. Patients are told that [Johns Hopkins or Geisinger] does a lot of medical 
research studies to compare widely used drugs to each other to figure out which 
drugs work best. Patients who might have been given either of the drugs in the 
study anyway might automatically be enrolled in these studies if they are eligible.  
 
 2. Patients who might have been given either of the drugs in the study anyway are 
told about each study they are eligible for. Patients then might be automatically 
enrolled in these studies if they are eligible. 
 
 3. Patients who might have been given either of the drugs in the study anyway are 
told about each study they are eligible for. Patients are then enrolled in these 
studies if they are eligible but are told that if they do not want to be part of the 
medical research study, they don’t have to. 
 
 4. Patients are told about each study they are eligible for. Patients who might have 
been given either of the drugs in the study anyway are then asked if they would 
like to be a part of the study before they are enrolled. 
 
 
18. Thinking about our discussion today and your own feelings, please state why you 
think the models you selected are appropriate and why the models you did not select 
are not appropriate in the space below. If you need more room, you can write on the 






Appendix 10: Interview and Focus Group Coding Scheme 
 
 Codes related to policy implications [policy] 
 Few trials will compare interventions that are so similar so it doesn’t make 
sense to have different consent standards [few trials like this] 
 Slippery slope 
 Hard enough enforcing one standard 
 Litigation against institution [litigation] 
 Documentation 
 
 Codes related to the study setting [study setting] 
 Autonomy interests (autonomy is highly regarded in setting in which the 
research is conducted) 
 Trust of community/importance of considering community context 
[community trust] 
 Need for community input if alternative models are to be used 
[community input] 
 Recognition that institution is a teaching hospital [teaching hospital] 
 
 Codes related to the study design [study] 
 Risk 
 Financial risk 
 Involves drugs which are powerful agents which could adversely 
impact patients [trial involves drugs] 
 Alters clinical care 
 Limits treatment options 
 Randomization  
 Impacts clinical/therapeutic decision making (including 
discussions of impact on the patient/provider relationship) 
 Impacts the ability patients to participate in health care 
decisions (this code is also in model characteristics section 
so need to see if participant is talking about the study or the 
model)  
 Characteristics of the drugs being compared 
 Drugs being compared in the trial are similar [similar drugs] 
 Involves non-experimental/FDA approved/widely used drugs 
[widely used drugs] 
 Allows doctors to switch drugs [switching allowed] 
 Imposes a burden on participants (including discussions of collecting data 
that is not routinely collected) [imposes burdens] 
 Impacts the ability of or the likelihood that patients will experience 
optimal clinical outcomes [optimal clinical outcome] 
 Relies on personal health information (PHI)/medical records [PHI] 
 
 Codes related to characteristics of the model 




 Respect for autonomy/paternalistic 
 Respect (participants just mentions respect without discussing 
autonomy) 
 Patient used as a means to an end/guinea pig [means to an end] 
 Information/disclosure 
 Patients should know what is happening with their bodies  
 Informed about the study 
 The amount or type of information provided (use this code 
if the participant is saying that the model doesn’t provide 
enough information, provides too much information, or if 
they are talking about the type of information that should 
be disclosed to participants) 
 Amount of information will scare or overwhelm 
people or lead to the hypochondriac effect 
 Deception/being explicit/being transparent 
 Understanding 
 May not understand why they are being asked to do extra 
things 
 May not understand their options 
 Voluntariness/intentional action 
 Rights of participants to control participation/ability to 
control participation [ability to control participation] 
 Forced participation 
 Pressured to participate 
 Only assertive people will refuse to 
participate 
 Coercion 
 Resistibility (how easy or burdensome  it is to get 
out of participating in a study) 
 Treating participants as partners (makes participant feel 
important and that their opinions matter)  
 Model limits the ability of patients to participate in 
healthcare decisions (this code is also in study 
characteristics section so need to see if participant is talking 
about the study or the model) [limiting participation in HC 
dec] 
 Fairness/discrimination/equity 
 Protecting patients 
 
Ethical concerns about the impact the model will have on participants or on the study 
[model impact] 
 Impact on trust 
 Patient trust of doctors or the health care system [patient trust] 
 Impact of patient/provider dynamics 




 Impact on the likelihood that patients will feel wronged or betrayed or 
angered/would switch docs or HC systems [patients may feel wronged] 
 Impact on the number of people who will participate  
 Impact on the ability to complete the research 
 Impact on internal validity 
 Impact on patient behavior (patient may change behavior if they 
know they are in the study) 
 Adherence (also included in this category is discussions of 
participants being committed to the study or providing accurate 
information) 
 Selection bias 
 Impact on external validity/generalizable knowledge 
 Impact on the efficiency of the research  
 Burden on clinicians or researchers [because takes more time to 
explain] 
 Burden on patient [because takes more time to explain] 
 Time to enroll patients 
 Time to do the research 
 Cost 
 Impact on altruistic motivation 
 
 Other (potential) codes [Other] 
 Balancing comments 
 Informed consent lite (ask people but just discuss main side effects) 
 Distinction between opting in and opting out 
 Distinction between model 2 and 3 doesn’t exist in the real world 
 Any good doctor would tell patients they can opt out 
 Amount of information provided as part of normal clinical practice 
 Percent of people who generally agree to participate in studies 
 Many patients just defer to doctors judgments/trust that doctors wouldn’t 
do anything harmful 
 Different people will prefer different models because of 
 Age 
 Health condition 
 Length of time with health condition 
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